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ABSTRACT 
 
Zachary Lewis Rodgers: Cobalamin-Fluorophores’ Photochemistry and Biomedical Applications 
(under the direction of David S. Lawrence) 
 
 As science focuses on the finer details of complex processes occurring in biology, the need 
for tools responsive to researcher control have become critical to communicate with cellular 
functions in both a spatial and temporal manner. To this end, light responsive “caging groups” 
have been used to generate molecular constructs with which researchers can activate using directed 
irradiation to elicit biological responses where and when they want. This advancement in 
molecular control has greatly improved our ability to study biological systems in their dynamically 
intricate form. 
 Most of these photoresponsive moieties perform well within a petri dish, but their 
application is limited in vivo. Current photochemical tools require high energy light for their 
activation. Dermal tissue contains bio chromophores that absorb this light and prevents its 
penetration to less than a few millimeters making photoactivation impossible. However, tissue has 
an “optical window” in the red and near infrared (600 – 1000 nm) where light penetrates efficiently 
to clinically relevant depths. Therefore, researchers have sought long wavelength responsive 
caging groups but have had little success to date. 
 Herein, I report the development of an entire class of red and near infrared responsive (600 
– 800 nm) caging groups based on Vitamin B12 or cobalamin. Upon modification with a 
fluorophore antenna, these metal complexes can capture long wavelength light to perform 
photochemical work in the form of bond scission reactions. The effect is compatible with a range 
iv 
of fluorophores covering the entire near infrared spectrum, and bond scission proceeds rapidly 
with extremely high efficiencies. In this work, the initial development and characterization of these 
molecules as photoactivateable groups will be discussed. Furthermore, I will demonstrate how 
these molecules can be applied for clinical applications, such as drug delivery and tissue scaffold 
formation, to provide safer and less invasive treatments.  
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CHAPTER ONE: COBALAMIN PHOTOCHEMISTRY AND ITS EXTENSION INTO THE 
NEAR INFRARED1 
 
Chapter Abstract 
In this chapter, Vitamins B12, or cobalamins’ (Cbl), photochemical sensitization with near 
infrared (NIR) fluorophores will be discussed. These sensitization interactions aided in the 
development of NIR responsive optomolecules that overcome the disadvantages of the current 
photosensitive systems used in biological systems. First, background on the current 
photoresponsive toolkit, Cbl structure and photochemistry relevant to this work will be discussed. 
Later, I will detail the discovery and scope of Cbl-fluorophore interactions for NIR photolysis of 
alkylCbls. These interactions occur throughout the NIR spectrum in a tunable fashion (600 – 800 
nm). Moreover, this chapter will demonstrate how up to four Cbl-fluorophore conjugates in a 
mixture can be selectively photo-activated in an orthogonal fashion; the first example of a 
photolabile system with this degree of control. 
1.1. Communicating with biology 
 In contrast to a reaction flask, chemistry within a cell is significantly more complex. For 
instance, cells have a multitude of reactions occurring simultaneously at varying degrees of 
intensity and specificity within the same location. This complexity compounds further when one 
considers that the location or timing of a cellular reaction can have significant effects on the 
                                                          
1 Some figures reproduced with permission from Shell, T. A.; Shell, J. R.; Rodgers, Z. L.; 
Lawrence, D. S. Tunable Visible and Near-IR Photoactivation of Light-Responsive Compounds 
Using Fluorophores as Light Capturing Antennas. Angew. Chemie 2014, 126, 894–897.  © 2014 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim) 
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ultimate outcome. Therefore, it is not surprising that cells tightly control their chemistry by 
possessing a highly spatially and temporally organized system of organelles and signaling 
pathways to control where, when, and what events take place. For example, cytochrome c when 
bound within mitochondria aids in cellular respiration and energy production contributing to the 
cell’s survival (Scheme 1.1).1,2 But upon cytochrome c release into the cytoplasm, it activates an 
apoptotic pathway that culminates in the cell’s death. This spatiotemporal complexity occurs on 
the macroscale as well with chemical differentiation between various tissues, organs, and 
hormones within an organism. 
 This high level of organization and sophistication makes biological systems difficult to 
probe and study dynamically. For several decades, biologists have attempted to use agents that 
perturb cellular functions and elicit a response for study. However, they often lack the means to 
control both where and when the agent becomes active.2–4 This leads to off-target activation or 
accumulation resulting in a confounding number of additional variables. For example, the ability 
of a small molecule to study a cell’s protein kinetics may not only depend on target specificity, but 
also its ability to penetrate the lipid bilayer.5,6 If membrane permeabilization is the rate limiting 
step, then action on the probe cannot be accurately studied by simple addition of the probe to cell 
media. However, having a trigger in place that allows substantial concentrations of the probe to 
accumulate before activation would alleviate this problem. Complications such as this have driven 
the search for specific tools that allow spatiotemporally controlled communication with probing 
small molecules, peptides, and proteins.2–4,7 
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Scheme 1.1. Complexity of cellular processes in the antithetical functions of cytochrome c 
localization. In the mitochondria, cytochrome c aids in the shuttling of electrons during ATP 
synthesis leading to the cells’ survival. However, upon release into the cytoplasm, it complexes 
into the apoptosome inducing apoptosis and cell death. This organizational complexity of 
molecular function occurs throughout biology on the micro and macroscale necessitating the 
development tools and probes for directed molecular control. 
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1.1.1. Advantages of Photoresponsive Agents and Tools 
Light responsive agents provide attractive options for researcher controlled activation. 
Typically, a molecule of interest is modified with a photoresponsive moiety that inactivates the 
compound by blocking an essential functional group8–13, inducing structural changes14–16, or 
altering its cellular location (Scheme 1.2a).17–19 Upon researcher controlled light stimulation, say 
from a microscope laser, the photosensitive moiety undergoes a chemical response to yield an 
active agent. This provides investigators exquisite control of their molecule of interest, since they 
can direct the excitation source to where and when they want. As opposed to chemical modulators, 
most activating light behaves orthogonally to biological systems and does not incur significant 
damage or disturb other processes within the cell. 
 Kaplan and coworkers were the first to demonstrate this approach when they successfully 
blocked ATP hydrolysis by modification of the γ-phosphate with an ultraviolet (UV) sensitive 
ortho-nitrobenzyl (ONB, Scheme 1.2b).20 Upon irradiation, the ONB group cleaved to provide 
native ATP, which was subsequently acted upon by the ATPase function of Na:K ion pumps. This 
approach of modifying an essential residue was classically referred to as “caging”.2,4,7 Now, this 
term generally refers to substrate inactivation by any number of methods. The advantages of this 
approach quickly became apparent and adopted as a practical method to study complex biological 
systems dynamically. 
1.1.2. Examples of Photoresponsive Agents 
Since that time, the photoresponsive toolkit has expanded to encompass many new 
photoprotecting groups and inactivation strategies (Scheme 1.3).3,7,21 The ONB22 and coumarin8,23–
25 protecting groups are commonly employed for the inactivation of small molecules, peptides, and 
proteins via modification of essential residues. In the case of the ONBs, they undergo photo-
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oxidation reactions with long UV irradiation to release heteroatom functionalities, such as the 
alcohol of serine amino acids to allow for subsequent phosphorylation by kinases.8,12. Several new 
moieties, such as metal complexes26–28, boron dipyrromethenes9,29,30, and heptamethine dyes10,31, 
provide slightly longer wavelength responsive groups, but their application has been limited to 
date. 
 As mentioned, biological modulators may also be inactivated by isomerization causing 
structural disruption. Azobenzenes have been used to induce structural changes in peptides and 
proteins with their reversible trans to cis isomerization in response to light.15,16,32 The reversible 
behavior provides even greater dynamic control with an “on/off” switching, and researchers have 
used azobenzenes to mimic retina protein action in blind mice and partially restore their vision.33,34 
Finally, proteins, particularly those associated with circadian rhythms and plant biology, 
have found use as photo-activated agents.35,36 Their exact photoinduced response can vary from 
relocation within a cell, recruitment of another protein, opening of ion channels, or increases in 
substrate turnover. These agents are genetically expressed within the system of interest, and their 
application has been invaluable to fields like neurology. For example, channel rhodopsins 
expressed in mouse neurons allow light controlled potentiation or suppression of seizures, which 
has provided insight about brain dynamics in epilepsy.37,38 Since these proteins require genetic 
expression, they’re application is restricted to models that are easily genetically modified, and 
therefore limits their extension as clinical tools for now. 
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Scheme 1.2. Classic photocaging approach. a) Substrates and actuators can be modified with a 
photoresponsive “lock” to inactivate or cage them. This act can prevent biological activity on the 
substrate via modification of an essential functionality, inducing structural changes, or 
sequestrating the molecule of interest to an off-target site. Later, light exposure can remove or 
cause structural changes within the agent to provide an active substrate. b) Kaplan and coworkers 
first demonstrated this concept with caged ATP. Here, the hydrolysable γ phosphate is blocked 
with an ONB until light exposure liberates native ATP. This phosphate can then be cleaved by the 
ATPase function of enzymes. 
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Scheme 1.3. Common caging groups. The classical “caging” approach of modifying essential 
residues has produced a diverse range of photoresponsive moieties that respond throughout the 
near UV and short visible range.7 Upon light exposure, these groups undergo photocleavage 
reactions to release a blocked heteroatom functionality and activate the substrate. The various 
ONB derivatives are the most common, as well as blue light sensitive coumarins (not shown). 
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1.1.3. Limitations of Current Photoresponsive Agents 
 Without a doubt, the current photo-responsive toolbox has yielded significant 
advancements in our understanding and manipulation of biology. However, the current arsenal 
comes with a significant disadvantage. The short wavelengths used for these molecules’ activation 
does not pose a problem for in vitro use but does so in vivo. Dermal tissue contains a high 
concentration of chromophores, like melanin and hemoglobin, which absorb a significant amount 
of UV and visible light, respectively (Figure 1.1).39,40 This prevents the necessary activating light 
from penetrating into tissue more than a few millimeters. Therefore, most of the current 
photoresponsive caging groups will only work superficially which limits their extension to in vivo 
models and biomedical applications.41,42 
 However, tissue possesses an “optical window” between 600 – 1000 nm where light can 
penetrate to clinically relevant depths (Figure 1.1).43 Here, both melanin’s and hemoglobin’s 
extinction coefficients (ε), or the propensity for photon absorption, reach their minimum values 
allowing light to pass through freely. Several clinical technologies already exploit light within this 
range with great success. Fluorescence guided surgery uses targeted red and near infrared (NIR) 
imaging agents, like indocyanine green, to identify malignancies for removal.44,45 Likewise, 
photodynamic therapy employs NIR light and photosensitizers to generate singlet oxygen 
species.46,47 This produces a very targeted, cytotoxic environment to cancers like melanoma via 
light irradiation. Unfortunately, current photo-activated groups are extremely limited in the NIR 
wavelength range or the chemistry they can perform in response to said light. 
 To circumvent this limitation, researchers have devised several “upconverting” strategies 
with their own disadvantages. First in two-photon excitation, common caging groups are pulsed 
with a huge flux of NIR light roughly equal to double the wavelength of their normal excitation 
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(ONB, λex ~ 365 nm → 720 nm).48–50 Occasionally, two photons simultaneously arrive at the 
surface of the caging group, and their combined energy converts to a shorter wavelength capable 
of activating the photochemical reaction. The small cross section where simultaneous absorption 
occurs allows for very targeted activations, and has been used to successfully release 
neurotransmitters.49 However, on a macroscale, such as in drug delivery where large doses may be 
required, this process lacks acceptable efficiency and can only deliver tiny amounts of active 
substrates. 
 Alternatively, clinicians have investigated upconverting nanoparticles for activating caging 
groups.51–53 These particles doped with lanthanides contain a large amount of f orbitals that provide 
many long lived excited states that act as an energy “ladder”. Electrons within these lanthanides 
accumulate several NIR excitations before emitting a shorter wavelength of light roughly equal to 
the sum of their absorptions. This emitted light can then be used to excite nearby UV sensitive 
moieties such as ONBs.53 These nanoparticles have found some limited application in light 
triggered drug delivery and theranostics, but they contain expensive lanthanide dopants with 
questionable associated toxicities.54 
 Due to these short comings, a NIR, single photon responsive caging group is highly desired 
for use in vivo. Recently, heptamethine dyes have showed promise for this purpose, but they suffer 
from low quantum yields (Φ, molecules reacted / photon absorbed) and limited cargo diversity.10,31 
Therefore, my dissertation research has focused on identifying and developing NIR responsive 
molecules for biomedical applications. 
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Figure 1.1. Optical window of tissue. Most photo-responsive moieties respond to wavelengths 
shorter than 600 nm, which significantly limits their use in vivo. Tissue contains chromophores, 
such as hemoglobin and melanin, that block this short incident light. However, these bio 
chromophore’s absorption reaches a minimum region between 600 – 1000 nm (red and NIR) 
known as the optical window of tissue. Light in this range can penetrate tissue efficiently and is 
already employed in biomedical applications, like fluorescence guided surgery and photodynamic 
therapy, to great effect. Photo-responsive agents for use in biomedical applications would greatly 
benefit from a single photon responsive class of compounds that respond to light within this range.  
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1.2. Cobalamins 
 In 1920, Dr. George Whipple discovered that anemic dogs fed with raw liver rapidly 
recovered from their weakened state.55 The discovery yielded a viable treatment for pernicious 
anemia and, subsequently, a 1934 Nobel Prize in Medicine for Whipple. Over a decade later in 
1948, two chemists, Karl Folkers and Alexander Todd, simultaneously isolated the cobalt 
containing curative factor and named the discovery vitamin B12 or cobalamin (Cbl).
56 Since that 
time, several forms, biological functions, and applications of Cbls have been identified making it 
one of the most extensively studied metal complexes to date.55,57,58 
1.2.1. Structure 
 Most Vitamin B12 derivatives contain the same basic architecture.
55,57,58 Broadly, Cbls are 
classified as cobalt corrinoids with a pseudo-octahedral geometry (Scheme 1.4). The cobalt metal 
center normally exists in a stable (+3) oxidation state with a d6-low spin configuration. However, 
both the (+2) and (+1) oxidation states are accessible via biological (flavin reductases)59 or 
chemical reduction (NaBH4)
60. Upon (+3) to (+2) conversion, the upper β axial ligand is lost and 
the lone, unpaired electron resides in the dz
2
 orbital as a “persistent radical”. Under anaerobic 
conditions, the CoII radical can exist for an extended period and be used to control radical processes 
via reversible termination or chain transfer processes (discussed in Chapter 3).61–63 Further 
reduction to the (+1) oxidation state causes formation of a super nucleophilic species with a square 
planar geometry.55,58,64 As I will discuss later, these super nucleophiles allow access to an array of 
Cbls via SN2 with electrophiles. 
The equatorial sites around the metal center are occupied by a negatively charged, nineteen 
carbon corrin ring. Unlike related twenty carbon porphyrins, the corrin ring is nonaromatic and 
contains four partially saturated pyrroles.55,65,66 The α-axial site is occupied by a dimethyl 
12 
 
benzimidazole (DMBI) base linked as a ribonucleotide to the corrin ring via a phosphodiester 
bond. As one might expect, DMBI coordination is sensitive to the pH and electron donating nature 
of the trans ligand.55,58,66–68 Strong electron donating ligands can induce substitution of the DMBI 
for a molecule of water at pH < 4.67,69 This effect is thought to play a role in docking of Cbl 
cofactors to enzymes, such as methyl malonyl-CoA mutase, by displacement of the DMBI with a 
protein histidine residue.70 Nevertheless, DMBI dissociation can significantly affect the 
photophysical properties of the complex. Therefore, care must be taken in purification of alkyl 
derivatives to prevent DMBI dissociation in acidic media. 
Finally, the β-axial ligand varies between B12 cofactors and tolerates a range of ligands that 
differ in bonding interactions and strength.55,58,71–75 Common moieties include -CN (CNCbl), -OH 
(HO-Cbl), -SR (thiolato-Cbl), -CH2R (alkylCbl), -(C=O) R (acylCbl), -CH=CHR (alkenylCbl), 
and -C≡CR (acetylideCbl). In the body, the alkylCbls, methylCbl (MeCbl) and adenosinylCbl 
(AdoCbl), provide the bioactive forms of Vitamin B12. However, there are dozens of alkylCbls 
available via standard synthetic protocols, such as –CH2CH3 (ethyl), -(CH2)2CH3 (propyl), -
(CH2)17CH3 (stearyl), -(CH2)3NH2 (propylamine), and -(CH2)3CO2H (butyrate).
76,77 More 
substituted alkyl groups (2o and 3o) are not well tolerated presumably due to steric interactions and 
increased stabilization of the resulting carbon centered radical product by hyper conjugation. As a 
result, highly substituted carbons undergo rapid elimination yielding alkenes and Cbl hydride 
species.62,63 
Probably intentional by biological design, the cobalt-carbon (Co-C) bond of alkylCbls is 
extremely weak (~ 25 – 44 kcal/mol)55,78–80 and undergoes homolytic scission to generate a Co+2 
and alkyl radical upon gentle heating (< 50 oC)80 or enzymatic coaxing (Scheme 1.5).81 Mutase 
enzymes utilize this homolytic behavior of the Co-C bond to catalyze the isomerization of several 
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biomolecules.70,82 Alternatively, the processing of MeCbl in the body centers on heterolytic 
reactions83,84 but the alkyl radical is accessible via photoirradiation.67,85 Under normal ambient 
conditions, alkylCbls are stable complexes that can be stored for extended periods of time without 
significant degradation (t1/2~ six months).
80 
1.2.2. Cobalamin Photochemistry 
Scientists have studied Cbl photochemistry since the late-1950s to understand the 
electronic states accessed after light absorption.65,67,72,82,86–90 In the UV and visible spectrum, 
intense bands vary based on the nature the β axial ligands (Figure 1.2). In the UV, the intense γ 
band (300 – 400 nm) with ε ranging from 10,000 to 30,000 M-1cm-1 corresponds to one (non-alkyl 
Cbl) or several (alkyl and thiolato Cbls) π→π* corrin transitions.65,67,82,91 When the β-axial ligand 
is strongly donating (alkyl or thiolate), this band produces an “atypical” spectrum that splits into 
two maxima between 300 – 400 nm indicating commonalities in bonding and ligand charge 
donation.85,92 Conversely, ligands such as –OH and –CN produce a “typical” spectrum with one 
intense band (ε~ 20 - 30,000 M-1cm-1) centered on 350 nm. At longer visible wavelengths (450 – 
600 nm), the characteristic α/β absorption bands produce modest ε generally less than 10,000 M-
1cm-1.55 Upon dissociation of either the β-axial ligand as seen in CoII species or the DMBI base at 
low pH, the α/β band undergoes a hypsochromic shift to ~ 480 – 490 nm. Although not definitively 
determined, the electronic transition occurring at these wavelengths in alkylCbls arises from a 
d/π→π* metal-to-ligand charge transfer (MLCT) state. Although, more recent studies indicate the 
transition may actually arise from a sigma-bond-to-ligand charge transfer (SBLCT) originating 
from a loss of electron density at the Co-C bond itself.93 Finally, low intensity (ε < 100 M-1cm-1) 
d-d transition bands lie throughout the near infrared spectrum (> 600 nm).   
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Scheme 1.4. Structure of vitamin B12 (Cbl). These CoIII complexes are low spin d6, with pseudo 
octahedral geometry. The metal center is coordinated at the equatorial sites by a nineteen carbon 
corrin ring with four partially saturated pyrroles’ coordinating the metal center. The lower α axial 
site is coordinated by a DMBI linked via a phosphodiester bond to the corrin ring. The ribose 
sugar’s primary hydroxyl provides an easily modifiable site for further functionalizations (vide 
infra). The β axial site (denoted by X) varies between derivatives with –CN, -OH, -CH3, 
glutathione and adenosine being the most common analogues in biological systems. The structure 
on the right is an abbreviated structure for simplicity in some figures.  
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Scheme 1.5. Homolysis of alkylCbls. Visible light irradiation or gentle heating results in 
homolytic bond scission to produce a solvent caged radical pair. The pair can either undergo 
recombination to generate an intact complex or react with molecular oxygen to allow release of 
the alkyl ligand. The high lability exhibited by alkyl cobalamins arises from the low bond Co-C 
bond dissociation energy (~30 - 44 kcal/mol). However, these complexes are stable when kept at 
room temperature and in the dark (t1/2 > 6 months).  
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Figure 1.2. Ground state absorption spectra of several Cbl species. CNCbl (blue dashed line), 
alkylCbl (solid blue line), alkylCbl without DMBI coordination (solid green line), Cbl +2 oxidation 
(dashed green line), Cbl +1 oxidation (solid red line).82 The α/β bands correspond to MLCT 
transitions, while the γ band transitions likely arise from the π→π* transitions of the corrin ring. 
Low intensity d-d transitions exist at wavelengths greater than 600 nm but have low extinction 
coefficients.  
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The photochemistry of cobalamin complexes varies depending on the ligated β-axial 
ligand. Excitation of non-alkyl cobalamins, such as CNCbl and acetylideCbl, exhibit limited 
photolability of their axial ligands with excitation resulting in relaxation to the ground state within 
10 ps.65,82,91,94 However, some reports implicate homolytic Co-OH bond scission upon UV 
excitation of HO-Cbl.95,96 On the other hand, alkyl, acyl, and thiolato-Cbls exhibit much greater 
photolability.72,73,85,87,97 Thiolato-Cbls photo-degradation and photochemistry will be discussed 
further in Chapter 4. 
Upon excitation, most alkylCbls undergo an initial MLCT or SBLCT, but some ambiguity 
exists as to the precise electronic transition occurring here.65,72,82,93,98,99 More recent theoretical 
considerations in MeCbl have also implicated ligand field transitions occurring upon 
excitation.93,98 Nevertheless, this initial excitation relaxes on a ps timescale to a long lived CoII and 
alkyl caged radical pair (Scheme 1.5). Transient absorption (TA) studies indicate this solvent caged 
pair is accessed with near quantitative efficiency (> 90%) upon light absorption.82,100 This radical 
pair can either undergo geminate recombination to the ground state or become solvent separated 
and trapped by molecular oxygen. As one might expect, the “observed” Φ depends on the radical 
pair solvent separation, so viscosity and radical size are important considerations.  Regardless, 
most simple alkylCbls display a wavelength independent photolysis Φ of 20 – 30% throughout 
their visible absorptions.55 MeCbl is an exception to this rule as its Φ (< 15%) is reduced at the 
α/β absorption due to an additional route to ground state relaxation.72,87 Under aerobic conditions, 
the alkyl radical can react with oxygen to form a peroxy species, abstract from a biological H donor 
generating a saturated carbon, or, in the case of adenosine, undergo intramolecular cyclization.87,88 
In solution, the peroxy species normally decays to either an alcohol or aldehyde, while the CoII 
oxidizes to form HO-Cbl. With such large Φ, alkylCbls are attractive to attach and release 
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payloads from in response to light, because they show greater susceptibility to visible light than 
many common UV sensitive caging groups.9,26,76,101,102 Moreover, alkylCbls tolerate a diverse 
range of cargo provided it can be linked through a primary carbon. 
Unfortunately, despite having low intensity d-d transitions at longer wavelengths, 
alkylCbls exhibit stability when exposed to wavelengths within the optical window of tissue 
(Figure 1.1, 600 – 1000 nm). This limits Cbls use in vivo as optomolecules capable of performing 
photochemical work in response to tissue penetrating light. However, previous work with Cbl, 
cob(III)aloximes, and fluorophores points to a possible solution to this problem. 
1.2.3. Cobalamin Quenching Interactions 
 Beginning in the mid-1970s, researchers noted the capacity of Cbls to quench the excited 
state of fluorescent molecules.103–107 Jacobsen and coworkers generated “profluorescent” 
analogues of several nucleosides through ligation to Cbl via the β-axial Co-C bond. Once attached, 
the fluorescent nucleosides were quenched and exhibited no detectable emission upon 
excitation.103 However upon photolysis or cyanolysis of the Co-C bond, the fluorescence was 
rescued as the liberated nucleoside diffused away from the quenching Cbl interaction. This result 
was not surprising as the nucleoside emission overlapped significantly with the absorption profile 
of the vitamin’s corrin ring; an indicative feature of energy transfer based quenching mechanisms. 
Moreover, previous X-ray crystallographic work showed a close proximity between the corrin ring 
and the fluorescent base allowing for efficient quenching to occur either via collisional (Dexter) 
or Förster resonance energy transfer (FRET). 108,109 In the 2000s, researchers hoping to image 
tumor cells using fluorescence also investigated Cbl-fluorophore conjugates.104–107 Of course, 
similar quenching interactions were noted for both organic and inorganic fluorophores ligated to 
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the vitamin. One wonders if using longer emitting fluorophores whose emission did not overlap 
with Cbl would eliminate these quenching interactions altogether.  
However, work by Kemp points to properties of related alkyl cob(III)aloximes that shows 
this may not be the case. The work demonstrated that the triplet excited state of sensitizing 
molecules, like rubrene or uranyl acetate, was efficiently quenched by 
ethyl(aqua)cob(III)aloxime.110 Quenching of the sensitizer’s triplet state led to Co-C bond scission 
as well. Interestingly, the cobaloximes could efficiently quench the sensitizers’ excited state even 
if its energy (40 kcal/mol, ~704 nm) was lower than the longest absorption energy of the 
cobaloxime (63 kcal/mol, ~456 nm). Kemp reasoned that energy transfer must be occurring to a 
photodissociative state of the cobaloxime not directly accessible via ground state absorption.  
Accessing electronic states via longer wavelength sensitization has also been shown in 
other metal complexes.109 For example, researchers have long known that [Ru(bpy)3]
2+ and  trans-
[Cr(NH3)2(NCS)4]
- sensitize the [Cr(CN)6]
3- phosphorescent state directly via energy 
transfer.111,112 In the latter example, the trans-[Cr(NH3)2(NCS)4]
- absorbs light at longer 
wavelengths (λmax ~ 550 nm) than the [Cr(CN)6]3- can absorb (λ < 500 nm). After initial absorption 
of 550 nm light and intersystem crossing, the trans-[Cr(NH3)2(NCS)4]
- excited state energy (2Eg, 
~38 kcal/mol) is thermodynamically uphill from the phosphorescent state (2Eg, ~35 kcal/mol) of 
the [Cr(CN)6]
3-.112 Therefore, energy transfer and population of this state can now occur with the 
longer 550 nm irradiation. This energy transfer results in concurrent [Cr(CN)6]
3- phosphorescence 
and trans-[Cr(NH3)2(NCS)4]
- quenching. This longer wavelength populating effect is also seen 
using organic based sensitizers with [Cr(CN)6]
3- such as erythrosine and eosin.111 Similar 
sensitization processes are often exploited through ligation of the sensitizer directly to the metal 
complex for applications ranging from phosphorescent lanthanides used in dendrimers and 
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counterfeit protection to ligand releasing complexes for the delivery of nitric oxide.109,113–117 The 
sensitization provided by the ligated antenna greatly improves both luminescence and ligand 
release upon light exposure. 
1.3. Cobalamin Sensitization 
 As stated above, the alkylCbl complex fails to absorb light longer than 600 nm limiting it 
in vivo.67,72,102 However, the studies previously discussed indicate that it may be possible to 
sensitize Co-C bond scission to longer wavelengths. Hypothetically, the low bond strength of ~ 30 
kcal/mol corresponds to a photon of about 1000 nm; well within the optical window of tissue.43 
Also despite the α/β band absorption at < 600 nm, TA studies have indicated that this initial 600 
nm excitation decays several times to lower energy states before the final caged radical pair 
intermediate.82,100 Therefore, Can near infrared fluorophores sensitize alkylCbls with sufficient 
energy to allow for photolysis within tissue’s optical window (Scheme 1.6)?  
First, we examined this premise by investigating if the fluorophore tetramethyl rhodamine 
(Scheme 1.7, TAMRA, λmax- 555 nm, ε~ 93,000 M-1cm-1) that absorbs in the same range of Cbl 
(λmax- 510 nm, ε~ 8,100 M-1cm-1) could increase the rate of bond scission. If TAMRA can transfer 
its excited state energy to the Cbl and aid in bond scission, its increased photon absorption versus 
the unmodified Cbl should increase the overall rate and efficiency of photolysis due to greater 
absorptive events.109,113–117 
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Scheme 1.6. Simplified diagram of NIR sensitization of alkylCbl photolysis. Normally, light up 
to 600 nm induces rapid homolytic bond scission. The work in this chapter examines if another 
route to bond scission may be possible using NIR light. In this approach, covalently linked, NIR 
absorbing fluorophores serve as light capturing antennas that can be excited with tissue penetrating 
light. Since the Cbl bond dissociation energy is low (~ 30 kcal/mol), the energy of photons with 
wavelengths as long as 1000 nm could provide sufficient energy to the metal complex to induce 
Co-C bond cleavage. Energy transfer in the diagram refers to sensitization of the Cbl by the dye’s 
excited state and not necessarily a defined energy transfer mechanism as electron transfer 
processes are also possible. 
  
22 
 
 
Scheme 1.7. Functionalization of Cbl derivatives. a) The ribose hydroxyl activation occurs using 
1,1’-carbonyl ditriazole and subsequent treatment with a primary amine affords a carbamate 
linkage. Here, ethylene diamine provides an amine functional handle for later coupling reactions. 
b) Reductive alkylation of HO-Cbl readily proceeds with formation of super nucleophilic CoI 
via reduction with activated zinc. Treatment of the super nucleophile with an alkyl halide 
electrophile installs the Co-C bond after SN2. Here, 3-chloropropylamine was used to make 
propylamineCbl.   
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Scheme 1.8. Synthesis of fluorophore modified Cbls. Fluorophores were activated with N-hydroxy 
succinimidly esters for reaction with primary amine functionalities. PropylamineCbl reaction with 
the NHS esters yielded Cbls with fluorophores linked to the labile β-axial Co-C bond (left) in good 
yields (Cbl-(1-6)). The same esters were utilized in reaction with AdoCbl-Etd to provide AdoCbl 
modified with fluorophores (AdoCbl-(1-4)). The structures of the fluorophores are shown on the 
bottom. Unfortunately, Atto725’s (Cbl-4, AdoCbl-3) and Alexa700’s (Cbl-6) structures are 
proprietary and have not been published.  
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1.3.1. Coenzyme B12 Nucleotide Loop Functionalization 
The Cbl scaffold provides two easily modifiable sites at the ribose 5’-OH and the β-axial 
ligand. To begin, I synthesized a coenzyme B12- TAMRA derivative (AdoCbl-1, Scheme 1.7a-
1.8) via modified protocol that installed the TAMRA fluorophore on the nucleotide loop.106,118 
Reaction of AdoCbl with 1,1’-carbonyl ditriazole (CDT) activates the ribose 5’-hydroxyl (Scheme 
1.7a). Subsequent treatment of the activated B12 with a primary amine, here ethylene diamine, 
yields a carbamate linkage and amine functional handle (AdoCbl-Etd) to which fluorophores can 
be coupled. AdoCbl-Etd was then reacted with uronium (TSTU) activated TAMRA to yield 
coenzyme B12-TAMRA (AdoCbl-1, Scheme 1.8). Several other fluorophore modified coenzymes 
were made as well by reacting their N-hydroxy succinimidly ester (NHS) forms with AdoCbl-Etd 
to form coenzyme B12-Cy5 (AdoCbl-2), coenzyme B12-Atto 725 (AdoCbl-3), and coenzyme B12-
Dylight800 (AdoCbl-4). 
1.3.2. β-axial Functionalized Cobalamins 
The β-axial site provides another site for facile modification. In this study, β-(3)-
propylamineCbl (propylamineCbl) provided the Cbl precursor for fluorophore attachment at the 
β-axial site. To install the propylamine ligand, HO-Cbl was reduced by activated Zn0 in degassed 
MeOH (Scheme 1.7b).64,107  Upon addition of the Zn reductant, the Cbl solution undergoes a rapid 
color change from a red, Co+3 state to a blue, Co+1 state within 10 min. The Co+1 square planar 
Cbl, known as a super nucleophile, reacts with primary halide electrophiles to provide new and 
useful functional handles. After the indicative color change, 3-chloropropylamine was added and 
the solution quickly went from blue to orange signifying successful formation of the Co-C bond 
via SN2. The increased reduction potential of the new alkylCbl species assures the product resists 
reduction by Zn and the yields of alkylation are near quantitative. Finally, the NHS forms of several 
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fluorophores were reacted with propylamineCbl to yield Cbls β-axial functionalized with 
fluorophores that absorb throughout the red and near infrared spectrum: TAMRA (Cbl-1), acetyl 
(Cbl-2), SulfoCy5 (Cbl-3), Atto725 (Cbl-4), Dylight800 (Cbl-5), Alexa700 (Cbl-6) (Scheme 
1.8). 
1.3.3. Photolytic Rate Determinations 
The high Φ of alkylCbls produces rapid conversion to HO-Cbl when irradiated under 
aerobic conditions.87,88 As a consequence of the new -OH ligand’s electronics, the Cbl absorption 
spectra undergoes significant changes particularly within the UV at 350 nm (Figure 1.3). Since the 
ε at this wavelength has previously been determined for both species, the conversion from alkyCbl 
to HO-Cbl can be monitored using UV/Vis absorption spectroscopy.87,119 The concentration of 
HO-Cbl in solution during photolysis is then easily determined using equation 1.1. 
(Eq. 1.1)  [HO − Cbl (µM)] = [
ΔAbsorbance350 nm
(εHO−Cbl− εalkylCbl)
] ∗ 106 µM 
 Furthermore, researchers have determined the Φ for several alkylCbl species throughout 
their visible absorption.87 Therefore, since both the ε and Φ are known, we can estimate the Φ and 
efficiency (ε x Φ) of photolysis for our new AdoCbl-1 and Cbl-1 at 546 nm using equation 1.2 
and 1.3 which compares their rate constants of photolysis to the unmodified derivatives.120  
(Eq. 1.2)  
km
ku
= (εΦm/εΦu) 
(Eq. 1.3) Φ𝑚 =
[(
km
ku
)∗εΦu]
εm
 
Here, the subscript u designates the value corresponding to the unmodified Cbl and m the value of 
the fluorophore modified Cbl. We can determine the rate constants (k) from the slope of the first 
order rate plot (ln [HO-Cbl] vs. time) for each compounds’ photolysis. However, we can only 
apply these equations to our two green light absorbing derivatives because unmodified alkylCbls 
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remain impervious to photoexcitation in the red and NIR. Moreover, chemical actinometers 
responsive to NIR light are extremely limited and environmentally sensitive making Φ 
determination difficult for AdoCbl-2-4 and Cbl-3-6.121 Therefore, we have limited molecules at 
our disposal for comparison purposes. 
1.3.4 Rate and Quantum Yield Comparison  
 The photolysis of equimolar concentrations (10 µM) of AdoCbl and AdoCbl-1 were 
carried out using a Xe flash lamp equipped with a bandpass filter (546 ± 10 nm, < 15 mW/cm2). 
Of course, the strongly absorbing TAMRA antenna imparts a tenfold higher photon absorption to 
AdoCbl-1 (ε546~ 86,000 M-1cm-1) versus unmodified AdoCbl (ε546~ 8,100 M-1cm-1) (Table 1.1). 
One would expect that, if the fluorophore could contribute energy to the photolysis pathway, the 
greater photon harvesting of AdoCbl-1 should increase the propensity for photolysis. In this case, 
the increase in photons absorbed can be thought of as “adding additional reactants” to drive the 
photolysis process forward. 
 Indeed as Figure 1.4a and Table 1.1 demonstrate, the photolysis rate of AdoCbl-1 (km = 
0.89 ± .32 s-1) more than doubles when compared to AdoCbl (ku = 0.38 ± .04 s
-1). Using eq 1.3 
with the known ε (8,100 M-1cm-1) and Φ (30%) of AdoCbl, we can estimate the Φ of AdoCbl-1 
as 6.6 ± 2.4%. A fourfold drop in Φ seems drastic, but this arises from a sharp increase in the total 
photons being absorbed contributing to a larger denominator in the simplified Φ equation 
(molecules reacted / photons absorbed). When factoring in the ε to provide a photolytic efficiency 
(εΦ), we see that the photolysis rates’ ratio is recapitulated in the efficiency values for AdoCbl 
(2,430 M-1cm-1) and AdoCbl-1 (5,676 M-1cm-1). Likewise, when examining the photolysis of the 
β-axial acetylated Cbl-2 (ku = .57 ± .08 s-1, Φ = 30%) versus TAMRA modified Cbl-1 (km = .71 ± 
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0.17 s-1, Φ = 3.5 ± 0.8%), similar trends of rate enhancement and Φ was noted (Figure 1.4b, Table 
1.1). 
 These results reveal that fluorophores do enhance overall photolysis rate and efficiency in 
these systems through behaving as a light capturing antenna. Since fluorophore quenching was 
previously reported for fluorophore-Cbl conjugates103–107, it is not surprising that the fluorophore 
captures sufficient energy to excite the Cbl into a state on the pathway to homolytic bond scission. 
Although, one would expect if this sensitization occurred with near unit efficiency that the 
photolysis rate would increase much more than two fold, since TAMRA’s ε is an order of 
magnitude greater than unmodified the Cbls. This suggests that the excited state of the fluorophore 
and/or Cbl can still relax to the ground state via other processes, such as fluorescence, internal 
conversion, or radical recombination.82,100 
1.4. Cobalamin Sensitization into the Near Infrared 
 Due to observing the favorable relationship fluorophores induced on Cbl photolytic rates, 
I wanted to examine our initial premise that NIR sensitive fluorophores could induce Co-C scission 
upon direct excitation (Scheme 1.6). As mentioned above, I synthesized several Cbl-fluorophore 
conjugates that absorbed strongly in the NIR. First, I examined if energy interactions (quenching) 
occurred between the ligated photosystems, and what affects these interactions may have on 
photolytic behavior. As mentioned above, quenching is indicative of interactions between the two 
chromophores and can be used as a favorable marker of long wavelength energy interactions.  
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Figure 1.3. Absorption spectra comparison of an alkylCbl (solid) versus HO-Cbl photoproduct 
(dashed line). The strong transition at 350 nm (Δε350) allows for monitoring of the conversion to 
photoproducts with UV/Visible spectroscopy in tandem with Equation 1.1. 
 
Table 1.1. Apparent photolysis rate constant (kapp), Φ, ε, and efficiency (εΦ) estimates for 
Cbls photolyzed at 546 nm. 
Property 
(R) 
AdoCbl 
(unmodified)a 
AdoCbl-1 
(TAMRA) 
Cbl-1 
(TAMRA) 
Cbl-2 
(Acetyl)a 
kapp (s
-1
)
b 0.38 ± .04 0.89 ± 0.32 0.71 ± 0.17 0.57 ± 0.08 
ε (M
-1
cm
-1
) 8,100 86,000 86,000 8,100 
Φc 0.3 0.066 ± 0.024 .035 ± 0.08 0.3 
εΦ (M
-1
cm
-1
) 2,430 5,676 ± 2060 3,010 ± 688 2,430 
a. Φ and ε taken from ref. 87 b. calculated from the slope ln[CblOH] vs time plot c. 
calculated using equation 1.3. 
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Figure 1.4. Photolysis plots of a) AdoCbl (squares) and AdoCbl-1 (circles) b) Cbl-2 (squares) 
and Cbl-1 (circles). Both samples were 10 μM in water. The plot is represented as a HO-Cbl 
photoproduct increase versus time. The initial rate of the photolysis reaction was extrapolated from 
the slope of the linear portion of the plots (0 – 3 min). 
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1.4.1. Fluorescent Spectroscopy 
Quenching interactions between the fluorophore and Cbl complex were determined using 
fluorescent spectroscopy. Cbl samples (Cbl-1, (3-6), < 1 µM) were placed in a quartz cuvette and 
irradiated at several red and NIR wavelengths corresponding to each fluorophore’s λmax. Samples 
were placed in the sample holder with the irradiation gate shut to prevent premature photolysis 
before fluorescent counting. Several seconds after measuring was initiated, the irradiation gate was 
opened to expose the sample to excitation. The change in luminescence versus time was noted and 
quenching was measured as a % fold change by: 
(Eq. 1.4)  % ∆Fλ = (
Ffinal
Finitial
) ∗ 100% 
(Eq 1.5)  % photolysis =  %∆Fλ / %∆Fmax change 
The extent of photolysis (%, Eq. 1.5) for each conjugate at each of the irradiation 
wavelengths (546, 646, 700/727, and 777 nm) was determined using partial fold changes in the 
fluorophores’ fluorescence (% ΔFλ) after illumination at λ and then compared to the maximum 
fold increase achievable (%ΔFmax change). The irradiation time for a wavelength was set by the 
conjugate that completely photolyzed the fastest at that particular wavelength. For example, Cbl-
1 photocleaves within 5 min at 546 nm, so all other conjugate samples were irradiated with 546 
nm for this time period. Likewise, Cbl-3 photocleaves within 30 sec at 646 nm, so all conjugates 
were irradiated with 646 nm for this time. After irradiation at each wavelength for the given time, 
the partial fold change was determined as a percent of the initial fluorescence at the fluorophores 
λex/em and this value could then be divided by the predetermined maximal fold change for the 
conjugate to provide a “yield” of photocleavage at that wavelength. 
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1.4.2. Cobalamin-Fluorophore Quenching Interactions 
Previous work by Fedosov and Grissom indicated quenching interactions between several 
visible light sensitive fluorophores and Cbls.103,104,106,107 For example, fluorescein’s luminescence 
Φ decreased from 95% to 13% upon ligation to Cbls (~ sevenfold). As mentioned, fluorescent 
quenching shows an energy interaction between the two chromophores that allows for 
depopulation and suppression of the luminescent pathway from the fluorophore’s excited state. 
Indeed, Cbl-1 exhibits an increase in TAMRA fluorescence when irradiation within a fluorometer 
liberates the fluorophore due to photolysis (Figure 1.7a, Table 1.2). This result is unremarkable 
because the ground state absorption (300 – 600 nm) and emission spectra of TAMRA (580 nm) 
overlap. 
Yet, this spectral overlap does not exist in Cbl-3-6 and AdoCbl-2-4 as the absorption of 
these fluorophores lies energetically downhill from Cbls’ α/β absorption band (< 600 nm, Figure 
1.5-1.6). However, as the aforementioned work of Kemp indicates, it may be possible to sensitize 
Cbl photolysis with longer wavelength fluorophores.110 This interaction is easy to identify because 
it would result in quenching of the fluorophore excited state. Hopefully, these excited state 
interactions could lead to a photo-dissociative state in the Cbl. 
To examine this, I carried out fluorescence spectroscopy of Cbl-1,3-6 to examine the effect 
of Cbl on the ligated fluorophores’ luminescence. Cbl-3 exhibited significant quenching of 
SulfoCy5 fluorescence (~ 2.5 fold) and steady irradiation (646 nm) within the fluorometer 
provided a rapid increase in fluorescent intensity (Table 1.2, Figure 1.7b). This increasing 
fluorescence points to relief of the quenching interaction presumably through Co-C bond scission 
and diffusive separation of the two chromophores. Furthermore, liquid chromatography- mass 
spectrometry (LC-MS) characterization of the irradiated solution confirmed this assumption by 
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showing complete conversion of Cbl-3 to HO-Cbl-3 and an oxidized ligand (Scheme 1.9, Table 
1.4). These quenching interactions were not limited only to SulfoCy5. All the other fluorophores 
tested (Cbl-4-6) exhibited similar quenching and release interactions, but the extent of quenching 
tended to decrease with increasing fluorophore absorption wavelength (Figure 1.7-1.9, Table 1.2-
1.3). Furthermore, LC-MS analysis confirmed the successful photolysis of these compounds 
through identification of HO-Cbl-4-6 photoproducts (Table 1.4). 
 Furthermore, all conjugates exhibited wavelength selectivity in their extent of photolysis 
(Table 1.3). Comparing Figure 1.6 to Table 1.3, we see that where the ligated fluorophore absorbs 
most strongly, the Cbl conjugate undergoes complete homolysis in the given irradiation time. 
However when the conjugates are excited at wavelengths that they either did not or only weakly 
absorbed, no or incomplete photolysis was noted. For example, Cbl-3 undergoes complete Co-C 
homolysis within 1 min when irradiated at 646 nm, but undergoes poor photolysis at 546 nm within 
30 s; the time required to completely photolyze Cbl-1. Similarly, Cbl-5 photolyzes completely at 
its λmax (777 nm), partially at 727 and 546 nm, and fails to photolyze at 646 nm. Cbl-5’s photolysis 
behavior closely mirrors its absorption spectrum since it absorbs most strongly at 777 nm, minorly 
at 727 and 546 nm, and hardly at all at 646 nm. These results indicate that photolysis is tuned 
specifically to the excitation of the fluorophore. This selectivity provides a tunable motif to induce 
photolysis without significant cross talk between additional NIR photoresponsive (i.e. fluorescent 
imaging) agents provided the two don’t have similar, overlapping absorptions. Therefore, these 
results open the possibility of orthogonal Cbl photocleavage in a complex mixture using 
fluorophores with non-overlapping absorptions (Section 1.5). Such orthogonal activation provides 
a high degree of control in releasing multiple bioactive agents within a single system.  
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Figure 1.5. UV/Vis spectral overlay of β-axial ligated fluorophore Cbls. Samples were 4 µM in 
PBS and absorb throughout the red and NIR spectrum. 
 
 
Figure 1.6. Normalized absorption spectra of β-axial Cbl-fluorophore conjugates; Cbl-1 
(TAMRA, blue), Cbl-3 (SulfoCy5, green), Cbl-4 (Atto725, red), and Cbl-5 (Dylight800, dark 
red).  
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Scheme 1.9. Aerobic photolysis products of alkylCbls. Here, the possible oxidized and H 
abstraction products are shown in the form of aldehydes (usually a hydrate), peroxy species, or 
saturated carbons. LC-MS characterization of photolyzed Cbl solutions (20 µM) was used to 
identify the resulting species.  
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Figure 1.7. Photolysis plots of a) Cbl-1 and b) Cbl-3. Samples were 1 µM and photolysis is 
represented as a fluorescent increase (Cbl-1 - [546/580 nm], Cbl-3 – [646/660 nm]) in water. As 
the Co-C bond cleaves, the fluorophore quenching is relieved due to diffusive separation of the 
two chromophores. (n = 3) 
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Figure 1.8. Photolysis plots of a) Cbl-4 and b) Cbl-5. Samples were 1 µM and photolysis is 
represented as a fluorescent increase (Cbl-4 - [727/750 nm], Cbl-5 – [777/792 nm]) in water. As 
the Co-C bond cleaves, the fluorophore quenching is relieved due to diffusive separation of the 
two chromophores. (n = 3) 
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Figure 1.9. Photolysis plots of Cbl-6. Samples were 1 µM and photolysis is represented as a 
fluorescent increase (702/723 nm) in water. As the Co-C bond cleaves, the fluorophore quenching 
is relieved due to diffusive separation of the two chromophores. (n = 3) 
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Table 1.2. Fluorescent fold changes of Cbl-fluorophore conjugates by irradiation wavelength. 
Cbl λem/exa 
(nm) 
% Change in Fluorescence by Wavelengthc 
546 646 700/727b 777 
Cbl-1 546/580 720 ± 120 * * * 
Cbl-3 646/662 32 ± 51 245 ± 51 * * 
Cbl-4 727/752 257 ± 33 145 ± 21 415 ± 21 37 ± 21 
Cbl-5 777/794 6 ± 3 * 6 ± 3 28 ± 3 
Cbl-6 700/715 21 ± 1 18 ± 2 37 ± 1 * 
* No detectable increase a)Primary excitation band of the fluorophore conjugate b) Only Cbl-
6 was excited at 700 nm c) Determined from equation 1.4. 
 
Table 1.3. Percent photolysis of Cbl-fluorophore conjugates by irradiation wavelength. 
Cbl λmaxa 
(nm) 
% Photolysis by wavelength (nm)
c 
546 646 700/727b 777 
Cbl-1 546 100 ± 17 * * * 
Cbl-3 646 13 ± 21 100 ± 21 * * 
Cbl-4 727 62 ± 8 35 ± 5 100 ± 5 9 ± 5 
Cbl-5 777 22 ± 12 * 20 ± 12 100 ± 12 
Cbl-6 700 56 ± 3 48 ± 5 100 ± 3 * 
* No detectable increase a. Primary excitation band of the fluorophore conjugate b. only Cbl-
6 was excited at 700 nm c. determined from equation 1.5 
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Table 1.4. LC-MS characterization of Cbl-fluorophore photoproducts by wavelength 
Cbl
a Conditions (nm)b Retention Time 
(min) 
Observed Mass Designated 
Structure 
 
 
 
Cbl-1 
Dark 12.2 900.7 (M+2), 600.8 (M+3) Cbl-1 
 
 
546 
10.0 665.1 (M+2) HO-Cbl 
12.8 486.2 (M+) TAMRA-1 
13.1 504.2 (M+) TAMRA-2 
13.7 470.2 (M+) TAMRA-3 
 
 
 
Cbl-3 
Dark 11.6 1013.6 (M+2), 676.4 (M+3) Cbl-3 
 
 
646 
9.7 665.0 (M+2) HO-Cbl 
11.8 713.3 (M+) SulfoCy5-1 
12.0 730.2 (M+) SulfoyCy5-2 
12.4 696.3 (M+) SulfoCy5-3 
 
 
 
Cbl-4 
Dark 12.3 893.2 (M+2), 595.9 (M+3) Cbl-4 
 
 
730 
9.7 665.0 (M+2) HO-Cbl 
13.3 473.3 (M+) Atto725-1 
13.6 489.3 (M+) Atto725-2 
14.2 455.2 (M+) Atto725-3 
Cbl-5
c Dark 12.9 1139.7 (M+2), 760.4 (M+3) Cbl-5 
780 9.9 665.0 (M+2) HO-Cbl 
 
Cbl-6 
Dark 11.6 1179.9 (M+2), 787.0 (M+3) Cbl-6 
 
700 
9.794 665.0 (M+2) HO-Cbl 
10.581 1061.0 (M+), 531.3 (M+2) Alexa700-2 
a. Cobalamin solutions: 20 µM, 50 µL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min c. Dylight 
photoproduct absorbs outside the LC-MS UV/Vis detector (maximum 600 nm, Dylight 800 
λ
max
~777 nm) making only the cobalamin species visible 
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1.4.3. Coenzyme B12 Fluorophore Photolysis Products 
 Next, I determined if irradiation of fluorophores linked to cobalamin via the nucleotide 
loop could also induce NIR photolysis of the β-axial ligand. Since the fluorophore would remain 
attached to the cobalamin scaffold, I used LC-MS analysis to confirm successful conversion to 
photoproducts post irradiation. Under aerobic conditions, several oxidized adenosinyl products 
and HO-Cbl form (Scheme 1.10).88 Here, the oxidation process occurs via oxygen trapping of the 
resultant alkyl radical forming a peroxy species. This then decomposes into several products 
including aldehydes (hydrate), alcohols, or alkyl groups.90 The relative ratios of these products 
depends on the incubation time and further light irradiation. This suggests that the Cbl product 
may play a role in catalyzing the decomposition of the peroxy radical species. Nevertheless, my 
concern centered on the formation of at least some of these oxidized products, since this would 
imply that fluorophore based excitation still led to the homolytic dissociation pathway. 
 To examine this premise, I photolyzed solutions of AdoCbl and AdoCbl-(1-4) at each 
wavelength covered by the fluorophores to show selectivity (546, 646, 730, and 780 nm). Longer 
irradiation times were used in this study compared to the fluorometer studies to allow for a 
substantial and detectable amount of adenosine products. Samples were then analyzed for the 
photolysis products using LC-MS. Looking at Tables 1.5-1.9, a similar wavelength dependence 
emerges for AdoCbl-(1-4) conjugates as seen in the fluorescence quenching studies. Since 
photolysis times were longer, irradiation produced the expected, oxidized adenosine species 
wherever the AdoCbl-(1-4) absorbed. For example, AdoCbl-4 produced HO-Cbl-4 and ribose-
5’-aldehyde as the hydrate at 546, 730, and 780 nm, but remained intact under 646 nm irradiation 
(Table 1.9). Likewise, AdoCbl-2 produces 5’-peroxy adenosine and ribose-5’-aldehyde at 546 and 
646 nm, but remains intact at 730 and 780 nm where it fails to absorb (Table 1.7). These 
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encouraging results demonstrate that (1) fluorophore ligation to the nucleotide loop can still tune 
photolysis into the NIR, (2) oxidized products likely result from formation of an alkyl radical even 
at longer wavelengths, and (3) AdoCbl-(1-4) photolyze with the same wavelength selectivity seen 
in Cbl-(1-6). Affirmation of the second point will help in the development of useful photoactivated 
radical chemistry in Chapter 3.  
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Scheme 1.10. Aerobic photolysis products of AdoCbl-(1-4). Generally, alkylCbl photolysis 
results in oxidized ligand products. Here, the possible oxidized and H abstraction products from 
AdoCbl-(1-4) photolysis are shown in the form of aldehydes (usually a hydrate) or peroxy species. 
LC-MS characterization of photolyzed AdoCbl solutions (20 µM) and comparison to previous 
literature reports was used to identify the resulting species.88 
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Table 1.5. LC-MS characterization of AdoCbl photoproducts by wavelengths 
Photolysis 
Conditions (nm)
b 
Retention Time 
(min) 
Observed Mass Designated 
Structure 
Dark 10.4 790.4 (M+2), 527.4 (M+3) AdoCbl 
 
546 
2.6 284.1 (M+) Adenosine-1 
5.5 284.1 (M+) Adenosine-2 
9.6 664.9 (M+2) HO-Cbl 
646 10.4 790.4 (M+2), 527.4(M+3) AdoCbl 
730 10.5 790.4 (M+2), 527.4(M+3) AdoCbl 
780 10.4 790.4 (M+2), 527.4(M+3) AdoCbl 
a. AdoCbl solutions: 20 µM, 50 μL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min. 
 
Table 1.6. LC-MS characterization of AdoCbl-1 photoproducts by wavelength. 
Photolysis 
Conditions (nm)
b 
Retention Time 
(min) 
Observed Mass Designated 
Structure 
Dark 11.7 1039.9 (M+2), 520.4 (M+3) AdoCbl-1 
 
546 
2.5 284.1 (M+) Adenosine-1 
5.4 284.1 (M+) Adenosine-2 
11.6 914.3 (M+2), 609.8 (M+3) HO-Cbl-1 
646 11.7 1039.9 (M+2), 520.4 (M+3) AdoCbl-1 
730 11.7 1039.9 (M+2), 520.4 (M+3) AdoCbl-1 
780 11.7 1039.9 (M+2), 520.4 (M+3) AdoCbl-1 
a. AdoCbl-1 solutions: 20 µM, 50 µL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min. 
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Table 1.7. LC-MS characterization of AdoCbl-2 photoproducts by wavelength. 
Photolysis 
Conditions (nm)
b 
Retention Time 
(min) 
Observed Mass Designated 
Structure 
Dark 11.6 1152.7 (M+2), 768.8 (M+3) AdoCbl-2 
 
546 
2.5 284.1 (M+) Adenosine-1 
4.9 284.1 (M+) Adenosine-2 
11.4 1027.4 (M+2), 684.9 (M+3) HO-Cbl-2 
 
646 
2.5 284.1 (M+) Adenosine-1 
5.3 284.1 (M+) Adenosine-2 
11.5 1027.0 (M+2), 685.2 (M+3) HO-Cbl-2 
730 11.6 1152.5 (M+2), 768.8 (M+3) AdoCbl-2 
780 11.6 1152.7 (M+2), 768.8 (M+3) AdoCbl-2 
a. AdoCbl-2 solutions: 20 µM, 50 µL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min. 
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Table 1.8. LC-MS characterization of AdoCbl-3 photoproducts by wavelength 
Photolysis 
Conditions (nm)
b 
Retention Time 
(min) 
Observed Mass Designated 
Structure 
Dark 11.8 1032.3 (M+2), 688.5 (M+3) AdoCbl-3 
 
546 
2.4 284.1 (M+) Adenosine-1 
12.3 906.8 (M+2), 604.8 (M+3) HO-Cbl-3 
 
646 
2.6 284.1 (M+) Adenosine-1 
12.0 1032.3 (M+2), 688.5 (M+3) AdoCbl-3 
12.2 907.4 (M+2), 605.0 (M+3) HO-Cbl-3 
 
730 
2.4 284.1 (M+) Adenosine-1 
4.4 284.1 (M+) Adenosine-2 
12.3 906.7 (M+2), 604.8 (M+3) HO-Cbl-3 
780 11.9 1032.4 (M+2), 688.5 (M+3) AdoCbl-3 
a. AdoCbl-3 solutions: 20 µM, 50 µL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min. 
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Table 1.9. LC-MS characterization of AdoCbl-4 photoproducts by wavelength. 
Photolysis 
Conditions (nm)
b 
Retention Time 
(min) 
Observed Mass Designated 
Structure 
Dark 11.8 1279.6 (M+2), 853.3 (M+3) AdoCbl-4 
 
546 
2.4 284.1 (M+) Adenosine-1 
4.9 284.1 (M+) Adenosine-2 
12.5 1153.5 (M+2), 769.0 (M+3) HO-Cbl-4 
646 12.8 1279.0 (M+2), 853.0 (M+3) AdoCbl-4 
 
730 
2.4 284.0 (M+) Adenosine-1 
4.7 284.1 (M+) Adenosine-2 
12.6 1154.2 (M+2), 769.2 (M+3) HO-Cbl-4 
 
780 
2.1 284.0 (M+) Adenosine-1 
12.4 1154.2 (M+2), 769.2 (M+3) HO-Cbl-4 
a. AdoCbl-4 solutions: 20 µM, 50 µL water b. Photolysis source was Xe flash lamp equipped 
with band pass filters corresponding to the wavelength indicated (± 10 nm) for 20 min. 
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1.5. Orthogonal Photocleavage 
 The advantage of using photoactivating groups to study or treat complex biological systems 
lies in the ability to both spatially and temporally target the desired site of activation.2–4 However, 
the ability to excite one molecule selectively over another provides even greater dynamic control 
by allowing precise delivery of a series of bioactive agents or events.7 For example, a researcher 
may want to deliver an enzyme substrate with one wavelength to study it for a given time. Later, 
they could use an orthogonal wavelength of light to release an inhibitor to suppress activity on the 
substrate or pathway.8 
Scientists have demonstrated this concept using several photoactivated groups for the 
orthogonal release of small molecule agonsists11, proteins12, peptides8, nucleotides23, and 
neurotransmitters49. Unfortunately, current photoactivatable groups limits such systems to a 
maximum of two or three orthogonal agents, and even then, some unintended photocleavage of 
the non-targeted group still occurs. Both of these complications arise from the narrow spectral 
range at which groups like the ONBs and coumarin esters operate.11 However, the behavior seen 
in the Cbl-fluorophore conjugates may provide a solution, since they show wavelength selective 
behavior over a much broader range (> 150 nm) (Figure 1.5-1.9). Indeed, previous researchers 
within my lab already improved the spectral operating range of orthogonal release using Cbl’s 
normal MLCT absorption at ~ 560 nm in tandem with ONBs and coumarins.122 Therefore to 
culminate these initial investigations, I explored the feasibility of orthogonal activation of a single 
Cbl-fluorophore conjugate within a mixture of several. 
1.5.1. Sequential, Tetraorthogonal Photoactivation 
When comparing Figure 1.5 – 1.6 and Table 1.2-1.3., an inherent longer to shorter stepwise 
photolysis trend appears in the data. For example, Cbl-5 undergoes photolysis at 777 nm, but the 
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other conjugates remain unperturbed. When we move the irradiation to the shorter 730 nm, Cbl-4 
begins to rapidly photocleave, but not Cbl-3 or Cbl-2. Again, moving to 646 nm, we see that Cbl-
3 now cleaves but not Cbl-2. This tight longer to shorter wavelength control led to the question, 
could we selectively control one Cbl conjugate in a mixture of up to four? To date, no one else has 
demonstrated this degree of control since three photoresponsive groups were the most used 
previously.122,123 
To begin, I substituted Cbl-6 for Cbl-4 in this study. Cbl-4’s Atto725 undergoes slight 
photolysis at 777 nm and its primary absorption peak lies closer to Cbl-5 than Cbl-3. The 
Alexa700 fluorophore’s absorption (λmax – 702 nm) lies more evenly between Cbl-3 and Cbl-5 
which hopefully reduces possible excitation spillover that could induce premature photolysis. 
After synthesizing the new Cbl-6 conjugate (Scheme 1.7-1.8), mixtures of Cbl-1, Cbl-3, Cbl-6, 
and Cbl-5 were made with all four conjugates at equimolar concentrations. 
Irradiation of the samples occurred in the fluorometer sequentially from the longest to the 
shortest wavelength. Illumination at each wavelength lasted until the fluorescence of the target 
fluorophore stabilized. The monochromators were then adjusted to the next shorter wavelength 
and the target’s fluorescent fold change was again monitored until stabilization. We determined 
the extent of photolysis in the same way detailed in Section 1.4.1.  
Figure 1.10 demonstrates the success of this tetra-orthogonal approach by comparing the 
mole fraction of HO-Cbl produced versus irradiation wavelength. At 777 nm, only Cbl-5 shows 
a fold change comparable to photolysis of it alone, while the other three conjugates’ baseline 
fluorescence remained undisturbed. When the monochromator was shortened to 700 nm, Cbl-6 
photocleaves while Cbl-3 and Cbl-1 remain intact. Upon shortening the illumination to 646 nm, 
Cbl-3 produces its characteristic fluorescence change. Finally, 546 nm treatment cleaves Cbl-1.  
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These results demonstrate the possibility of releasing up to four bioactive agents in an 
orthogonal manner. However, since the irradiation sequence proceeds from the longer to shorter 
wavelength, scientists must carefully plan the sequence of release they wish to achieve. Thus, this 
could cause additional synthetic effort and complexity to shuffle the order of delivery, because one 
would have to re-ligate the bioactive agent onto a different Cbl-fluorophore conjugate to change 
its order of release. 
1.5.2. Non-sequential, Orthogonal Photoactivation 
 Due to these concerns, I wanted to demonstrate the use of Cbl-fluorophore conjugates for 
irradiation sequence independent release of at least two agents. Other researchers claim to have 
demonstrated orthogonal release in a sequence independent manner, but close examination of the 
literature shows that many reports induce at least partial photoactivation of the other, unintended 
optomolecule.7,8,11,23 This outcome is not unexpected, since the commonly employed ONBs and 
coumarin esters closely overlap in their absorption spectra. Conversely, examination of Cbl-3’s 
and Cbl-5’s spectra reveals two very distinct excitation maximums that do not overlap at all 
(Figure 1.11). Moreover, photolysis of Cbl-5 at Cbl-3’s λmax of 646 nm does not produce 
detectable photocleavage and vice versa for λmax – 777 nm. Therefore, I hoped to show that at least 
two Cbl-fluorophore conjugates can photoactivate independently of the illumination sequence 
while leaving the other conjugate intact. 
 After making mixtures of Cbl-3 and Cbl-5 at equimolar concentrations, I examined the 
luminescence changes and computed percent photolysis as outlined in Section 2.3.1. When first 
irradiating at the shorter 646 nm, only Cbl-3 produces a fluorescence change while Cbl-5 remains 
at baseline (Figure 1.12). Following this with 777 nm irradiation, Cbl-5 increases in fluorescence 
at a comparable level to the free conjugate to provide both photolyzed conjugates. Conversely with 
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777 nm irradiation first, only Cbl-5 photocleaves while Cbl-3 remains intact. Completing the cycle 
with 646 nm provides a photolyzed Cbl-3.  Based on the fold changes, the photolysis of both 
compounds behaved in a completely orthogonal fashion with no excitation spillover to the 
unintended conjugate. This superb level of control will be applied and demonstrated further in 
Chapter 3 for the orthogonal delivery of therapeutic agents.  
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Figure 1.10. Orthogonal photolysis of four Cbl conjugates in a mixture. Photolysis by wavelength 
is represented as the fraction photolyzed within a fluorometer of each conjugate (1 µM) is at a) 
777 nm, b) 700 nm, c) 646 nm, and d) 546 nm. Each conjugate photolyzes only at its wavelength 
of activation provided the irradiation sequence proceeds from the longest to shortest wavelength. 
This sequence works because the Cbl conjugates have non-overlapping excitations which prevents 
unintended photolysis. The mole fraction of photolyzed product was determined by comparison of 
the fluorescent fold change in the mixture versus photolysis of the free conjugate by itself (Eq 1.5).  
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Figure 1.11. Normalized absorption spectra of Cbl-fluorophore conjugates used in the 
biorthogonal photocleavage; Cbl-3 (SulfoCy5, green) and Cbl-5 (Dylight800, dark red). The non-
overlapping excitations provides a means to selectively target one over the other in a mixture 
simply by changing the exciting wavelength. 
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Figure 1.12. Bioorthogonal photolysis of Cbl-5 and Cbl-3. Through careful selection of the 
covalently linked fluorophores, orthogonal photolysis of Cbls can be achieved regardless of the 
irradiation order. Here, Cbl-5 (Dylight800, red) and Cbl-3 (SulfoCy5, green) were mixed (25 nM) 
and irradiated within a fluorimeter. The mole fraction of photolyzed product was determined by 
comparison of the fluorescent fold change in the mixture versus photolysis of the free conjugate 
by itself (Eq. 1.4 – 1.5). When 777 nm was used first, only Cbl-5 underwent photohomolysis. 
Conversely, Cbl-3 only responds when 646 nm irradiation is used. Completion of the irradiation 
sequence with the other wavelength furnishes the final photocleaved product.   
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1.6 Conclusion 
 Researchers have long studied the photochemistry of Cbl complexes. The alkylCbls 
perform useful chemical work as Co-C bond scission reactions to release the β-axial ligand in 
response to light as long as 600 nm. However, these reactions can occur at longer, tissue 
penetrating NIR wavelengths through attachment of fluorophores. The fluorophores serve as a 
light capturing antennae that harvests long wavelength light and transfers the captured energy to 
the metal complex inducing bond scission. However, the distinction should be made that 
photoinduced electron transfer from the excited fluorophore could also be responsible for the 
behavior seen in these derivatives. The Cbl-fluorophore interactions occur throughout the NIR in 
a tunable fashion by responding specifically to light at the fluorophores’ λexcitation. Due to this 
specificity and tunability, orthogonal activation of one Cbl-fluorophore conjugate is achievable in 
a mixture of up to four with sequential illumination (long to short) or a mixture of two in an 
irradiation sequence independent manner. Later chapters will discuss in detail the applications of 
this significant advancement for biomedical applications. 
1.6. Materials and Methods 
1.6.1. General 
Hydroxocobalamin hydrochloride (HO-Cbl) was purchased from MP Biomedicals. TAMRA was 
purchased from AnaSpec. SulfoCy5 succinimidyl ester was purchased from Lumiprobe. 
Dylight800 succinimidyl ester was purchased from Thermo Fisher Scientific. All other reagents 
were purchased from Sigma-Aldrich and used without prior purification. The 546 ± 10 nm 
bandpass filter was purchased from Newport.  The 646 ± 10, 700 ± 10, 730 ± 10, and 780 ± 10 nm 
bandpass filters were purchased from Cheshire Optical. 
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1.6.2. Synthesis 
Purification: Unless otherwise noted, all Cbl conjugates were purified via reverse phase (C18) flash 
and HPLC chromatography using a binary solvent system (A:B, A- H2O w/ .1% TFA, B- CH3CN 
w/ .1% TFA). The initial A:B ratio was held at 97:3 for 5 min before increasing linearly to a ratio 
of 1:9 over 40 min. The ratio was then held at 3:97 for 10 min. Product elution was detected by 
UV/Vis monitoring at 350 nm and confirmed by LC-MS. The solvent was removed via 
lyophilization. 
 
Synthesis of β-(3)-propylamine cobalamin (propylamineCbl): β-(3)-propylamineCbl was prepared 
from HO-Cbl and 3-chloropropylamine hydrochloride according to a literature procedure.107 
Orange solid; 82% ESI MS [M + H+]+ calcd. for C65H98N14O14PCo: m/z = 1388.6, found 1388.7; 
[M + 2H+]+2 calcd. for C65H99N14O14PCo: m/z = 694.8, found 694.5 
 
Synthesis of Cobalamin-TAMRA Conjugate (Cbl-1): Cbl-1 was prepared from propylamineCbl 
and 5-carboxytetramethylrhodamine (TAMRA) according to a literature procedure.107 Red solid, 
82%; ESI MS [M+ + H+]+2 calcd. for C90H118N16O18PCo: m/z = 900.4, found 900.5 
 
Synthesis of β-(3)-acetamidopropyl cobalamin (Cbl-2): Acetic acid (0.0022 g, 38 μmol), 
N,N,N′,N′-tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate (TSTU, 0.0242 g, 80 μmol), 
and DIPEA (0.0234 g, 181 μmol), were mixed for 1 h in a 2:2:1 dimethylformamide:dioxane:water 
solution (250 μL). propylamineCbl (0.0052 g, 3.7 μmol) was added and the reaction was mixed 
for 18 h. Orange solid (0.0039 g, 73%); ESI MS [M + 2H+]+2 calcd. for C67H100N14O15PCo: m/z = 
715.3, found 715.5. 
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General synthesis and characterization of cobalamin-fluorophore conjugates (Cbl-3, Cbl-4, Cbl-
5, and Cbl-6). The N-hydroxysuccinimidyl ester of a fluorophore (1 eq.), propylamineCbl (1.5 
eq.), and diisopropylethylamine (6 eq.) were mixed in dimethylformamide for 18 h. The desired 
compound was purified by HPLC (semi preparative C-18 column). 
 
Cobalamin-SulfoCy5 Conjugate (Cbl-3): blue solid, 89%; ESI MS [M-1 +H2O, + 2H
+]+2 calcd. for 
C96H133N16O22PS2Co: m/z = 1013.4, found 1013.6 
 
Cobalamin-Atto725 Conjugate (Cbl-4): blue solid, 66%; ESI MS estimated (propriety structure 
and mass) for [M]+2: m/z = 892.9, found 893.2; estimated for [M]+3: m/z = 595.3, found 595.9. 
 
Cobalamin-Dylight800 Conjugate (Cbl-5): blue solid, 92%; ESI MS [M-2 + 4 H+]+2 calcd. for 
C110H148CoN16O25PS3: m/z = 1140.0, found 1139.8, [M
-2 + 5 H+]+3 calcd. for 
C110H149CoN16O25PS3: m/z = 760.3, found 760.4. 
 
Cobalamin-Alexa700 Conjugate (Cbl-6): blue solid, 72%, ESI MS estimated (propriety structure, 
counter ions, and mass) for [M]+2: m/z = 1179.9, for [M]+3: m/z = 787.0. 
 
Synthesis of coenzyme B12-ethylenediamine conjugate (AdoCbl-Etd): Coenzyme B12 (AdoCbl, 
0.0209 g, 13 μmol) and 1,1΄-carbonyldi-(1,2,4-triazole) (CDT, 0.0142 g, 87 μmol) were added to 
an oven-dried round bottom flask. The vessel was purged with Ar. Dry dimethylformamide (0.2 
mL) was added to the flask and the mixture was stirred at room temperature for 1 h. 
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Ethylenediamine (0.0270 g, 450 μmol) was added to the reaction mixture and stirring continued 
for another 18 h. The desired compound was purified by HPLC and removal of solvent by 
lyophilization afforded an orange solid (0.0189 g, 86%); ESI MS [M + 2H+]+2 calcd. for 
C75H108N20O18PCo: m/z = 833.4, found 833.4; [M + 3H
+]+3 calcd. for C75H109N20O18PCo: m/z = 
555.9, found 556.2. 
 
Synthesis of coenzyme B12-TAMRA conjugate (AdoCbl-1): N,N,N′,N′-Tetramethyl-O-(N-
succinimidyl)uranium tetrafluoroborate (TSTU, 0.0139 g, 46 μmol), TAMRA (0.0127 g, 30 μmol) 
and DIPEA (0.0230 g, 178 μmol), were mixed for 2 h in a 2:2:1 dimethylformamide:dioxane:water 
solution (250 μL). AdoCbl-Etd (0.0039 g, 2.3 μmol) was added and the reaction was mixed for 
18 h. The desired compound was purified by HPLC and lyophilization afforded a red solid (0.0026 
g, 53%); ESI MS [M+ + H+]+2 calcd. for C100H128CoN22O22P: m/z = 1039.9, found 1039.8; [M
+ + 
2H+]+3 calcd. for C100H129CoN22O22P: m/z = 693.3, found 693.6; [M
+ + 3H+]+4 calcd. for 
C100H130CoN22O22P ::m/z =  520.5, found 520.5. 
 
General synthesis of coenzyme B12-fluorophore conjugates (AdoCbl-2, AdoCbl-3, and AdoCbl-4). 
The N-hydroxysuccinimidyl ester of a fluorophore (1 eq.), AdoCbl-Etd (1.5 eq.), and 
diisopropylethylamine (6 eq.) were mixed in dimethylformamide for 18 hrs. The desired 
compound was purified by HPLC (semi preparative C-18 column) and removal of solvent by 
lyophilization afforded a solid. 
 
Coenzyme B12-SulfoCy5 Conjugate (AdoCbl-2): blue solid, 87%, ESI MS [M
-1 + H2O] calcd. for 
C107H143N22O26PS2Co: m/z = 1153.4, found 1152.7;  
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Coenzyme B12-Atto725 Conjugate (AdoCbl-3): blue solid, 69%, ESI MS estimated for 
C75H106N20O18PCo-Atto725 [M
+ + H+]: m/z = 1032.0, found 1032.3; estimated for (M+ + 2 H+): 
m/z = 688.6, found 688.5. Note: The formula and exact mass of Atto725 carboxylic acid have not 
been reported but is estimated for 413 with a +1 charge. 
 
Coenzyme B12-Dylight800 Conjugate (AdoCbl-4): blue solid, 90%, ESI MS [M
-2 + 4H+]+2 calcd. 
for C120H158N22O29PS3Co: m/z = 1279.0, found 1279.6; [M
-2 + 5 H+]+3 calcd. for 
C120H159N22O29PS3Co: m/z = 853.0, found 853.2.  
 
1.6.3. Photoproduct Analysis of Cbl-(1-6), AdoCbl, and AdoCbl-(1-4). 
Photolysis of Cbl-fluorophore conjugates (20 µM, 200 µL) was performed using an Oriel Xe flash 
lamp (800 mJ, 62 Hz) with selective bandpass filters (546 ± 10, 646 ± 10, 700 ± 10, 730 ± 10, and 
780 ± 10 nm). Photolyzed samples were analyzed in positive ion mode by LC-MS using a linear 
gradient binary solvent system (solvent A: 0.1% formic acid/H2O; solvent B: 0.1% formic 
acid/CH3CN) with a ratio of A:B that varied from 97:3 (0 - 5 min) to 3:97 (5 - 18 min). Product 
elution was detected at 265 nm for AdoCbl-(1-4) to identify the adenosine products and these ions 
were compared to previous literature reports on the photolysis of AdoCbl.88 For Cbl-(1-6), both 
350 nm and 600 nm wavelengths were used for detection of HO-Cbl and fluorophore products, 
respectively.  
1.6.4. Determination of fluorescent increases of Cbl-1 and Cbl-(3–6) 
Maximum fold change at λmax. Fluorescence readings of Cbl-fluorophore conjugate(s) solutions 
were observed using a PTI Model 710 LPS-220 after tuning the instrument to the appropriate 
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photolytic wavelength. Cbl samples (1 µM, 150 µL H2O) in a quartz cuvette were placed in the 
sample chamber with the irradiation gates closed. Data recording was initiated 10 s before the 
irradiation gate was opened to prevent premature photolysis. The excitatory light of the 
fluorometer was used as the photolysis source. The fluorescent increase and fold change was 
calculated as the average (n = 3) ratio of final fluorescent counts divided by the counts 1 s after 
gate opening. Leveling of the fluorescent curve was used to indicate complete photolysis and 
confirmed by LC-MS analysis of the samples. 
 
Percent photolysis at non-maximal λ. The extent of photolysis for each β-axial ligated fluorophore 
at all wavelengths studied (546, 646, 727, and 777 nm) was determined using fluorescent fold 
changes collected with a PTI Mode 710 LPS-220 fluorometer. Samples (1 µM, 150 µL) in a quartz 
cuvette were scanned at their λex/em and the irradiation gates quickly shut afterward to provide a 
baseline fluorescence (Finitial) before photolysis. The fluorometer was then tuned to λ of interest 
and the gates were opened. Irradiation time varied by wavelength and was set by the fastest 
photolyzing Cbl conjugate at that wavelength. For example, Cbl-3 (646 nm) photolyzes 
completely within 30 s so all other samples were irradiated at 646 nm for this time. After 
photolysis, the conjugate’s fluorescence (Ffinal) was again scanned at its primary λex/em. By dividing 
Ffinal by Finitial, a fold change by wavelength was computed (Δ Fλ) (Eq.1.4). The percent photolysis 
at each wavelength could then be calculated using the maximal fluorescent increase (Δ Fmax) 
produced at each conjugate’s maximal absorption band (Eq. 1.5): 
(Eq. 1.4)  % ∆F𝜆 = (
Ffinal
Finitial
) ∗ 100 % 
(Eq 1.5)  % photolysis =  %∆Fλ / %∆Fmax change 
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Tetraorthogonal photolysis. Mixtures of Cbl-1, Cbl-3, Cbl-5, and Cbl-6 (25 nM, 150 µL H2O) 
were placed in the fluorometer and each conjugate was photolyzed to completion at their λmax to 
determine the maximum fluorescent fold change (Δ Fmax) within the mixture. This Δ Fmax value 
was set as 100% photolysis within the solution. New mixtures were then irradiated going from 
the longest (777 nm) to the shortest wavelength (546 nm) and the fluorescent fold change was 
recorded (Δ Forthogonal). The ratio of these two values were recorded to determine the mole 
fraction of photolysis occurring at each λ. Successful orthogonality at each wavelength was 
demonstrated by a ratio approaching 1 (> 0.95). 
 
Biorthogonal Photolysis. The above procedure (tetraorthogonal photolysis) was repeated using 
mixtures of Cbl-3 and Cbl-5 (250 nM, 150 µL DMF), but the irradiation sequence in which 
wavelength (646 or 777 nm) was used first for irradiation. The second wavelength would then 
complete the irradiation sequence (646 → 777 nm or 777 → 646 nm). The fraction of photolysis 
was computed the same way as above.  
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CHAPTER TWO: COBALAMINS AS DRUG DELIVERY AGENTS1 
Chapter Abstract 
Drug delivery systems that can be targeted externally to release therapeutics within a 
disease site are intriguing, since they provide excellent spatial and temporal control of drug 
delivery. Light presents an ideal modulator but the current light activated groups limit the type of 
deliverable therapies and fail to respond to light within tissue’s optical window for deep tissue 
treatment. In this chapter, I will detail my efforts to develop alkylCbls as drug delivery scaffolds 
that respond to tissue penetrating light. These new photo-therapeutics can respond to light 
throughout the NIR to release a range of chemotherapeutics. Moreover, I will discuss the 
adaptation of these systems into natural erythrocyte carriers that protect and serve as drug 
reservoirs until light stimulation induces release. 
2.1. Drug Delivery Systems 
The potency of a new molecular therapy constitutes only one part of a viable treatment 
puzzle. Often, newly discovered treatments exhibit poor pharmacokinetic profiles due to limited 
in vivo solubility and short circulation half-lives.1,2 Throughout the past four decades, the 
engineering of drug delivery systems (DDSs) has sought to greatly improve the pharmacokinetic 
profile and treatment viability of new therapeutics.3–5 Research has centered on several 
                                                          
1Some figures reproduced with permission from 1Shell, T. A.; Shell, J. R.; Rodgers, Z. L.; 
Lawrence, D. S. Tunable Visible and Near-IR Photoactivation of Light-Responsive Compounds 
Using Fluorophores as Light Capturing Antennas. Angew. Chemie 2014, 126, 894–897. 2Smith, 
W. J.; Oien, N. P.; Hughes, R. M.; Marvin, C. M.; Rodgers, Z. L.; Lee, J.; Lawrence, D. S. Cell-
Mediated Assembly of Phototherapeutics. Angew. Chemie - Int. Ed. 2014, 53, 10945–10948. © 
2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
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approaches, but nanoparticle encapsulation1,2 and bioconjugation6 are the most common. In 1995, 
these efforts were rewarded with the approval of Doxil (a PEGylated liposome) by the FDA for 
the delivery of doxorubicin 7 Since that time, dozens of DDSs varying in form and application 
have been approved for the treatment of several diseases ranging from cancer8 to macular 
degeneration9. 
Without a doubt, research on new delivery strategies has advanced the ways in which 
doctors can treat diseases. The ability to program DDSs for specific release rates in vivo was 
significant. However, the early and simple DDSs behaved non-specifically, and, as a result, could 
deliver their payloads unintentionally to off target sites like the liver, kidneys and spleen due to 
the body’s clearance mechanisms.2 Not only does this limit the effective dose at the desired site, 
but also leads to unintended side effects in healthy tissues. Indeed, Dox exhibits strong cardiotoxic 
side effects that ultimately limits the lifetime dose a patient may receive to < 550 mg/m2, and 
liposomal formulations of the drug are known to leech the treatment off-target.7 Therefore, as DDS 
technology advanced, the desire to overcome non-specific delivery spurred the development of 
systems capable of “smart” or targeted delivery.10–14 
2.1.1. Stimuli Responsive Delivery Strategies 
 Ideally, DDSs should only accumulate or release their payload in a diseased site. This 
increases the effective dose where needed while limiting overall patient dosage and collateral 
damage. New complexity in DDS engineering allowed for the development of “targeted” systems 
that improve accumulation within a disease site.15–17 The first targeted systems involved finely 
tailoring DDS properties, such as size and charge, to exploit tumors’ leaky vasculature via the 
enhanced permeation and retention effect.18,19 Later targeting iterations used conjugation of 
ligands, such as antibodies20 and folate21, specific to the targeting of markers present within a 
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diseased site. However, translating these systems into the clinic can encounter complications. 
Specifically, disease markers’ ubiquity and density variability within other tissues can cause 
undesired targeting of healthy tissue.22,23 Moreover, diseases like cancer can have phenotypes that 
not only vary from patient to patient but also from cell to cell making marker identification 
difficult.24 
Due to these complications, interest in stimuli responsive release for tighter control of drug 
delivery has grown.12,14,25 With recent advancements in polymer, nanoparticle, and bioconjugation 
chemistry, researchers have ingeniously adapted stimuli sensitive mechanisms for the actuated 
release of chemotherapies26, proteins27, peptides28, and nucleic acids29. Stimuli may be delineated 
into two main classes based on the potentiation signal. Type one refer to endogenous biological 
stimuli, such as differences in pH30, hypoxia31, redox potentials32, blood sugar33, and enzymatic 
activity34,35, that actuate release from condition sensitive moieties. However, type one chemistries 
can suffer similar drawbacks as targeting strategies, since some stimuli also reside in off-target 
sites.  
Due to this, externally applied stimuli provide an attractive, alternative option, because 
clinicians can aim the source directly at a desired site. As a result, electromagnetic radiation36,37 
(visible, infrared, radio, etc.), magnetic fields38,39, and ultrasound40 provide excellent actuators, 
since they penetrate tissue deeply and innocuously. For example, magnetite nanoparticles respond 
to weak, alternating magnetic fields with rotational movement. This rotational momentum can 
translate into heat for thermal ablation or drug release. Type two delivery systems have been well 
accepted (ThermoDox®, Visudyne®, NBTXIV, and NanoTherm®) and further developments 
emerge rapidly.12 
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2.1.2. Light Responsive Delivery Systems 
 Light responsive DDSs have received considerable attention for several reasons.30,41–43 
First, clinicians or even patients can target light in a spatiotemporal manner. The temporal aspect 
of light irradiation also allows for the suppression of drug release by simply stopping irradiation, 
so dosing can be tuned proportionally to the irradiation intensity and time. Second, longer 
wavelength light (> 300 nm) does not produce significant tissue damage during transmission. 
Third, cheap irradiation sources, such as fiber optics and light emitting diodes (LEDs), exist at a 
variety of wavelengths for rapid integration into the clinic.44,45 Finally, light allows for orthogonal 
communication with several compounds in the same area by using differences in their activating 
wavelengths.46–48 Orthogonal communication provides the ability to synergistically dose an area 
with two therapies in a particular order or release a compound while simultaneously probing 
cellular response at another wavelength with a theranostic sensor. 
 To this end, chemists have developed a host of ways to deliver active therapeutics in 
response to light. Light can induce drug delivery via photo-induced isomerizations of 
azobenzenes49,50, photoinduced unraveling of polymers42,51, thermal ablations with plasmon 
resonating gold nanorods13,52,53, and reactive oxygen species generation from photosensitizers54,55. 
The broad applicability of light induced drug delivery has allowed the adaptation of light 
controlled delivery to a diverse range of carrier systems, biological environments, and treatments. 
Bond scission reactions involving a prodrug approach or release from a nanoparticle are quite 
common. For example, ONBs provide UV cleavable tethers to release therapies from nanoparticles 
and polymers, including peptides like insulin and small molecules like camptothecin.37,53,56,57 
Several other photo-activated groups can provide the same photo-cleaving action, but all suffer 
from one major disadvantage which prevents their translation into clinically viable DDSs.  
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As detailed in Chapter One, endogenous, biological chromophores prevent deep tissue 
activation of these molecules, since hemoglobin and melanin absorb most of the necessary 
activating light.58,59 For example, ONBs require ~365 nm light for photocleavage, but this 
wavelength can only penetrate dermal tissue to a depth of three millimeters.60 This limitation has 
relegated light sensitive DDS to in vitro proof of concepts or superficial delivery at the skin.12 Due 
to this, researchers have devised two-photon61 or upconverting62 strategies that circumvent this 
problem by using penetrating, NIR light to activate UV sensitive moieties. However, these systems 
are inefficient and, in the case of upconverting nanoparticles, require costly and toxic lanthanide 
dopants.63 Both of these NIR strategies require further development before their broad application. 
The problems associated with the limited photochemical toolbox and upconversion has 
driven the investigation of single photon, NIR responsive agents. Thus far, these efforts remain 
largely unrewarded with only a few examples of new photoresponsive agents, such as red shifted 
azobenzenes50 and meso-cyanine dyes64,65. Furthermore, these new compounds have limited 
payload diversity, poor Φ of photolysis (< 1%), and unwanted side reactions, such as thermal 
isomerization in azobenzenes or reactive oxygen generation in cyanine dyes. Consequently, photo-
activated DDSs require a photoresponsive moiety that responds to NIR irradiation with high Φ and 
accommodates a range of therapies. 
2.2. Cobalamin Endosomal Sequestration 
 As detailed in Chapter One, the Cbl scaffold can respond to NIR light when ligated to a 
NIR absorbing fluorophore.66,67 Cbls can also tolerate a variety of payloads ligated to the β-axial 
position.68 The dual benefit of the Cbl scaffold can be exploited for the purposes of drug delivery. 
Ideally, a therapeutic payload will be ligated to the β-axial position and a NIR absorbing 
fluorophore at the ribose 5’-OH for close association of the energy capturing antenna (Scheme 
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2.1). However, Section 2.3.1 will discuss how the latter fluorophore ligation can be relaxed using 
self-assembled photosystems on cellular membranes.69  
Normally, functionalities like ONBs and coumarins inactivate prodrugs through 
modification of an essential residue needed for activity.70–72 A tethering strategy to a nanoparticle 
or protein carrier may also inactivate a therapy by sequestration away from the site of action.37,53,57 
However, alkylCbls provide only one releasable ligand type in the form an alkyl radical, so we 
had to devise an appropriate strategy for the inactivation of drugs.73,74 To this end, we used Cbl’s 
cellular metabolism and membrane impermeability to inactivate cell permeable chemotherapies. 
 After entering the body, a series of proteins shuttle vitamin B12 within the saliva, gut, 
intestinal endothelium, and blood stream.75,76 Upon reaching a cell expressing the transcobalmin 
II receptor, the cell endocytoses and retains the vitamin within endosomes for processing. Rapidly 
dividing cells, such as in cancer, endocytose higher amounts of Cbls, leading to the use of Vitamin 
B12 as a targeting moiety in nanoparticle systems before.
68,77,78 Hence, we were intrigued by Cbl’s 
endosomal retention as a means to control the delivery of normally membrane permeable drugs. 
For instance, Dox easily traverses the lipid bilayer to intercalate DNA within the nucleus resulting 
in cell death (Scheme 2.2).7 However, Cbl induced retention within endosomes would prevent this 
from occurring until light activation could liberate the drug. 
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Scheme 2.1. Basic structure for Cbl photo-therapeutics. A therapeutic payload can be released 
from the Cbl scaffold through attachment to the photolabile β-axial bond. Green light irradiation 
or NIR excitement of a nearby fluorophore (dye) induces the scission of the Co-C bond to release 
the cargo.  
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Scheme 2.2. Strategy for the endosomal delivery of chemotherapies. Cells endocytose Cbls and 
retain it within endosomes for processing. This membrane impermeabilization provides a strategy 
for the light controlled delivery of cell permeable chemotherapeutics. For example, Dox freely 
diffuses across cell membranes to bind DNA within the nucleus. However in our approach, Dox 
ligated to the β-axial position of a Cbl anchor would remain endosomal. Upon exposure to light, 
the drug is liberated and can escape from endosomes to its site of action. In the case of Dox, this 
strategy would prevent cytotoxicity until exposure to light.  
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2.2.1. Cobalamin Drug Conjugates and Synthesis 
 Our initial objective was to inactivate drugs via endosomal sequestration. Based on this 
objective, the chosen chemotherapy payloads must freely diffuse into cells upon light liberation. 
For the initial study, we chose three compounds with defined sites of action and cell membrane 
permeability: BODIPY® 650 (Bod), adenosine-3’,5’-cyclic monophosphate (cAMP), and Dox 
(Scheme 2.3). To begin, I constructed Cbl scaffolds using the CoIII reduction/alkylation procedure 
discussed in Chapter One (Scheme 2.4).66,79 Treatment of the CoI ion with 3-chloropropylamine 
or 4-bromobutyric acid provided propylamineCbl or butyrateCbl, respectively, for further 
ligations. From here, the NHS ester of Bod was coupled directly to the propylamineCbl yielding 
Cbl-Bod (Scheme 2.5), and Dox could be coupled after HBTU activation of butyrateCbl to afford 
Cbl-Dox (Scheme 2.6).  Before coupling to Cbl, a modified derivative of cAMP was synthesized 
by using neat reaction of ethylene diamine with 8-bromo-cAMP under microwave conditions to 
provide Etd-cAMP (Scheme 2.7a). After activation of butyrateCbl with TSTU, treatment with 
Etd-cAMP afforded the Cbl-cAMP construct (Scheme 2.7b). The Cbl-cAMP and Cbl-Dox for 
the initial study did not contain any fluorophores ligated at the ribose-5’-OH like the example 
shown in Scheme 2.1, so they do not activate at wavelengths longer than 600 nm. However, Cbl-
Bod provided a longer wavelength construct, because Bod is a dual fluorophore/photosensitizer 
absorbing within the near infrared (λmax - 646 nm).  
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Scheme 2.3. Cbl therapeutics for endosomal encapsulation. Dox behaves as a topoisomerase 
inhibitor within the nucleus and a frontline chemotherapy in several cancers. BODIPY dyes 
photosensitize the production of singlet oxygen and have been employed for photodynamic 
therapy after localization into organelle membranes. cAMP is a ubiquitous signaling molecule 
used for the activation of protein kinases. Both Cbl-Dox and Cbl-cAMP only respond to 
wavelengths shorter than 600 nm, but Cbl-Bod absorbs within tissues optical window at 646 nm.   
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Scheme 2.4. Synthesis of a) butyrateCbl and b) propylamineCbl from CNCbl.  
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Scheme 2.5. Synthesis of BODIPY®650 Cbl (Cbl-Bod) from propylamineCbl. 
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Scheme 2.6. Synthesis of doxorubicin Cbl (Cbl-Dox) from butyrateCbl.  
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Scheme 2.7. Synthesis of a) ethylenediamine-cAMP (Etd-cAMP) from 8-bromo cAMP and b) 
cAMP Cbl (Cbl-cAMP) from butyrateCbl.  
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2.2.2. Cobalamin uptake and payload release within cells 
 Bod provided a long wavelength releasable chemotherapy in the initial study of endosomal 
sequestration. Bod belongs to the class of boron dipyrromethene photosensitizers that have been 
investigated for generation of cytotoxic reactive oxygen species in cancers like melanoma.80,81 
Like other red and NIR fluorophores, Cbl significantly quenches the luminescence of Bod upon 
ligation to the vitamin (~2.3 fold, Figure 2.1a). Under irradiation (650 nm), the fluorescence 
rapidly recovers from Co-C bond scission providing diffusional quenching relief. The potential 
gradients of intracellular organelles strongly draws these dyes to localize within the membranes of 
the mitochondria and endoplasmic reticulum (ER) where they damage sensitive structures upon 
light stimulation. Therefore, successful demonstration of the endosomal entrapment strategy 
should show Bod fluorescence migration from endosomes to the mitochondrial network upon 
photolysis.   
 HeLa cells were dosed with Cbl-Bod, and Bod localization was monitored using 
fluorescence microscopy after cells were left in the dark or photolyzed (Figure 2.2, λex - 650 nm). 
Rhodamine-B dextran and MitoTracker Green markers were used to distinguish between Bod 
localization within either the endosomes or mitochondria, respectively. In the dark, the Bod 
fluorescence distributed in a punctate pattern that significantly overlapped with rhodamine-B 
fluorescence (Pearson’s coefficient = 0.89). This indicated the dye had remained trapped within 
the endosomes due to Cbl ligation. However, subsequent irradiation resulted in a large increase of 
Bod fluorescence indicative of relief from the Cbl induced quenching (Figure 2.1). Moreover, the 
Bod migrated and co-localized with the MitoTracker Green (Figure 2.2, Pearson’s coefficient = 
0.81). These results indicated that endosomal sequestration with Cbls appears a viable strategy for 
the inactivation of cell permeable therapeutics prior to light activation. 
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 Next, we investigated this strategy for the light mediated activation of the other small 
molecule constructs. First, cAMP induces the activation of signaling pathways responsible for a 
host of cellular responses.82–84 For this study, we chose to use REF52 cells for identification of 
protein kinase A (PKA) activation upon release of cAMP. This cell line undergoes drastic changes 
within its cytoskeleton upon PKA activation.82,83 For instance, treatment of REF52s with a freely 
cell permeable cAMP (CPT-cAMP) derivative induces stress fiber depolymerization and cell 
rounding (Figure 2.3).  Likewise, cells in the presence of Cbl-cAMP show the same effect with 
fewer stress fibers and greater cell rounding after green light irradiation (520 nm, Figure 2.4d). In 
contrast, cells incubated with Cbl-cAMP but left in the dark showed no perturbations of the 
cytoskeletal network (Figure 2.4c). Again, these results validate the hypothesis that Cbl ligation 
allows for light selective delivery of small molecules by inhibiting their cell permeability. 
 Finally, we investigated Cbl-Dox for light controlled cytotoxicity. Normally, the 
anthracycline Dox permeates cell membranes easily and intercalates DNA to inhibit topoisomerase 
II resulting in cell death.7 Due to this, Dox is a frontline chemotherapy for several cancers but 
comes with severe side effects, especially cardiotoxicity, from its non-specific behavior.85,86 As a 
result, development of DDSs to selectively deliver this important chemotherapy have greatly 
increased in variety and publications. 
 We hoped to demonstrate the efficacy of Cbl-Dox endosomal sequestration in limiting 
cytotoxicity until activated with green light (Scheme 2.2). HeLa cells were treated with Cbl-Dox, 
photolyzed with green light (530 nm) for varying times, and then analyzed for cytotoxicity after 
24 h using a tetrazolium cell viability assay. In the dark, Cbl-Dox elicited no significant viability 
reduction when compared to the control (Figure 2.4). Upon exposure, an irradiation time 
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dependent response arises with longer illuminations inducing greater cell death. Furthermore, the 
cytotoxicity of irradiated Cbl-Dox reaches comparable levels after 30 s to free Dox (35 – 40%).  
 These initial studies demonstrated that the membrane impermeability of Cbl can be used 
for the successful inactivation of small molecules by binding them to Cbl.75–77 Light irradiation 
can then be used to liberate the cell permeable chemotherapies. Additionally, the Cbl-Dox study 
shows varying illumination provides remotely controlled dosing with longer irradiations inducing 
a greater cytotoxicity. The endosomal uptake of these Cbl-drug conjugates provides a means to 
deliver chemotherapies in a targeted manner to avoid potential off-target cytotoxicity.  
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Figure 2.1. Photolysis induced fluorescent increase of Bod a) in the fluorometer (1 μM, λex/em – 
650/684 nm) or b,c) HeLa cells. Cbl-Bod (500 nM) was loaded into HeLa cells by co-incubation 
and then photolyzed by imaging with an Olympus IX-81 widefield microscope. Each frame of c) 
represents 5 min.  
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Figure 2.2. Photolysis (650 nm) induced translocation of Bod in HeLa cells. a) Cbl-Bod (500 nM) 
before photolysis. b) Rhodamine B-dextran endosomal marker. c) Overlay of (a) and (b). d) Cbl-
Bod (125 nM) after photolysis e) Mito-Tracker Green mitochondria marker. (f) Overlay of (d) and 
(e). Before photolysis, Cbl-Bod co-localized with the endosomal marker (Pearson’s coefficient = 
.89), but Bod migrated to the mitrochondria as indicated by co-localization with MitoTracker 
Green (Pearson’s coefficient = .81).   
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Figure 2.3. Light-dependent Cbl-cAMP mediated rearrangement of REF52 actin cytoskeleton. 
REF52 cells were exposed to cAMP derivatives (500 µM) under different irradiation conditions 
and stained with DyLight488–phalloidin to visualize the actin stress fibers. a) No treatment, media 
alone. b) CPT-cAMP as a positive control. c) Cbl-cAMP, no illumination. d) Cbl-cAMP with 
illumination. Cell rounding is indicative of PKA activation due to the release of cAMP from the 
endosomes and penetration into the cytoplasm.  
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Figure 2.4. Photolytic delivery of Dox from Cbl-Dox. Cells were incubated with Cbl-Dox (10 
µM), illuminated (dark, 30, 45, or 75 s), and cell viability was assessed using a cell viability assay 
24 h after treatment. Lack of cell death in the dark indicates anchoring of Dox in the endosomes 
by Cbl, but photolysis elicits Dox’s normal, apoptotic function as evidenced by the reduced cell 
viability.  
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2.3. Cobalamin phototherapeutics’ adaptation to natural erythrocyte carriers 
 The active transport and endocytosis of Cbl offers an intriguing option for targeting nutrient 
hungry cancer cells in vivo. However, we were concerned that simple reliance on Cbl metabolism 
may lack hardiness and specificity while in circulation. DDSs that utilize Cbl ligands for targeting 
of cancer cells show lowered specificity in vivo where healthy cells also take in Cbl.77 As a result, 
we began investigating carrier systems for the shuttling of Cbl photo-therapeutics throughout the 
body. Ideally, these systems should (1) prevent photo-therapeutic degradation, (2) limit leaching, 
(3) provide a long lived drug reservoir, (4) travel throughout the body, and (5) camouflage the 
cargo from the immune system. 
 Many DDSs have been engineered with these needs in mind. Despite significant 
advancements in our engineering and understanding of these systems in vivo, adaptation of viable 
DDSs into the clinic remains difficult.2 As an alternative, many researchers have turned to natural 
cell87–90 or protein carriers35,91. Cellular carriers (i.e. red blood cells [RBCs]92,93, leukocytes94, and 
stem cells95) are particularly interesting because they provide many advantages difficult to 
replicate. Some of these advantages include high mobility, large encapsulation volumes and 
surface areas, long lifetimes (months), pathology homing, low immunogenicity, and enhanced 
loading.87,90  
 We became interested in using RBCs for many of the aforementioned benefits. In fact, one 
recent review references RBCs as the “champion of drug delivery”, because they circulate up to 
120 days, have a large loading capacity, and are easily isolated and stored for several days.93 
Rheumatologists already exploit sustained RBC delivery of dexamethasone (DEX) for the 
treatment of arthritis and Crohn’s disease in the clinic.96,97 RBCs loaded via dialysis with a prodrug 
form of the steroid (dexamethasone-21-phosphate) slowly convert and release active DEX for 
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several days. This eliminates the need for repeated, high dose injections that can lead to deleterious 
side effects.98 RBCs have demonstrated diverse compatibility for loading everything from small 
chemotherapeutics to enzymes. Yet, limited work exists on adapting RBCs for spatiotemporally 
triggered drug release instead of the current, steady state delivery used.93 
 Therefore, we sought to adapt our Cbl photo-therapeutics to incorporate with RBC carriers. 
Several methods exist for the incorporation of drugs with cellular carriers including phagocytosis, 
electroporation, and chemical modification.87,90 We pursued two generalizable strategies for the 
facile loading of RBCs. First in Section 2.3.1, we modified our Cbls with lipids for the hydrophobic 
mediated assembly of photo-therapeutics on the surface of RBC membranes. In Section 2.3.2, our 
second strategy focused on using hypotonic loading to load complete Cbl photo-therapeutics in 
the interior of the RBCs. 
2.3.1. Cell Membrane Mediated Assembly of Phototherapeutics 
 When first contemplating RBC mediated delivery, we wanted a strategy that allowed for 
facile loading and assembly of complete Cbl photosystems without significant modifications to 
the cell. It occurred to us that the large surface area of the RBC lipid bilayer provides an excellent 
template for the assemblage of photo-therapeutics. Previous work within our lab demonstrated that 
ONB caged peptides modified with lipid tails localized into the membrane of mitochondria and 
RBCs upon simple mixing.99 This “painting” of lipid membranes provided protection to the caged 
peptide until photo-activation released it.100 
 Inspired by this work, we devised a strategy using stearyl lipid (C18) modified Cbls and 
fluorophores to induce binding to RBC membranes (Scheme 2.8). In Chapter One, we reasoned 
Cbl’s covalent linkage to NIR fluorophores allowed for efficient sensitization between the two 
chromophores due to their close proximity.66 In this strategy, we removed the linkage. Instead, we 
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investigated whether self-assembly on the outer membrane could hold the Cbl and fluorophore 
closely to allow for NIR sensitization.69  
2.3.1.1. C18-Cobalamin-Drug and C18-Fluorophore Synthesis 
 To provide the impetus for membrane adsorption, stearyl amine (CH3(CH2)17NH2) was 
ligated to the underside CNCbl’s ribose-5’-OH via a carbamate linkage using activation with 1,1’-
carbonyl-ditriazole to afford stearylamine-Cbl (Scheme 2.9, C18-Cbl). Next, reduction followed 
by alkylation of the β-axial ligand site yielded propylamine or butanoic acid functionalized Cbls 
(C18-propylamineCbl and C18-butyrateCbl) for accommodation of chemotherapeutics (Scheme 
2.10). To C18-propylamineCbl, TAMRA and fluorescein (FAM) fluorophores were attached 
using uronium coupling (HBTU) to serve as reporter compounds (C18-Cbl-TAM and C18-Cbl-
FAM, respectively) during release trials (Scheme 2.11 - 2.12). 
 Rheumatoid arthritis (RA) affects the extremities’ joints which lie close to tissue’s surface 
for easy access by light stimulation. We envisage light stimulation to allow for spatiotemporal 
dosing within arthritic joints by a clinician or patient application of an irradiation source directly 
on an enflamed joint. RA desperately needs therapies targeted in this manner, because its primary, 
immunosuppressive treatments have mild to severe complications with their chronic high 
dosing.98,101,102 
For this preliminary study, we decided to use the three RA drugs of dexamethasone (DEX), 
colchicine (COL), and methotrexate (MTX), because RBCs have already demonstrated the ability 
to deliver some of these compounds (Scheme 2.11).92,93 COL was deacetylated by a previously 
reported procedure to yield an aminoCOL derivative for amide coupling.103 DEX was modified 
by a hydrolysable succinate linker as previously reported for easier coupling.104 aminoCOL was 
then coupled to C18-butyrateCbl (C18-Cbl-COL, Scheme 2.13), while MTX and DEX to C18-
95 
 
propylamineCbl (C18-Cbl-MTX and C18-Cbl-DEX) using uronium activation (HBTU, Scheme 
2.12). 
In this and future studies, most of the fluorophores chosen were cyanine based dyes 
(Scheme 2.14). These dyes consist of two alkylated indole centers in π conjugation via a 
polymethine bridge.105 The length of the polymethine bridge tunes the absorption wavelength, 
because each addition of two methine units red shifts the absorbance about 100 nm (Cy3: λmax = 
543 nm, Cy5: λmax = 646 nm, Cy7: λmax = 760 nm). This allows for construction of diverse, 
wavelength distinct species to cover the red and NIR spectrum. Unfortunately, the high 
commercial cost of cyanine fluorophores seemed prohibitive for large scale applications 
Therefore, I synthesized these dyes and their corresponding C18 conjugates from 
inexpensive precursors using modified literature procedures (Schemes 2.15 – 2.18).106–108 Using 
Fischer indole synthesis, phenylhydrazines and 3-methyl butanone refluxing in acetic acid affords 
the 3,3-dimethyl-indolenine (1) in good yields (Scheme 2.15a). Indolenines alkylate easily upon 
refluxing in neat methyl iodide, 6-bromohexanoic acid, or 1,3-propane sultone to yield an activated 
indolenium species (2 – 7). The indoleniums are refluxed in acetic acid and acetic anhydride with 
a suitable polymethine condensation partner, such as malonaldehyde dianilide, to attach the first 
indole group (Scheme 2.15b - 2.16). After solvent removal, the second indolenium is added in a 
mixture of pyridine/acetic anhydride yielding a complete cyanine dye (Cy5, Cy5SO3-, Cy7, 
Cy7SO3-, and chloroDY800). Treatment of chloroDY800 with sodium phenoxide yields a red 
shifted cyanine dye via SRN1 (DY800, Scheme 2.16).  
Later, I found chloroDY800 was sensitive to unintended SRN1 from aniline and pyridine 
during the attachment of the second indole (Scheme 2.16).107 This greatly reduced the synthesis’ 
yield. Therefore, I designed a meso FL800 dye that avoided reacting in pyridine. Here, two 
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equivalents of propylsulfonate indolenium (3) are refluxed with the polymethine precursor (N-[(3-
(Anilinomethylene)-2-chloro-1-cyclohexen-1-yl) methylene]aniline) in a solution of sodium 
acetate and ethanol (Scheme 2.17). This reaction provided a single dye product (chloroFL800) in 
excellent yield. SRN1 of the chloro-FL800 with 4-mercaptophenylacetic acid was used to red shift 
the absorbance and install a carboxylate functional handle (FL800, λmax = 786 nm).107 This 
workaround greatly improved production. The cyanine dye – C18 conjugates were coupled to 
stearylamine using either carbodiimide (DIC) or HBTU coupling (Scheme 2.18).  
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Scheme 2.8. RBC mediated assembly of Cbl photo-systems. Lipidated Cbl-drugs and fluorophores 
bind to the erythrocyte’s membrane upon mixing for shuttling throughout the body. The close 
proximity of the two chromophores on the cell’s surface allows for Cbl NIR sensitization and 
photolysis of the Co-C bond. The Cbl can release the bound drug to adjacent cells and initiate 
treatment. We aimed to release RA therapies with this technology since NIR light can penetrate to 
joints allowing for targeted delivery.  
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Scheme 2.9. Synthesis of lipidated Cbl (C18-Cbl) from CNCbl. Functionalization of the nucleotide 
occurred using 1,1’-carbonyl ditriazole activation of the ribose hydroxyl and subsequent treatment 
with stearylamine. The lipid tail aids in the binding of lipid membranes via the hydrophobic effect.  
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Scheme 2.10. Synthesis of functional C18-Cbl with  a)propylamine (C18-propylamineCbl) or b) 
butyrate (C18-butyrateCbl) ligand at the β-axial site.  
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Scheme 2.11. Structure of lipidated C18-Cbl-drugs. The lipid tails serves as an anchor to bind the 
Cbl construct to an RBC membrane. The drugs chosen (COL, DEX, and MTX) are used in the 
treatment of RA and can have serious side effects from their chronic high doses. The two 
fluorophores (TAMRA and FAM) served as model drug constructs to monitor release using 
fluorescence.  
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Scheme 2.12. Synthesis of lipidated C18-Cbl-drugs from C18-Cbl-propylamine.  
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Scheme 2.13. Synthesis of lipidated colchicine Cbl (C18-Cbl-COL) from C18-butyrateCbl.  
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Scheme 2.14. Structure of lipidated C18-dyes. The lipid tails serves as an anchor to bind the dye to 
the RBC membrane. The structure of AlexaFluor700 is proprietary and unreported.   
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Scheme 2.15. Synthesis of a) cyanine dye precursors (1-7) and b) Cy dyes.  
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Scheme 2.16. Synthesis of DY800 (λmax = 776 nm).  
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Scheme 2.17. Synthesis of long wavelength FL800 (λmax = 786 nm).  
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Scheme 2.18. Synthesis of lipidated dyes using a) carbodiimides (DIC) or b) uronium activators 
(HBTU) followed by treatment with stearylamine.  
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2.3.1.2. C18-Cobalamin membrane partitioning 
We first investigated the ability for the C18-Cbls to localize within a hydrophobic 
environment and then release their cargo to an aqueous one. In an octanol-water partition study, 
C18-Cbl-MTX and C18-Cbl-TAM localize within the hydrophobic octanol layer upon vortexing 
and separation of the two layers (Figures 2.5 – 2.6).99 After exposure to 525 nm irradiation, 
fluorescence spectroscopy and LC-MS indicate that both TAMRA and MTX release from the C18-
Cbls and migrate to the aqueous layer. This hydrophobic partitioning also occurred upon exposure 
to whole RBCs. Loading of C18-Cbls was accomplished through simple incubation (20 min) of 
RBCs (10% hematocrit) with varying concentrations of C18-Cbls (0 - 40 µM) followed by washing 
and storage (2 days). Upon loading C18-Cbl-TAM (2 µM), fluorescent microscopy confirmed the 
localization of the conjugate to the membrane periphery of the RBC (Figure 2.7). Imaging the 
complex at 570 nm resulted in rapid release (< 1 s) of the TAMRA from the membranes into the 
surrounding solution indicating successful Co-C bond scission. C18-Cbl-drugs also loaded onto 
RBCs membranes easily with limited structural damage as assessed by RBC hemolysis (Figure 
2.8). 
 Next we quantified the drug retained in the RBC pellet and left unloaded in the wash 
supernatants by LC-MS quantification. Incubation produced a significant amount of bound Cbl to 
the RBC membrane even after several washings (Figure 2.9). Moreover, the amount of bound drug 
increased linearly with the initial loading concentration. We estimated that the amount of loaded 
drug per red blood cell ranged between 0.3 – 1.0 fmol (initial loading - 4 µM). Once the drugs 
were loaded, we assessed the effectiveness of release after complete photolysis (525 nm, 2 h) by 
LC-MS analysis of the photolyzed RBC supernatants (Figure 2.9b, white bars). Both C18-Cbl-
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DEX and C18-Cbl-COL provided near quantitative release of their cargo into the supernatant, but 
only ~ 35% of MTX released from C18-Cbl-MTX under the given conditions.   
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Figure 2.5. Partition study of C18-Cbl-TAM before and after photolysis. C18-Cbl-TAM (10 μM) 
is soluble in hydrophobic octanol (100 µL) but liberated TAMRA migrates to the aqueous phase 
(500 µL) after photolysis (546 nm). At each time point, the octanol-water partitions were vortexed 
together, allowed to separate, and a small sample of the aqueous layer removed for analysis. The 
concentration of liberated TAMRA in the aqueous layer was determined by fluorescence (λex = 
555 nm, λem = 585 nm) (n = 3).  
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Figure 2.6. Partition study of C18-Cbl-MTX (5 μM) from a hydrophobic (octanol, 100 μL) to a 
hydrophilic (water, 500 μL) environment after photolysis (525 nm). C18-Cbl-MTX is soluble in 
octanol but liberated MTX migrates to the aqueous phase. The concentration of liberated MTX in 
the aqueous layer was determined by LC-MS and represented as a percent of the total MTX added 
(n = 3).  
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Figure 2.7. Fluorescent microscopy of C18-Cbl-TAM loaded RBCs with a widefield microscope. 
a) Long wavelength (λex = 650 nm, λem = 684 nm) imaging for RBC visualization and prevention 
of premature Co-C photolysis. b) Imaging and photolysis of C18-Cbl-TAM (10 µM loading, λex = 
570 nm, λem = 590 nm) over time. The act of imaging rapidly photolyzes the Cbl construct in the 
first frame and the TAMRA fluorescence migrates from the periphery of the RBC into the 
supernatant.   
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Figure 2.8. RBC stability when exposed to C18-Cbl-drugs (C18-Cbl-MTX = black bars, C18-Cbl-
COL = grey bars, and C18-Cbl-DEX = white bars). Lysis was determined by the absorbance (550 
nm) of leaked RBC heme compared to the absorbance of a detergent lysed RBC sample (0.05 
w/v% SDS, Eq 2.1). Overall lysis remained low even at high drug concentrations. (n = 3)  
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Figure 2.9. C18-Cbl-Drug release from human RBCs. (a) Drug released from RBCs versus 
loading concentration from photolysis (525 nm, 2 h). Drug concentrations were determined by LC-
MS in tandem with standard curves. [C18-Cbl-MTX (blue), C18-Cbl-COL (orange), and C18-Cbl-
DEX (grey)] (b) C18-Cbl-Drug (4 μM) concentrations loaded (black bars) and photo-released 
(white bars) from RBCs after incubation. (n = 3)  
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2.3.1.3 Delivery of Active Drugs from Erythrocyte Membranes 
 After confirming C18-Cbls associates with RBC membranes, we wanted to determine the 
released photoproducts. Ligation of the chemotherapeutics to Cbl requires some structural changes 
and the exact structure of the photoproduct can change depending on the environment.73,74 
Therefore, it becomes important that the photoproducts’ structure is determined (Scheme 2.19, 
Table 2.1). Normally, photolysis of alkylCbl produces oxidized products at the primary carbon, 
but it is conceivable that the radical may also abstract a hydrogen from a biological –H donor like 
glutathione or membrane proteins.109 The latter seems likely for both C18-Cbl-MTX and C18-Cbl-
COL as LC-MS indicated substantial formation of a saturated carbon (butanoyl) as opposed to 
oxidation (Table 2.1). Although photolysis of C18-Cbl-DEX affords free DEX presumably 
through ester hydrolysis by blood esterases.110,111  
 Additionally, all three drugs still maintain activity as demonstrated by HeLa cell response 
and enzymatic binding upon photolytic release. For example, photolysis of C18-Cbl-MTX still 
produces bound HeLa cell dihydrofolate reductase (DHFR, Figure 2.10 – 2.11), its protein target, 
as assessed by the Cellular Thermal Shift Assay (CETSA).112 CETSA uses binding of MTX to 
DHFR to greatly improve the protein’s resistance to heat denaturation. Sample heating (> 50 oC) 
selects for MTX bound DHFR within treated cell lysates while denaturing MTX free DHFR. As 
indicated by western blot, HeLa cells exposed to light and the RBCs loaded with C18-Cbl-MTX 
produced significantly more thermostable and properly folded DHFR than cells left in the dark 
showing successful MTX delivery. However, the effective inhibitory concentration of C18-Cbl-
MTX increased slightly relative to free MTX (Figure 2.11). 
The other two constructs also induced their characteristic effects on HeLa cells. COL 
disrupts a cell’s networks of microtubules to produce tangled clumps of tubulin (Figure 2.12).101,103 
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As a result, C18-Cbl-COL photolysis from RBCs inhibits microtubule formation in HeLa cells 
comparably to free COL (Figure 2.13), but no such effect is found in cells left in the dark. Just like 
free DEX (Figure 2.14), C18-Cbl-DEX induces translocation of its glucocorticoid receptor α 
(GRα) from the cytoplasm to the nucleus after light irradiation (Figure 2.15).96 Once again, the 
lack of irradiation did not produce GRα migration from the cytoplasm. 
Since the binding of lipids to the membrane is non-covalent, we determined if the C18-Cbl-
drugs could “jump” or translocate between the RBC and HeLa cell membranes using C18-Cbl-
DEX (Figure 2.16). HeLa cells were incubated in the dark with C18-Cbl-DEX loaded RBCs and 
then washed several times to remove the RBCs. The HeLa cells were then photolyzed and 
monitored for GRα translocation. If significant jumping had occurred, HeLa cell bound C18-Cbl-
DEX should induce relocation, but we observed no such effect indicating that a lion’s share of the 
construct was washed away with the RBCs. 
  
117 
 
 
 
 
 
Scheme 2.19. Photo-products from aerobic photolysis of C18-Cbl-drugs determined by LC-MS 
 (X = -H, -OH, =O).  
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Table 2.1 Structure identification from C18-Cbl-Drug photolysis by LC-MS.  
C
18
-Cbl-Drug Photoproduct Elution Time (min) Yield (mole fraction) 
 
X = H X = OH X = O C18-Cbl X = H Other Products 
C18-Cbl-MTX 3.3 2.9 3.1 6.8 0.83 0.17 
(Mass) (494.2) (510.2) (528) (812.8) 
  
C18-Cbl-COL 4.7 4.4 4.4 6.7 0.20 0.80 
(Mass) (426.1) (442) (460) (812.7) 
  
C18-Cbl-DEX 5.5 5.5 5.5 6.7 
(812.7) 
n/a n/a 
(Mass) (514.3) (533) (532) 
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Figure 2.10. Cellular Thermal Shift Assay (CETSA) of MTX release from C18-Cbl-MTX loaded 
RBCs. HeLa cells were incubated with C18-Cbl-MTX (300 μL, 5 μM)-loaded RBCs (5% 
hematocrit) and exposed to different irradiation conditions. MTX bound DHFR is significantly 
more thermostable so resists the CETSA heating step while unbound DHFR denatures. No folded 
DHFR is detected in the absence of photolysis. With increasing 520 nm irradiation times, C18-Cbl-
MTX loaded RBCs produces stable DHFR. The band intensity of GAPDH was used as a 
normalizing standard.   
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Figure 2.11. Percent inhibition of DHFR by concentration of free MTX (circles) or photolyzed 
C18-Cbl-MTX (triangles) bound to RBCs.  
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Figure 2.12. Free COL effects on microtubules at varying concentrations. COL was added to 
HeLa cells with a) DMSO only b) 250 nM c) 500 nM d) 1 μM e) 2 μM, or f) 4 μM. Between 1 – 
2 µM, tubulin clumping and cell rounding occurs. HeLa cells were stained with mouse anti-tubulin 
(secondary Alexa488).  
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Figure 2.13. Effects on HeLa cells’ microtubules from RBCs (5% hematocrit) loaded with C18-
Cbl-COL (6 µM). (a) Photolysis (525 nm, 20 min), (b) dark, (c) no RBCs and dark, (d) no RBCs 
with photolysis (525 nm, 20 min). Disruption and clumping of microtubule networks only occurs 
from photolyzed C18-Cbl-COL as seen in a).   
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Figure 2.14. Effect of free DEX on of GRα location in HeLa cells. HeLa cells were stained with 
anti-GRα (Alexa488 antiRabbit, green) and nuclear HOESCHT 33342 (blue) then treated with a,b) 
DMSO or c,d) free DEX (250 nM). In the absence of DEX, GRα remains cytoplasmic, but upon 
treatment with DEX, the receptor migrates to the nucleus.  
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Figure 2.15. Treatment of HeLa cells with RBC bound C18-Cbl-DEX (1 µM) in the a) dark or b) 
with photolysis (525 nm, 10 min). HeLa cells were stained with anti-GRα (secondary Alexa 488 
antiRabbit). Upon treatment with loaded RBCs (5% hematocrit) and light irradiation, GR α 
migration to the nucleus is clearly seen. 
 
 
 
Figure 2.16.  “Jumping” assessment of C18-Cbl-DEX between RBC and HeLa cell membranes. 
RBCs (5% hematocrit) were loaded with C18-Cbl-DEX (1 μM) and then incubated with HeLa 
cells followed by washing away of the RBCs. The cells were then a) photolyzed (525 nm), b) left 
in the dark, or c) not exposed to RBCs. Following treatment, the cells were stained with anti-GRα 
GRα remains cytosolic indicating no C18-Cbl-DEX jumping between RBC and HeLa cell 
membranes.  
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2.3.1.4. Long Wavelength Activation of Lipidated Photosystems 
 NIR light penetrates tissue to clinically relevant depths, so we envisioned its application 
directly to the joints of RA patients could target release of these chemotherapeutics and lower the 
drugs’ side effects using our Cbl constructs.54,113,114 Indeed, others have explored mechanisms to 
deliver RA therapies selectively to joints.115,116 In contrast to Chapter One, the fluorophores can 
no longer be covalently linked to the Cbls, because the ribose-5’-OH is occupied with the lipid 
functionalization.66,117 Therefore, we wanted to examine if lipidated fluorophores co-localized on 
the RBC membrane could capture and transfer NIR energy to the lipidated Cbls (Scheme 2.8).  
As detailed in Section 2.3.1.1, I synthesized several stearylamine fluorophores that covered 
the red and NIR spectrum (Scheme 2.13): C18-Cy5 (λmax = 646 nm), C18-AlexaFluor700 (C18-
AF700, λmax = 700 nm), C18-Cy7 (λmax = 760 nm), and C18-DY800 (λmax = 776 nm). Confocal 
microscopy confirmed that the C18-Cy5 (5 μM) associates with the membrane of the RBCs after 
20 min incubation (Figure 2.17). We investigated the fluorophores’ capacity to sensitize the release 
of a model compound (TAMRA) from RBCs using C18-Cbl-TAM. First, we identified the optimal 
loading concentration for both the C18-Cbl-TAM and C18-Cy5. The two compounds were co-
incubated with RBCs at varying concentrations (0 – 10 μM), washed to remove any unbound 
lipids, photolyzed (660 nm, 30 min), and then the monitored for TAMRA fluorescence in the 
supernatant (Figure 2.18). Not surprisingly, a high C18-Cy5 : C18-Cbl-TAM loading ratio of 10 
µM : 1 µM provided optimal TAMRA release, but a ratio of 5 µM : 1 µM was used going forward 
to limit RBC hemolysis. We compared the efficiency of TAMRA and FAM release for all four 
C18-fluorophores at this loading ratio (Figure 2.19). All four could induce successful cargo release 
at irradiations corresponding to their λex, but C18-Cy5 provided the most robust release after 
correcting for the irradiation source’s photon flux. Furthermore, long wavelength photolysis of 
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C18-Cbl-TAM loaded RBCs in the absence of fluorophores only induced TAMRA release at 525 
nm indicating the necessity for the dyes (Figure 2.20). With C18-Cbl-MTX the effect was 
reproduced as the lipidated fluorophores successfully released MTX at their λex as assessed by 
LC-MS (Figure 2.21).  
We next paired our C18-Cbl-drugs with a lipidated fluorophore for NIR induced release. 
C18-Cbl-MTX, C18-Cbl-COL, and C18-Cbl-DEX were incubated with C18-Cy7, C18-DY800, and 
C18-Cy5, respectively, in the presence of RBCs. As before at 525 nm, long wavelength irradiation 
near the fluorophore’s excitation maximum induced the release and the corresponding effects of 
all three drugs. Irradiation (725 nm) of the C18-Cbl-MTX / C18-Cy7 pair shows the same binding 
of HeLa cells’ DHFR as free MTX by CETSA (Figure 2.22). Illumination (660 nm) of the C18-
Cbl-DEX / C18-Cy5 loaded RBCs caused migration of HeLa cell GRα to the nucleus (Figure 2.23), 
and photolysis (780 nm) of the C18-Cbl-COL / C18-DY800 pair caused microtubule disruption 
(Figure 2.24). Additionally, all three effects were suppressed in the absence of illumination. 
These results show that it is indeed possible to use cellular membranes as templates for the 
assembling and carrying of Cbl photosystems. Additionally, the ease of loading allows for the 
rapid adaptation of RBC carriers to a range of chemotherapies and fluorophores. This adaptability 
also allows for a specific wavelength of light to be employed simply by swapping out the C18-
fluorophore used. It may be possible to quickly translate these self-assembled systems to other cell 
membranes, such as macrophages or stem cells, to take advantage of these cells additional 
malignancy homing advantages.87  
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Figure 2.17. Confocal image of RBCs loaded with C18-Cy5 (5 µM). The Cy5 fluorescence 
distributes at the periphery of the RBC indicating membrane binding.  
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Figure 2.18. Heat map of TAM (mole fraction) release from RBCs (10% hematocrit) when 
exposed to different ratios of C18-Cbl-TAM : C18-Cy5 followed by photolysis (660 nm, 30 min). 
The most efficient sensitization and release is observed at high C18-Cy5:C18-Cbl-TAM (10:1) 
ratios. We used a ratio of 5 : 1 µM to avoid damaging the RBCs at higher concentrations.  
129 
 
 
 
Figure 2.19. Mole fraction of released a) TAMRA or b) FAM from RBCs loaded with C18-Cbl-
FAM/C18-Cbl-TAM and C18-fluorophores (ratio of 1 μM : 5 μM) after photolysis near the 
fluorophore’s λex (30 min irradiation @ 660, 725, or 780 nm). The total C18-Cbl-TAM (or FAM) 
bound to RBCs (5% hematocrit) was determined by measuring the supernatant fluorescence after 
complete photolysis (525 nm, 3 h irradiation) and comparing it with a standard curve (n = 3). The 
white bars represent the actual fraction released, the black bars are the fraction released normalized 
to the power output of the LEDs, and the gray bars are the fraction released normalized to the 
photon flux. (AF700 – Alexa700)  
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Figure 2.20. Mole fraction of released TAMRA from RBCs loaded with C18-Cbl-TAM by 
illumination wavelength. RBCs (5% hematocrit) were loaded with C18-Cbl-TAM (1 µM) without 
a co C18-fluorophore. Long wavelength illumination (660, 725, or 780 nm) does not release 
TAMRA. (n = 3)  
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Figure 2.21. Release of MTX from C18-Cbl-MTX/C18-fluorophore loaded RBCs. (a) MTX (1 
μM) release by irradiation (30 min) of each C18-fluorophore (5 μM, white bars) or left in the dark 
(black bars) was determined by LC-MS. (b) The normalized drug release of MTX release was 
calculated by the moles of drug (nmoles) released divided by the photon flux output of each LED 
board (μeinsteins)  
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Figure 2.22. Long wavelength release of MTX from C18-Cbl-MTX/C18-Cy7 loaded RBCs. a) 
Thermostable, HeLa cell DHFR was detected using the CETSA assay and irradiation (725 nm) 
produced significantly more folded DHFR due to MTX stabilization than a dark control. b) 
Quantification of Western blot intensities clearly shows more MTX bound DHFR after photolysis 
at 725 nm. 
 
 
 
Figure 2.23. DEX release from C18-Cbl-DEX/C18-Cy5 loaded RBCs. RBCs (5% hematocrit) 
were loaded with C18-Cbl-DEX/C18-Cy5 (1 μM / 5 μM) a) In the dark, GRα remains cytoplasmic, 
but b) 660 nm light induces GRα nuclear localization. GRα was visualized with antiGRα. 
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Figure 2.24. COL release from C18-Cbl-COL/C18-DY800 loaded RBCs. HeLa cells were 
treated with C18-Cbl-COL/C18-DY800 (1 μM / 5 μM) loaded RBCs (5% hematocrit) then left a) 
in the dark or b) irradiated (780 nm). Long wavelength irradiation results in drastic changes to 
microtubule structure.  
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2.3.2. Internal Erythrocyte Loading 
 Therapy loading is not restricted to the surface of cells. A large amount of research has 
focused on encapsulating cargo within the interior of erythrocytes, leukocytes, and stem 
cells.87,90,92,93 Interior encapsulation of cargo provides additional stealth advantages from the 
body’s immune system, since the carrier cells’ surface remains unmodified. Due to this, 
researchers have employed several loading methodologies to place therapeutics within the interior 
of cells. These range from physical methods like electroporation118 to biological approaches such 
as phagocytosis94. 
In fact, many cell based chemotherapeutics in clinical trials are loaded within the interior 
of the RBC by hypotonic hemolysis92,119. RBCs’ membranes tolerate deformation quite well, and 
this hardiness allows for temporary access of the RBC interior by reversible pore formation. 
Treatment of RBCs with low salt, hypotonic solutions causes the cell to swell and pores to form 
within the membrane. Chemotherapeutics co-incubated within the hypotonic solution can then 
freely diffuse into the interior. Placement of the RBCs back into an isotonic solution closes the 
pores and seals the therapy inside without damaging the RBC. The pores’ large size can 
accommodate the loading of small drugs, enzymes, and even nanoparticles. The hypotonic loading 
methodology has been investigated to deliver antiviral agents (azido thymidine), cancer 
chemotherapies (5-fluoro-2’-deoxyuridine), enzymes for replacement therapies (adenosine 
deaminase), and antithrombotic drugs (heparin).93 Indeed, this approach is so well accepted that 
automated systems now exist for hypotonic loading of dexamethasone-phosphate into RBCs for 
slow delivery of DEX over the course of several days.120 
Inspired by this rapid expansion of RBC applications, we wanted to merge our Cbl 
photosystems with the additional stealth and shuttling advantages of RBC internal loading. As 
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described in Section 2.2, cobalamins are membrane impermeable,75,77 and we intended to use this 
property to retain cell permeable drugs within RBCs after hypotonic loading (Scheme 2.20). 
Photoinduced liberation of the drug via loss of the Cbl anchor would then allow for the therapy to 
freely diffuse out of the RBC and into adjacent cells. 
2.3.2.1 Retention and Release of a Model Therapeutic (Cbl-Bod) 
 First, we investigated whether a Cbl construct could load efficiently within RBCs using 
hypotonic loading. For this study, we chose previously described Cbl-Bod, since its luminescence 
allows for easy quantification via a fluorescence standard curve.66 In a typical loading, pelleted 
human or murine RBCs were swollen in deionized water containing Cbl-Bod (5 µM, 5 min). 
Concentrated PBS was then added to bring the solution back to isotonicity (1x PBS) and the cells 
were allowed to reseal for 30 min. The cells were then washed and centrifuged thrice to remove 
any residual Cbl-Bod. Analysis of the RBC washes for hemoglobin release indicated that 
structural damage from loading was low to modest (< 30% hemolysis, Figure 2.25) and did not 
increase significantly in the presence of Cbl-Bod.  
 Next, we measured the amount of Bod released from RBCs into the supernatant before and 
after photolysis (660 nm, 30 s, Figure 2.26). RBCs exposed to light rapidly released Bod to the 
supernatant, while those left in the dark yielded little to no Bod (Figure 2.26a). Longer irradiation 
times liberated greater amounts of Bod, but the concentration reached a maximum within 3 min at 
a low photon flux (3.30 ± .02 mW/cm2, Figure 2.26b). Additionally, non-swollen or already sealed 
RBCs treated with Cbl-Bod showed no release of Bod upon light exposure indicating that RBC 
swelling is necessary for uptake of the Cbl construct (Figures 2.26 – 2.27). 
We also stored Cbl-Bod loaded RBCs for several days to test their long term retention and 
stability (Figure 2.28). The amount of Cbl-Bod leached to the supernatant in the dark increases 
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slightly over several days but the vast majority remains encapsulated within the RBCs. It remains 
unclear if the RBCs’ or the Cbl-Bod’s stability produces this small amount of leaching, but we are 
further probing the carrier system’s long term suitability. 
 Finally, we demonstrated that Cbl-Bod photolysis within RBCs could release Bod to its 
site of action. As mentioned in Section 2.2, Bod migrates to membrane potentials within organelles 
like the mitochondria and ER.80,81 Therefore, we treated HeLa cells with Cbl-Bod (5 μM) loaded 
RBCs (10% hematocrit) to see if Bod delivery was initiated with red light (Figure 2.29). HeLa 
cells were also stained with MitotrackerGreen® (mitochondria) and ER Blue/White (endoplasmic 
reticulum) to identify localization. After incubation and washing away of the RBCs, almost no 
staining of the HeLa cells’ organelles with Bod occurs in the dark. In contrast, red light exposure 
produces delivery and brilliant staining of the mitochondria and ER with Bod as indicated by co-
localization with both the MitotrackerGreen® (Pearson’s coefficient = 0.90) and ER Blue/White 
(Pearson’s coefficient – 0.84) markers. The collective evidence of the Cbl-Bod studies shows the 
feasibility of encapsulating and releasing therapeutics from RBCs’ interiors using Cbl 
photosystems.  
137 
 
 
 
 
 
Scheme 2.20. Hypotonic loading and long wavelength release of Cbl photo-therapeutics. Cbl 
conjugates with a payload and fluorophore can be loaded into the interior of RBCs in low salt 
solution. The low salt solution causes pores to form within the RBC membrane allowing Cbl 
conjugates to flow inside. Addition to isotonic PBS reseals the RBC encapsulating the photo-
therapeutic inside. Light can then induce cell permeable drug scission from the Cbl anchor 
allowing it to escape into the surrounding supernatant.  
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Figure 2.25. Effects of hypotonic loading procedure on RBC integrity. Lysis (%) is determined 
by the absorbance (550 nm) of 10% hematocrit sampled compared to a completely lysed control 
(.05 w/v% SDS, Eq 2.1). a) Hypotonic swelling in the presence or lack of Cbl-Bod induces 
comparable lysis (~ 30%). However, lack of swelling and storage in isotonic PBS maintains the 
membranes integrity. b) The % lysis arising during each washing step after hypotonic opening and 
resealing.  
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Figure 2.26. Bod release from RBCs. a) Cbl-Bod (5 μM) was hypotonically loaded into human 
RBCs and then photolyzed (660 nm) for varying amounts of time. The amount of released Bod 
was calculated using a fluorescence standard curve. b) Amount of released Bod from RBCs treated 
with a variety of conditions.  
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Figure 2.27. Cbl-Bod release after incubation with a) swollen then sealed RBCs or b) unopened 
RBCs. The fluorescence in RBC supernatant and washes were monitored for free Bod. Photolysis 
(660 nm) of RBCs yielded little Bod release to the supernatant. Most Bod was extracted in the 
washing of the non-swollen or previously sealed RBCs.  
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Figure 2.28. RBC internalization of Cbl-Bod over several days. RBCs were loaded with Cbl-Bod 
(5 µM) and monitored for Bod leached into the supernatant (white bars) or retained in the RBCs 
(black bars) overall several days. Photolysis (660 nm) of RBCs and supernatant yielded free Bod 
for monitoring using a fluorescent standard curve. Over several days, some Bod leaks out of the 
RBC but the vast majority remains retained within the RBC up to one week.  
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Figure 2.29. Cbl-Bod localization in HeLa cells after release from RBCs. Cbl-Bod (5 µM) was 
hypotonically loaded into RBCs (5% hematocrit) and incubated with HeLa cells. Cells were then 
left in the dark (top) or photolyzed (bottom, 660 nm, 10 min). HeLa cells were fixed and visualized 
for Bod fluorescence and localization using a confocal microscope. Bod localizes to the internal 
membranes of cells with potential gradients so MitoTracker Green and ER Blue/White markers 
were used to stain the mitochondria and ER, respectively. In the dark, limited Bod fluorescence is 
noted, but after photolysis, Bod co-localizes with both organelle markers (0.90 Pearson’s 
coefficient for MitoTracker Green and 0.84 for ER Blue/White). Photolysis clearly results in 
substantial release and localization of Bod into HeLa cell’s organelles.  
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2.3.2.2. Release of Therapeutics 
 We next investigated the use of our Cbl derivatives for the release of rheumatoid 
chemotherapies. Therefore, MTX and COL were chosen for ligation to Cbl due to their already 
prominent use in arthritis therapy.121,122 The two drugs were attached to Cbl in the same manner 
as in Section 2.3.1.1. Briefly, MTX was activated with HBTU and added to a solution of 
propylamineCbl to yield an amide linked Cbl-MTX (Scheme 2.21). Likewise, butyrateCbl was 
activated using HBTU and then treated with aminoCOL to provide amide linked Cbl-COL 
(Scheme 2.22). 
 With the two constructs, we tested their capacity to affect their normal cellular targets using 
the conditions described in Section 2.3.1.3. Both constructs were loaded into RBCs by the same 
method used for Cbl-Bod. Using the CETSA assay, we found Cbl-MTX loaded into RBCs could 
photolytically release MTX to bind and stabilize DHFR from denaturation (Figures 2.30 – 2.31).112 
In the dark, limited folded DHFR was found and at comparable levels to no treatment indicating 
poor release of the drug. In a similar manner, RBCs loaded with Cbl-COL only disrupted 
microtubule networks when exposed to light (Figure 2.32). These results show that internalization 
and later release does not greatly reduce therapy function. 
2.3.2.3. Synthesis of Long Wavelength Responsive Therapeutics 
 Next, I went about constructing complete phototherapeutics similar in structure to Scheme 
2.1. In addition to MTX and COL, our previous delivery success of Dox from Cbls motivated us 
to also deliver this valuable cancer chemotherapy from RBCs. Each therapy was paired with a red 
or NIR responsive fluorophore to impart sensitivity to tissue penetrating light (Cy5-Cbl-MTX, 
FL800-Cbl-COL, and Cy5SO3--Cbl-Dox). 
144 
 
 Cy5SO3--Cbl-Dox (λmax = 646 nm) and FL800-Cbl-COL (λmax = 786 nm) were 
constructed using the same general approach. First, cyanoCbl was functionalized with a primary 
amine at the ribose-5’-OH using 1,1’-cabonylditraizole followed by treatment with 
ethylenediamine to yield Etd-Cbl (Scheme 2.23).123 Reduction of Etd-Cbl with zinc followed by 
treatment with 4-bromobutyric acid provided the bifunctional Etd-butyrateCbl. TSTU activation 
generated the N-hydroxysuccinimidyl esters of Cy5SO3- and FL800 followed by treatment with 
Etd-butyrateCbl yielded Cy5SO3--butyrateCbl and FL800-butryateCbl (Scheme 2.24). 
Finally, activation of both complexes with HBTU followed by treatment with Dox or aminoCOL 
provided Cy5SO3--Cbl-Dox and FL800-Cbl-COL, respectively (Scheme 2.25). 
Construction of Cy5-Cbl-MTX (λmax – 646 nm) took slightly more care to avoid 
unintended side reactions. Cbl-MTX was formed first by the same method discussed above 
(Scheme 2.20). Next, CDT activation of Cbl-MTX followed by treatment with ethylene diamine 
yielded amine functionalized Etd-Cbl-MTX (Scheme 2.26). Finally, TSTU activated Cy5 was 
added to a solution of Etd-Cbl-MTX to provide the complete Cy5-Cbl-MTX (Scheme 2.27).  
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Scheme 2.21.  Synthesis of Cbl-MTX from propylamineCbl.  
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Scheme 2.22. Synthesis of Cbl-COL from butyrateCbl.  
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Scheme 2.23. Synthesis of Etd-butyrateCbl from CNCbl.  
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Scheme 2.24. Synthesis of Cy5SO3--butyrateCbl and FL800-butyrateCbl.  
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Scheme 2.25. Synthesis of Cy5SO3-- Cbl-Dox and FL800-Cbl-COL.  
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Scheme 2.26. Synthesis of Etd-Cbl-MTX from Cbl-MTX.  
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Scheme 2.27. Synthesis of Cy5-Cbl-MTX from Etd-Cbl-MTX and Cy5.  
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2.3.2.4 Long Wavelength Release of Therapeutics 
 We used the CETSA assay to analyze the efficacy of MTX release from RBCs loaded with 
Cy5-Cbl-MTX (Figure 2.30 – 2.31).112 Although there was a slight increase in intact DHFR in the 
dark, it was found significantly more thermostable upon exposure to the loaded RBCs and 
irradiation (660 nm) indicating successful red light induced MTX release. In a similar manner, 
FL800-Cbl-COL imparted its clumping effects on HeLa cell microtubules upon NIR exposure 
(780 nm, Figure 2.33). In the absence of light, the Cbl compound did not account for any 
significant changes in assay response. 
 Next, we wanted to demonstrate this approach’s power to deliver strong anticancer 
chemotherapies. Therefore, Cy5SO3--Cbl-Dox (10 µM loading) delivery from RBCs using red 
light (660 nm) was investigated (Figure 2.34). Dox contains an anthraquinone fluorophore (λmax – 
480 nm, λem – 580 nm) linked to a daunosamine sugar, so we could easily monitor its localization 
using fluorescence microscopy.124 Free Dox bypasses the lipid membrane to intercalate DNA at 
the minor groove. In the dark, we see no nuclear staining and overall Dox fluorescence remains 
low probably due to quenching interactions with the Cbl.66,79,125 When the loaded RBCs were 
irradiated with red light (660 nm), the Dox fluorescence intensity greatly increased and migrated 
into the nucleus. The response is indicative of successful release of Dox to the HeLa cell. These 
results show that it is indeed feasible to release cancer chemotherapies from RBCs in a targeted 
manner. Efforts within the lab are now being directed at assessing the cytotoxicity of Dox released 
in this manner using cell viability assays.66  
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Figure 2.30. a) Cbl-MTX and b) Cy5-Cbl-MTX stabilization of DHFR upon photolytic release 
from RBCs determined by CETSA. The MTX carrying Cbl was hypotonically loaded (10 μM) 
into RBCs and then incubated with HeLa cells in the dark or under irradiation (525 nm for Cbl-
MTX or 660 nm for Cy5-Cbl-MTX). HeLa cells were then heated and lysed to degrade unbound 
DHFR. Western blot was then used to analyze the amount of thermostable DHFR-MTX bound 
protein from cell lysates.  
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Figure 2.31. CETSA normalized band intensity of thermostable DHFR produced by a) Cbl-MTX 
and b) Cy5-Cbl-MTX released from RBCs. The bar graph represents the quantification of the 
western blot bands shown in Figure 2.31. Significantly more thermostable DHFR is produced 
upon treatment of Cbl loaded RBCs with light (a) 525 nm or b) 660 nm LEDs)  
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Figure 2.32. COL release from Cbl-COL loaded hypotonically into RBCs. HeLa cells were 
treated with Cbl-COL (10 μM) loaded RBCs and incubated (45 min) in the dark (left) or 
photolyzed (525 nm, right). HeLa cells treated with RBCs and exposed to light show microtubule 
depolymerization compared to cells left in the dark or untreated.   
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Figure 2.33. COL release from FL800-Cbl-COL loaded hypotonically into RBCs. HeLa cells 
were treated with FL800-Cbl-COL (10 μM) loaded RBCs and incubated (45 min) in the dark 
(left) or photolyzed (780 nm, right). HeLa cells treated with RBCs and exposed to light show 
microtubule depolymerization, while cells left in the dark or untreated showed well defined 
microtubule structures.   
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Figure 2.34. Dox localization studies when released from CySO3--Cbl-Dox loaded RBCs. HeLa 
cells were plated with the loaded RBCs (10% hematocrit, CySO3--Cbl-Dox-10 μM) then a) left in 
the dark or b) photolyzed. Images of the Dox, HOESCHT, and Cy5 fluorescence were taken every 
60 s on a widefield microscope. In the dark, Dox fluorescence remains low presumably through 
Cbl based quenching of the anthraquinone. Upon photolysis, Dox fluorescence increases 
substantially and migrated to the nucleus where it co-localized with the nuclear stain. The Cy5 
channel shows the Cy5SO3--Cbl fluorescence remaining within the RBCs.  
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2.3.2.4. Orthogonal, Long Wavelength Release of Two Therapeutics 
 Multidrug resistance (MDR) has become a significant problem within many diseases. The 
heterogeneity of cancer between patients and even individual cells has produced aggressive 
malignancies resistant to our most potent therapies.126,127 The exact mechanism of MDR can vary, 
but many cancer cells express drug efflux pumps to lower the intracellular drug concentration. As 
a solution, clinicians often dose cancer patients with multiple drugs at once or in succession to 
overwhelm the cancer’s defense mechanisms. Here, MDR protein antagonists are co-dosed with a 
cytotoxic agent to improve killing capacity, but many of these inhibitors, such as cyclosporine A, 
lack specificity leading to significant adverse effects.126,128 Furthermore, MDR is not limited to 
cancer alone and is problematic in the treatment of bacterial infections with our dwindling library 
of effective antibiotics.129 Therefore, mechanisms for the synergistic and dynamic dosing of 
chemotherapies are desperately needed to improve our treatment of MDR diseases. 
Inspired by this problem and building upon our previous investigation of orthogonal Cbl 
photolysis, we wondered if orthogonal release of two therapeutics from the same RBC was 
possible by simply changing the irradiation wavelength. The treatment path could allow physicians 
to dynamically dose with a specific chemotherapy at one wavelength and then later using a new, 
distinct wavelength to release another therapy that is now more effective due to the action of the 
first. For example, RBCs co-loaded with cyclosporine A and Dox could release the MDR 
antagonist first with one wavelength to knock out drug efflux pumps.127,130 After several minutes 
or hours, the cytotoxic Dox could be released with a second wavelength to a now more susceptible 
cancer cell. This approach could also provide better and more dynamic treatments for infections129 
and thrombosis35. 
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To test our approach, we co-incubated swollen RBCs with Cbl-Bod (2 µM) and FL800-
Cbl-COL (10 µM) to load both within the interior. The absorption profiles of Cbl-Bod (λmax = 
646 nm) and FL800-Cbl-COL (λmax = 786 nm) are distinct within the red and NIR. Therefore as 
our results in Chapter One demonstrated using Cbl-3 and Cbl-5, it should be possible to 
orthogonally activate these two species since their spectral profile does not overlap significantly.  
We exposed HeLa cells to the dual loaded RBCs, varied the irradiation conditions, and monitored 
the cells for the fingerprint responses of delivery (Figure 2.35). When the cells were incubated in 
the dark, we see neither Bod staining of the internal membranes nor the characteristic tubulin 
clumping associated with COL treatment confirming the stability of the co-loaded therapies. Upon 
red light exposure (660 nm), the mitochondria and ER light up from Bod delivery, but the 
microtubule network remains intact indicating low release of COL. Conversely, NIR irradiation 
(780 nm) caused rapid microtubule depolymerization from free COL, while the mitochondria and 
ER remained dim. Introduction of the cells to both wavelengths induced both the effect of Bod 
staining and COL mediated microtubule disruption. These results confirm our assumptions that 
we can successfully mediate the delivery of a specific chemotherapy from mixed load RBC by 
simply changing the activating wavelength used. Extremely encouraged by this finding, we are 
moving to apply this technology for the dynamic co-delivery of chemotherapy treatments. 
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Figure 2.35. Orthogonal release studies of FL800-Cbl-COL and Cbl-Bod when co-loaded in 
RBCs. HeLa cells were plated with the loaded RBCs (10% hematocrit, FL800-Cbl-COL-10 μM 
and Cbl-Bod-5 μM)  then left in the dark or photolyzed (660 nm, 780 nm or both, 40 min). Tubulin 
was imaged with anti-tubulin (secondary Alexa 488) and Bod was imaged with the Cy5 filter.  
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2.4. Conclusion 
 In this chapter, I have demonstrated the adaptation of Cbl photosystems for the delivery of 
model chemotherapies. This work constitutes a major improvement over the current light 
responsive DDSs, because, unlike other photoresponsive moieties, Cbls in conjunction with 
fluorophores can respond to tissue penetrating light to release a diverse array of chemotherapies. 
Additionally, Cbls can inactivate and shuttle these drugs through either endosomal sequestration 
or binding/internalization on RBCs until activation with long wavelength light. This platform also 
allows for the dynamic delivery of several chemotherapies from the same RBC carriers by simply 
adjusting the irradiation wavelength. Going forward, we intend to employ this technology as a 
means for targeted delivery of chemotherapies in cancer and rheumatoid arthritis disease models. 
2.5. Materials and Methods 
2.5.1. General 
CNCbl was purchased from Lallilabis, Inc. TAMRA and fluorescein was purchased from 
AnaSpec. Bodipy650 succinimidyl ester, MitoTracker Green, and Rhodamine B dextran (10,000 
MW) were purchased from Invitrogen. Alexa Fluor 700 carboxylic acid succinimidyl ester was 
purchased from Life Technologies.  Dylight 488 phalloidin were purchased from Thermo Fisher 
Scientific. Doxorubicin was purchased from LC Laboratories. All purchased fluorophores and 
reagents were used without further purification.  
 
8x10 Color Film Gels were manufactured by MacNan and supplied by Amazon. 525 nm and 660 
nm LEDs were purchased from LED Supply. 725 nm and 780 nm LEDs were purchased from 
Techmark.  Erythrocytes were purchased from Allcells and Zenbio.   
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2.5.2 Synthesis 
From Literature: ChloroFL800, amino colchicine, dexamethasone succinate, Cy5, and Cy7 were 
synthesized as previously described.103,104,108 
 
Purification: Unless otherwise noted, all large scale Cbl compound synthesis (> 20 mg) were 
purified with reverse phase (C18) chromatography using a binary solvent system (A:B, A: H2O w/ 
.1% TFA, B: CH3CN w/ .1% TFA) with a gradient held steady at (A:B ratio) 9:1 for 2 column 
volumes, then gradually increased to 1:4 over the next 10 CVs. Product elution was determined by 
UV/Vis detection and confirmed by LC-MS. Small scale reactions (< 20 mg) were purified by 
reverse phase HPLC (C18) using a linear gradient binary solvent system (solvent A: 0.1% 
TFA/H2O; solvent B: 0.1% TFA/CH3CN) with a ratio of A:B that varied from 97:3 (0 min) to 
10:90 (40 min). Product elution was determined by UV/Vis detection and confirmed by LC-MS. 
 
NOTE: Compounds are listed in the order they appear in the text. 
Synthesis of β-(propylamine)cobalamin (propylamineCbl): propylamineCbl was prepared from 
cyanocobalamin (CNCbl) and 3-chloropropylamine hydrochloride according to a literature 
procedure.79 Purification afforded an orange solid; 82%, ESI MS [M + 2 H+]+2 calcd. for 
C65H98N14O14PCo: m/z = 694.3, found 694.5. [M + 3 H
+]+3 calcd. for C65H99N14O14PCo
 : m/z = 
463.1, found 462.9. 
 
Synthesis of butyratecobalamin (butyrateCbl): CNCbl (0.5 g, 369 µmol) was dissolved in MeOH 
(10 mL, 5 w/v% NH4Br) and purged with Ar. Activated Zn powder (2.40 g, 36.9 mmol) was added 
and upon color change from red to blue, 4-bromobutyric acid was added and shaken for 1 h. The 
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product was precipitated with ether (2 x 40 mL) and purified by reverse phase chromatography to 
provide an orange solid; (66%), ESI MS [M + H+]+ calcd. for C66H96CoN13O16P: m/z = 1416.6, 
found 1416.8. [M + 2 H+]+2 calcd. for C66H97CoN13O16P: m/z = 708.8, found 708.9. 
 
Synthesis of BODIPY®650cobalamin (Cbl-Bod): BODIPY®650 N-hydroxysuccinimidyl ester 
(5.0 mg, 7.8 µmol), propylamineCbl (16.1 mg,11.7 µmol), and DIPEA (7.6 µL, 46.8 µmol) were 
mixed in DMF (400 µL) for 18 h. The desired compound was purified by HPLC and removal of 
solvent by lyophilization afforded a blue solid; (13.1 mg, 88%), ESI MS [M + 3 H+]+3 calcd. for 
C94H125N18O17PCoF2: m/z = 638.9, found 638.6. 
 
Synthesis of doxorubicin cobalamin (Cbl-Dox): Doxorubicin (Dox, 3.2 mg, 5.5 µmol), 
butyrateCbl (7.4 mg, 5.2 µmol), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU, 6.4 mg, 17 µmol), and triethylamine (1.7 mg, 17 µmol) were 
dissolved in DMSO (200 µL) and the reaction mixed for 18 hr. The compound was purified by 
HPLC and removal of solvent by lyophilization afforded an orange solid (8.4 mg, 83%); ESI MS 
[M + 2 H+]+2 calcd. for C93H124CoN14O26P: m/z = 971.4, found 971.5. 
 
Synthesis of Etd-cAMP: Ethylenediamine (0.1349 g, 2.2 mmol) and 8-bromoadenosine 3′,5′-cyclic 
monophosphate (0.0114 g, 28 µM) were mixed and microwave irradiated (Sharp domestic 
microwave, model number: R-1M50B) for 3 cycles (5 min). The addition of the reaction mixture 
to ether (3 mL) resulted in the formation of a precipitate, which was collected by centrifugation. 
The precipitate was washed two times with ether (3 mL). Further purification of the desired 
compound was achieved by HPLC (semipreparative C-18 column) using a linear gradient binary 
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solvent system (solvent A: 0.1% TFA/H2O; solvent B: 0.1% TFA/CH3CN) with a ratio of A: B 
that varied from 97:3 (0 min) to 10:90 (40 min). Removal of solvent by lyophilization afforded a 
white solid (0.0098, 91%); 1H NMR (600 MHz, D2O) δ = 3.28 (t, J = 5.59 Hz, 2H), 3.73 (t, J = 
5.69 Hz, 2H), 4.14 – 4.20 (m, 2H), 4.35 – 4.44 (m, 1H), 5.03 (d, J = 5.5 Hz, 1H), 5.10 - 5.14 (m, 
1H), 5.87 (s, 1H), 8.21 (s, 1H); 13C NMR (125 MHz, D2O) δ = 42.8, 44.0, 71.2, 75.0, 75.7, 81.0, 
95.1, 121.3, 145.8, 150.6, 152.8, 157.7; ESI MS [M + H+]+ calcd. for C12H18N7O6P: m/z = 
388.1134, found 388.1141; [M + Na+] calcd. for C12H17N7O6PNa: m/z = 410.0954, found 
410.0955. 
 
Synthesis of cAMP cobalamin (Cbl-cAMP): butyrateCbl (27.5 mg, 19 µmol) TSTU (12.6 g, 42 
µmol) and DIPEA (11.1 mg, 86 µM) were mixed for 2 h in 2:2:1 
dimethylformamide:dioxane:water solution (250 μL). Etd-cAMP (5.7 mg, 15 μmol) was added 
and the reaction mixed for 18 h. The desired compound was purified by HPLC and removal of 
solvent by lyophilization afforded a white solid (8.9 mg, 87%); ESI MS [M-1 + 3 H+] +2 calcd. for 
C78H113CoN20O21P2: m/z = 893.4, found 893.5. [M
-1 + 4 H+]+3 calcd. for C78H114CoN20O21P2: m/z 
=595.9, found 596.2. 
 
Synthesis of stearylamine cobalamin (C18-Cbl). CyanoCbl (200 mg, 148 µmol) and 1,1’-carbonyl-
ditriazole (CDT, 121 mg, 740 µmol) were dissolved in DMSO (10 mL) under an Ar atmosphere 
and stirred for 45 min.  Stearylamine (398 mg, 1.48 mmol) was added and further stirred for 1 h 
before being added to ether/chloroform (1:1, 90 mL). The precipitate was centrifuged and the pellet 
dried under vacuum. The solid was dissolved in EtOH (10 mL) and the solution separated from a 
CDT-mediated ODA dimer solid by centrifugation. The product was again precipitated in 40 mL 
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ether/chloroform (1:1) and collected by centrifugation.  Purification by flash chromatography 
(using MeOH as solvent B) and removal of the solvent by lyophilization furnished a red solid (178 
mg, 75% yield); ESI MS [M + H+]+ calcd. for C82H126CoN15O15P: m/z = 1650.8627, found 
1650.7273; [M + 2 H+]+2 calcd. for C82H127CoN15O15P: m/z = 825.9353, found 825.9091. 
1H NMR (DMSO-d6 ,400MHz):δ = 7.50 - 7.75 (m, 4 H), 7.35 (br. s., 1 H), 7.27 (br. s., 1 H), 7.17 
(d, J=17.6 Hz, 2 H), 7.04 (d, J=10.6 Hz, 2 H), 6.77 (br. s., 1 H), 6.71 (br. s., 1 H), 6.51 (br. s., 1 
H), 6.46 (s, 1 H), 6.24 (br. s., 2 H), 5.92 (s, 1 H), 4.62 - 4.80 (m, 2 H), 4.33 - 4.42 (m, 1 H), 4.18 - 
4.30 (m, 1 H), 3.90 - 4.15 (m, 4 H), 3.67 - 3.76 (m, 2 H), 3.08 (d, J=11.0 Hz, 1 H), 2.95 (d, J=6.3 
Hz, 2 H), 2.72 - 2.86 (m, 2 H), 2.54 (s, 2 H), 2.48 (br. s., 2 H), 2.42 (s, 2 H), 2.25 (d, J=5.5 Hz, 2 
H), 2.17 (br. s., 4 H), 2.07 (br. s., 3 H), 1.58 - 1.84 (m, 6 H), 1.46 - 1.57 (m, 2 H), 1.38 (d, J=5.9 
Hz, 2 H), 1.33 (br. s., 2 H), 1.20 - 1.29 (m, 27 H), 1.18 (br. s., 1 H), 1.15 (d, J=5.9 Hz, 2 H), 1.06 
(s, 2 H), 0.85 (t, J=7.3 Hz, 3 H), 0.33 ppm (br. s., 2 H).  
 
Synthesis of C18- propylamineCbl: C18-Cbl (100 mg, 61 µmol) was dissolved in EtOH (10 mL, 5 
w/v% NH4Br) under N2. Zn powder (200 mg, 3 mmol) was added and shaken for 20 min. To this 
slurry, 3-chloropropylamine (40 mg, 305 µmol) was added and the mixture stirred for 3 h. The 
product was precipitated twice in ether/chloroform (1:1, 50 mL). The resulting precipitate was 
collected by centrifugation and the pellet was dried under vacuum. Purification by flash 
chromatography (using MeOH as solvent B) and removal of the solvent by lyophilization afforded 
a red solid (99 mg, > 95%). ESI MS [M + H+]+ calcd. for C84H134CoN15O15P: m/z = 1682.9253, 
found 1682.9276; [M + 2 H+]+2 calcd. for C84H135CoN15O15P: m/z = 841.9666, found 841.9669. 
 1H NMR (DMSO-d6, 400 MHz): δ= 7.76 (s, 1H), 7.67 (s, 1H), 7.55 - 7.63 (m, 2 H), 7.51 (s, 1H), 
7.37 – 7.44 (m, 3 H), 7.34 (s, 1H), 7.29 (s, 1H), 7.10 – 7.19 (m, 3 H), 7.00 (s, 1H), 6.93 (s, 1H), 
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6.88 (s, 1H), 6.77 (s, 1H), 6.48 - 6.65 (br. m, 2 H), 6.25 (s, 1H), 6.12 (s, 1H), 4.71 (q, 2H, J = 7.04 
Hz), 4.36 (d, J = 8.61 Hz, 2H), 4.15 – 4.33 (br. m, 7H), 3.97 – 4.09 (m, 4H), 3.71 (t, J = 6.62 Hz, 
2H), 3.51 (br. s, 2H), 3.12 (d, J = 8.61 Hz, 1H), 2.92 - 3.07 (br. m, 3H), 2.75 (br. m, 1H), 2.44 – 
2.48 (br. m, 2H), 2.42 (s, 3H), 2.37 (s, 3H), 2.15 – 2.24 (m, 7H), 1.98 – 2.08 (m, 2H), 1.69 – 1.95 
(br. m, 8H), 1.64 (s, 3H), 1.37 (br. s, 3H), 1.19 – 1.29 (m, 28 H), 1.15 (d, J = 6.26 Hz, 3H), 1.06 
(s, 2H), 0.85 (t, J = 6.65 Hz, 3H), 0.47 (br. m, 3H), 0.32 (br. m, 2H), 0.07 (br. m, 2H),-0.40 (br. m, 
2H).  
 
Synthesis of C18-butryateCbl: C18-Cbl (150 mg, 92 µmol) was dissolved in EtOH (10 mL, 5 w/v% 
NH4Br) under Ar. Zn powder (598 mg, 9.2 mmol) was added and shaken for 20 min. After the 
solution’s color turned blue, 4-bromobutyric acid (46 mg, 276 µmol) was added and shaken for 
additional 1 h. The product was precipitated into ether (2 x 40 mL) and purified with flash 
chromatography. Removal of the solvent by lyophilization provided an orange solid (104 mg, 
66%). ESI MS [M + H+]+ calcd. for C85H133CoN14O17P: m/z = 1711.9042, found 1711.9075; [M + 
2 H+]+2 calcd. for C85H134CoN14O17P: m/z = 856.4560, found 856.4571. 
1H NMR (DMSO-d6 ,400MHz): δ = 7.58 - 7.73 (m, 3 H), 7.47 - 7.57 (m, 2 H), 7.31 - 7.40 (m, 2 
H), 7.13 - 7.26 (m, 3 H), 7.04 - 7.12 (m, 2 H), 6.92 - 7.00 (m, 2 H), 6.74 - 6.88 (m, 3 H), 6.59 - 
6.69 (m, 2 H), 6.04 - 6.43 (m, 5 H), 4.50 - 4.75 (m, 3 H), 4.32 - 4.46 (m, 2 H), 4.14 - 4.33 (m, 4 
H), 3.90 - 4.09 (m, 3 H), 3.72 - 3.87 (m, 2 H), 2.91 - 3.01 (m, 3 H), 2.08 - 2.46 (m, 16 H), 1.75 - 
2.00 (m, 8 H), 1.60 - 1.73 (m, 5 H), 1.32 - 1.52 (m, 7 H), 1.15 - 1.32 (m, 26 H), 1.02 - 1.14 (m, 4 
H), 0.93 - 1.02 (m, 2 H), 0.85 (t, J=7.1 Hz, 1 H), 0.50 - 0.76 (m, 4 H), 0.30 - 0.36 (m, 1 H), 0.01 - 
0.24 (m, 3 H), -0.66 - -0.40 ppm (m, 3 H). 
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General Coupling Procedure of C18-propylamineCbl with model therapeutics: The drug-
carboxylic acid (1 eq.), HBTU (1 eq.) and DIPEA (~ 4 eq.) were dissolved in anhydrous DMF 
(~15 mM drug) and stirred for 5 min.  C18-propylamineCbl (1.4 eq.) was then added and the 
solution stirred overnight. The coupling products were purified via HPLC (Viva C4 preparative 
column) using a binary solvent system (A: H2O w/ 0.1% TFA, B: CH3CN w/ 0.1% TFA) with a 
gradient that varied: steady 9:1 (0 – 10 minutes), gradually decreased to 0:100 (10 – 75 minutes), 
and steady again for the last five minutes (75-80). Product elution was confirmed by UV/Vis 
detection and LC-MS. Removal of the solvent by lyophilization afforded: 
 
C18-Cbl-TAM: pink solid (18.9 mg, 75%). ESI MS [M+ + H+]+2 calcd. for C109H155CoN17O19P: 
m/z = 1048.0377, found 1048.0386. 
1H NMR (DMSO-d6 ,400MHz): δ = 8.56 - 8.63 (m, 1 H), 8.42 - 8.47 (m, 1 H), 8.01 - 8.06 (m, 1 
H), 7.95 - 8.00 (m, 1 H), 7.74 - 7.81 (m, 1 H), 7.65 - 7.70 (m, 1 H), 7.53 (br. s., 3 H), 7.32 - 7.36 
(m, 1 H), 7.24 - 7.29 (m, 1 H), 7.03 - 7.21 (m, 4 H), 6.96 (br. s., 4 H), 6.73 - 6.81 (m, 2 H), 6.54 - 
6.60 (m, 1 H), 6.19 - 6.26 (m, 1 H), 6.09 - 6.17 (m, 1 H), 4.66 - 4.74 (m, 1 H), 4.13 - 4.39 (m, 5 
H), 3.96 - 4.08 (m, 2 H), 3.51 (s, 4 H), 3.27 (br. s., 5 H), 2.43 (br. s., 2 H), 2.30 - 2.36 (m, 2 H), 
2.16 - 2.27 (m, 5 H), 2.05 - 2.09 (m, 2 H), 1.70 (br. s., 3 H), 1.37 (br. s., 3 H), 1.18 - 1.31 (m, 28 
H), 1.15 (d, J=6.3 Hz, 2 H), 1.03 (br. s., 1 H), 0.85 (t, J=6.8 Hz, 3 H), 0.47 (br. s., 3 H), 0.15 - 0.29 
(m, 2 H), -0.27 - -0.10 ppm (m, 2 H) 
 
C18-Cbl-FAM: orange solid (22.0 mg, 90%). ESI MS [M-1 + 3 H+]+2  calcd. for 
C105H146CoN15O21P: m/z = 1021.9960, found 1021.9900. 
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(DMSO-d6 ,400MHz): δ = 8.53 (br. s., 1 H), 8.18 (s, 1 H), 7.99 (d, J=7.8 Hz, 1 H), 7.79 (br. s., 1 
H), 7.48 - 7.69 (m, 5 H), 7.28 - 7.46 (m, 5 H), 7.08 - 7.21 (m, 3 H), 6.96 (br. s., 2 H), 6.87 (br. s., 
2 H), 6.78 (br. s., 2 H), 6.67 - 6.71 (m, 2 H), 6.50 - 6.63 (m, 5 H), 6.31 (br. s., 3 H), 4.71 (dd, 
J=11.2, 6.5 Hz, 3 H), 4.24 - 4.42 (m, 7 H), 4.00 - 4.16 (m, 4 H), 3.73 (br. s., 2 H), 3.36 (d, J=7.0 
Hz, 2 H), 3.17 (br. s., 2 H), 3.02 - 3.11 (m, 2 H), 2.91 - 3.01 (m, 3 H), 2.69 - 2.85 (m, 4 H), 2.32 - 
2.41 (m, 7 H), 2.21 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.72 - 1.97 (m, 9 H), 1.69 (br. s., 3 H), 1.33 - 
1.44 (m, 6 H), 1.26 (br. s., 5 H), 1.22 (s, 27 H), 1.14 (d, J=6.3 Hz, 2 H), 0.94 (s, 2 H), 0.85 (t, J=6.7 
Hz, 3 H), 0.57 (br. s., 3 H), 0.29 - 0.40 (m, 1 H), 0.13 - 0.28 (m, 2 H), -0.38 - -0.20 ppm (m, 2 H) 
 
C18-Cbl-MTX: orange solid (51.8 mg, 37%). ESI MS [M + 2 H+]+2 calcd. for C104H155CoN23O19P: 
m/z = 1060.0469, found 1060.0476; [M + 3 H+]+3 calcd. for C104H156CoN23O19P: m/z = 707.0339, 
found 707.0341. 
1H NMR (DMSO-d6 ,400MHz): δ = 8.71 (s, 1 H), 8.19 - 8.26 (m, 1 H), 7.82 (d, J=12.9 Hz, 2 H), 
7.61 - 7.76 (m, 4 H), 7.58 (d, J=5.1 Hz, 3 H), 7.36 (d, J=9.8 Hz, 3 H), 7.05 - 7.21 (m, 3 H), 6.92 
(br. s., 2 H), 6.73 - 6.87 (m, 4 H), 6.61 (br. s., 2 H), 6.28 (d, J=16.4 Hz, 4 H), 4.87 (br. s., 2 H), 
4.71 (d, J=4.7 Hz, 2 H), 4.21 - 4.41 (m, 8 H), 4.04 (d, J=9.0 Hz, 3 H), 3.72 (br. s., 2 H), 3.30 - 3.42 
(m, 2 H), 2.88 - 3.18 (m, 5 H), 2.78 (br. s., 2 H), 1.38 (br. s., 4 H), 1.17 - 1.31 (m, 27 H), 1.14 (d, 
J=5.9 Hz, 3 H), 0.96 (d, J=7.4 Hz, 3 H), 0.85 (t, J=6.7 Hz, 4 H), 0.56 (br. s., 2 H), 0.24 (br. s., 2 
H), -0.02 (s, 2 H), -0.53 ppm (s, 2 H).  
 
C18-Cbl-DEX: orange solid, (18.1 mg, 70%). ESI MS [M + 2 H+]+2 calcd. for 
C110H166CoFN15O22P: m/z = 1079.0693, found 1079.0707. 
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1H NMR (DMSO-d6 ,400MHz): δ = 8.09 - 8.20 (m, 2 H), 8.02 - 8.07 (m, J=5.1 Hz, 1 H), 7.92 (s, 
1 H), 7.78 (s, 2 H), 7.60 - 7.69 (m, 2 H), 7.47 - 7.59 (m, 3 H), 7.21 - 7.37 (m, 4 H), 7.09 - 7.20 (m, 
3 H), 6.94 (br. s., 2 H), 6.77 (br. s., 3 H), 6.58 (br. s., 1 H), 6.22 (dd, J=10.2, 2.0 Hz, 2 H), 6.08 - 
6.16 (m, 2 H), 6.01 (s, 1 H), 5.38 (d, J=4.3 Hz, 1 H), 5.14 (s, 1 H), 5.04 (br. s., 1 H), 4.99 (s, 1 H), 
4.76 (br. s., 1 H), 4.66 - 4.74 (m, 2 H), 4.20 - 4.34 (m, 4 H), 4.07 - 4.19 (m, 3 H), 4.03 - 4.07 (m, 
1 H), 3.96 - 4.02 (m, 2 H), 3.80 - 3.89 (m, 2 H), 3.64 - 3.71 (m, 2 H), 3.54 - 3.60 (m, 3 H), 3.05 - 
3.21 (m, 6 H), 2.92 - 3.04 (m, 4 H), 2.40 - 2.47 (m, 5 H), 2.38 (br. s., 2 H), 2.16 - 2.24 (m, 5 H), 
1.65 - 1.84 (m, 7 H), 1.48 (s, 5 H), 1.38 (br. s., 4 H), 1.23 (s, 27 H), 1.15 (d, J=6.3 Hz, 2 H), 0.97 
- 1.11 (m, 4 H), 0.85 (t, J=7.3 Hz, 3 H), 0.78 (d, J=7.4 Hz, 2 H), 0.46 (br. s., 3 H), 0.27 - 0.38 (m, 
2 H), -0.02 - 0.12 (m, 3 H), -0.50 - -0.37 ppm (m, 2 H). 
 
Synthesis of C18-Cbl-COL: aminoColchicine (aminoCOL) was synthesized as previously 
reported.103 C18-butyrateCbl (63 mg, 37 µmol), HBTU (10 mg, 26 µmol), and DIPEA (15 µL, 86 
µmol) mixed dissolved in DMF (2 mL) and stirred for 5 min. aminoCOL (10 mg, 28 µmol) was 
added and stirred overnight. The product was purified by the C4 HPLC procedure used with the 
other drug couplings. Solvent removal provided an orange solid (22.9 mg, 43% yield).  
ESI MS [M + 2 H+]+2 calcd. for C105H155CoN15O21P: m/z = 1026.0295, found 1026.0299. 
1H NMR (DMSO-d6 ,400MHz): δ = 8.23 (d, J=7.4 Hz, 1 H), 7.78 (br. s., 1 H), 7.49 - 7.70 (m, 3 
H), 7.42 (br. s., 1 H), 7.35 (br. s., 2 H), 7.13 - 7.26 (m, 2 H), 7.02 - 7.13 (m, 3 H), 6.93 - 7.02 (m, 
2 H), 6.88 (d, J=7.4 Hz, 2 H), 6.77 (s, 2 H), 6.59 (br. s., 1 H), 6.13 - 6.35 (m, 3 H), 4.71 (dd, J=11.2, 
6.5 Hz, 2 H), 4.23 - 4.41 (m, 6 H), 4.14 (dd, J=17.8, 6.8 Hz, 3 H), 4.04 (d, J=7.0 Hz, 3 H), 3.88 (d, 
J=4.3 Hz, 3 H), 3.79 (s, 2 H), 3.61 (br. s., 1 H), 3.46 - 3.53 (m, 7 H), 3.30 - 3.43 (m, 2 H), 3.14 - 
3.21 (m, 1 H), 3.00 - 3.13 (m, 2 H), 2.96 (d, J=5.9 Hz, 2 H), 2.75 (s, 1 H), 2.31 - 2.41 (m, 5 H), 
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2.20 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.73 - 1.95 (m, 6 H), 1.59 - 1.71 (m, 5 H), 1.32 - 1.46 (m, 4 H), 
1.17 - 1.31 (m, 25 H), 1.05 - 1.16 (m, 6 H), 0.81 - 0.90 (m, 3 H), 0.42 - 0.63 (m, 4 H), 0.19 (br. s., 
2 H), -0.34 ppm (s, 2 H) 
 
Synthesis of lipidated Cy dyes (C18-Cy5 and C18-Cy7): Cy5 and Cy7 were synthesized as 
previously described. The carboxylate form of the dye (1 eq.) was mixed with 
diisopropylcarbodiimide (DIC, 1.5 eq) and DIPEA (5 eq.) in CH2Cl2 for five minutes. 
Stearylamine (2 eq.) was added and allowed to react for 1 h. The solution was diluted with 
additional CH2Cl2 and purified via normal phase chromatography using a binary solvent system 
(A: CH2Cl2, B: MeOH) with an initial A:B ratio of 90:10, gradually increasing to 1:4. Removal of 
solvent by rotary evaporation yielded: 
 
C18-Cy5: blue oil (74% from absorption @ 646 nm). ESI MS [M+] calcd. for C50H76N3O
+: m/z = 
734.5988, found 734.5983.  
1H NMR (CD2Cl2, 400 MHz): δ = 7.85 - 7.95 (m, 2 H), 7.37 - 7.46 (m, 4 H), 7.28 (q, J = 7.3 Hz, 
2 H), 7.11 - 7.18 (m, 2 H), 6.63 (t, J = 12.5 Hz, 1 H), 6.12 - 6.25 (m, 2 H), 4.01 (t, J = 7.6 Hz, 2 
H), 3.57 (s, 3 H), 3.12 - 3.21 (m, 2 H), 2.20 (t, J = 7.0 Hz, 2 H), 1.84 (br m, 6 H), 1.70 (s, 12 H), 
1.42 - 1.55 (m, 4 H), 1.26 (m, 28 H), 0.88 (t, J = 7.5 Hz, 3 H). 
 
C18-Cy7: blue-green oil (95.2% from absorption @ 760 nm). ESI MS [M+] calc. for C52H78N3O
+: 
m/z =760.6145, found 760.6324.   
1H NMR (CD2Cl2, 400 MHz): δ = 7.69 - 7.83 (m, 2 H), 7.35 - 7.45 (m, 4 H), 7.26 (m, 2 H), 7.14 
(d, J = 7.8 Hz, 1H), 7.09 (d, J = 7.8 Hz, 1H), 6.45 - 6.63 (m, 2 H), 6.19 (d, J = 13.7 Hz, 1 H), 6.08 
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(br m, 2 H), 3.95 - 4.03 (m, 2 H), 3.52 (s, 2 H), 3.17 (d, J = 6.3 Hz, 2 H), 2.19 (t, J = 7.2 Hz, 2 H), 
1.67 - 1.82 (br m, 21 H), 1.44 - 1.52 (br m, 4 H), 1.22 - 1.34 (m, 26 H), 0.88 (t, J = 7.4 Hz, 3 H).   
 
Synthesis of DY800. N-(5-carboxypentyl)-2,3,3-trimethyl indolium-5-sulfonate (5, 300 mg, 850 
μmol) and 3-chloro-2,4-trimethyleneglutacondianil hydrochloride (305 mg, 850 μmol) were 
refluxed in a solution of acetic acid/acetic anhydride (4 mL, 1:1 ratio) for 2 h. The solvent was 
removed and the residue re-dissolved in a mixture of pyridine and acetic acid (4 mL, 1:1 ratio). N-
(3-sulfopropyl)-2,3,3-trimethyl indolium-5-sulfonate (3, 325 mg, 850 μmol) was added and the 
solution was heated to 80 °C for 1 h. The product was then precipitated and washed with ethyl 
acetate (3x100 mL). The blue precipitate was purified by reverse phase chromatography and 
removal of the solvent by lyophilization yielded a green solid (chloroDY800, 180 mg, 25% yield, 
λmax = 786 nm). ChloroDY800 (100 mg, 120 µmol) was dissolved in anhydrous DMF (18 mL) 
and sodium phenoxide (139 mg, 1.2 mmol) was added under Ar. The solution was stirred for 1 h 
and then precipitated into diethyl ether (250 mL). The precipitate was purified and removal of the 
solvent by lyophilization afforded a green solid (86 mg, 79%). ESI MS [M-2 + 3 H+]+ calc. for 
C45H53N2O12S3: m/z = 909.2761, found 909.2764. 
1H NMR (DMSO-d6 ,400MHz): δ = 7.74 - 7.88 (m, 3 H), 7.56 - 7.65 (m, 3 H), 7.38 – 7.46 (m, 3 
H), 7.25 (d, J = 8.2 Hz, 1 H), 7.16 (d, J = 8.2 Hz, 2 H), 7.05 (t, J = 7.2 Hz, 1 H), 6.49 (d, J = 14.5 
Hz, 1 H), 6.13 (d, J = 14.1 Hz, 1 H), 4.33 (br s, 2 H), 4.08 (br s, 2 H), 2.68 - 2.80 (m, 4 H), 2.56 
(t, J = 6.5 Hz, 2 H), 2.19 (t, J = 7.2 Hz, 2 H), 1.88 - 2.02 (m, 4 H), 1.61 - 1.73 (m, 3 H), 1.50 - 
1.59 (m, 3 H), 1.21 - 1.40 (m, 12 H).  
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Synthesis of C18-DY800:  DY800 (2.0 mg, 2.2 μmol) and HCTU (1.4 mg, 3.3 μmol) were dissolved 
in anhydrous DMF (500 μL). After 5 min, stearylamine in chloroform (500 µL, 1 mg/mL) was 
added and mixed for 1 h. The product was extracted into aqueous solution with water (2 x 1 mL). 
The aqueous phase was then purified by HPLC using a stationary C4 phase with a A:B solvent 
system (A: H2O .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was gradually increased 
from 10:1 to 1:19. The solvent was removed by rotary evaporation to give a blue-green oil (35% 
yield, λmax = 776 nm in ethanol).  ESI MS [M-2 + 3 H+]+ calc. for C63H90N3O11S3: m/z = 1160.5737, 
found 1160.5738. 
1H NMR (DMSO-d6 ,400M Hz): δ = 7.72 – 7.87 (m, 3 H), 7.56 - 7.65 (m, 3 H), 7.37 - 7.45 (m, 3 
H), 7.19 - 7.26 (m, 1 H), 7.12 - 7.18 (m, 2 H), 7.02 - 7.09 (m, 1 H), 6.50 (d, J = 14.2 Hz, 1 H), 
6.12 (d, J = 14.5 Hz, 1 H), 4.29 - 4.37 (m, 2 H), 4.02 - 4.11 (m, 2 H), 2.98 (dd, J = 12.7, 6.8 Hz, 
3 H), 2.74 - 2.80 (m, 2 H), 2.65 - 2.74 (m, 2 H), 2.31 - 2.35 (m, 2 H), 2.02 (t, J = 7.4 Hz, 3 H), 
1.89 - 1.99 (m, 4 H), 1.60 - 1.72 (m, 3 H), 1.47 - 1.58 (m, 3 H), 1.26 - 1.40 (m, 12 H), 1.22 (s, 30 
H), 0.85 ppm (t, J = 6.8 Hz, 3 H).   
 
Synthesis of FL800: ChloroFL800 was synthesized as previously described. ChloroFL800 (150 
mg, 215 µmol) was dissolved in DMF (10 mL) and purged with Ar for 10 min. 4-
mercaptophenylacetic acid (216 mg, 1.29 mmol) was added and the solution was stirred for 2 h. 
The solution was treated with chloroform (10 mL), purified via flash chromatography and the 
solvent was removed under reduced pressure to produce a dark green powder in near quantitative 
yield (169 mg, 95%, λmax = 786 nm). ESI MS [M-1]-1 calcd. for C44H49N2O8S3: m/z = 829.2681, 
found 829.2631 
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1H NMR (400MHz ,DMSO-d6) δ = 8.63 (d, J = 14.1 Hz, 2 H), 7.53 – 7.47 (m, 4 H), 7.38 (t, J = 
7.8 Hz, 2 H), 7.25 - 7.15 (m, 6 H), 6.50 (d, J = 14.1 Hz, 2 H), 4.33 (t, J = 7.4 Hz, 4 H), 2.77 (t, J = 
6.3 Hz, 4 H), 2.54 (t, J = 6.7 Hz, 4 H), 2.04 - 1.94 (m, 4 H), 1.93 - 1.86 (m, 2 H), 1.44 (s, 11 H) 
 
Synthesis of cyanocobalamin-ethylene diamine (Etd-Cbl): cyanoCbl (1.0 g, 738 μmol) and CDT, 
605 mg, 3.69 mmol were added to an oven dried, round bottom flask (50 mL) and purged for 20 
min with Ar. DMSO (10 mL) was cannulated into the flask and stirred for 2 h. Ethylene diamine 
(247 uL, 3.69 mmol) was subsequently added and stirring was continued for an additional 24 h. 
The solution was precipitated into cold acetone (2 x 35 mL) and the resulting red solid was re-
dissolved in deionized H2O (15 mL) and purified via reverse phase chromatography. The red 
solution dried via lyophilization to produce a red powder (886 mg, 84%). ESI MS [M + H+]+ calc. 
for C66H95N16O15PCo: m/z = 1441.6236, found 1441.6364; [M + 2 H
+]+2 calcd. for 
C66H96N16O15PCo: m/z = 721.3516, found 721.4546.  
1H NMR (400MHz ,DMSO-d6) δ = 7.85 (br. s., 1 H), 7.75 (br. s., 1 H), 7.69 (d, J = 7.0 Hz, 1 H), 
7.56 (d, J = 5.5 Hz, 1 H), 7.47 (t, J = 5.7 Hz, 1 H), 7.35 (br. s., 1 H), 7.28 (s, 1 H), 7.18 (d, J = 17.6 
Hz, 1 H), 7.09 - 6.99 (m, 1 H), 6.81 - 6.68 (m, 1 H), 6.54 (br. s., 1 H), 6.47 (s, 1 H), 6.30 (br. s., 1 
H), 6.07 (br. s., 1 H), 5.94 (s, 1 H), 4.66 (d, J = 7.4 Hz, 2H), 4.51 (d, J = 8.0 Hz,2H), 4.30 (q, J = 
7.1 Hz, 2H) 4.11 - 4.00 (m, 1 H), 3.95 (d, J = 11.0 Hz, 1 H), 3.74 (dd, J = 5.3, 10.0 Hz, 1 H), 3.67 
- 3.57 (m, 1 H), 3.26 (br. s., 1 H), 3.07 (d, J = 11.0 Hz, 1 H), 2.95 - 2.85 (m, 1 H), 2.78 (br. s., 1 
H), 2.68 - 2.55 (m, 1 H), 2.44 (br. s., 5 H), 2.37 - 2.30 (m, 3 H), 2.25 (dd, J = 8.8, 15.1 Hz, 3 H), 
2.18 (d, J = 5.1 Hz, 6 H), 2.09 - 1.98 (m, 4 H), 1.95 - 1.84 (m, 3 H), 1.79 - 1.65 (m, 9 H), 1.55 (td, 
J = 7.9, 15.2 Hz, 3 H), 1.34 (br. s., 4 H), 1.25 - 1.15 (m, 12 H), 1.06 (s, 4 H), 0.33 (br. s., 4 H). 
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Synthesis of butyratecobalamin-ethylene diamine (Etd-butyrateCbl): Etd-Cbl (500 mg, 359 μmol) 
was dissolved in MeOH (5 w/v% NH4Br, 15 mL) and the solution was purged with Ar for 20 min. 
Activated Zn dust (23.9 g, 369 mmol) was added and the solution was shaken for 20 min. 4-
Bromobutyric acid (174 mg, 1.1 mmol) was quickly added and after 30 min, the Zn dust was 
allowed to settle and the MeOH supernatant was added to chilled ether (2 x 30 mL) inducing the 
precipitation of an orange solid. The resulting orange solid purified via reverse phase 
chromatography and lyophilization produced an orange powder in near quantitative yield (545 mg, 
98%). ESI MS [M + H+] calcd. for C69H102N15O17PCo: m/z = 1502.6648, found 1502.6648; [M + 
2 H+] calcd. for C69H103N15O17PCo: m/z = 751.8363, found 751.8363.  
1H NMR (400MHz DMSO-d6) δ = 7.99 - 7.82 (m, 4 H), 7.65 (br. s., 2 H), 7.56 - 7.41 (m, 3 H), 
7.38 (br. s., 1 H), 7.18 (br. s., 1 H), 7.13 (br. s., 1 H), 7.06 - 6.92 (m, 3 H), 6.86 (br. s., 1 H), 6.79 
(br. s., 1 H), 6.65 (br. s., 1 H), 6.39 (br. s., 2 H), 4.79 - 4.69 (m, 1 H), 4.44 (br. s., 1 H), 4.41 - 4.26 
(m, 4 H), 4.19 (d, J = 9.8 Hz, 1 H), 4.09 (dd, J = 4.3, 11.7 Hz, 1 H), 3.86 (br. s., 1 H), 3.32 - 3.19 
(m, 4 H), 3.11 (d, J = 6.3 Hz, 1 H), 2.93 - 2.79 (m, 3 H), 2.62 - 2.52 (m, 2 H), 2.43 - 2.36 (m, 8 H), 
2.36 - 2.17 (m, 12 H), 2.15 - 1.99 (m, 2 H), 1.93 (br. s., 3 H), 1.84 (d, J = 13.3 Hz, 4 H), 1.79 - 
1.59 (m, 8 H), 1.52 (br. s., 1 H), 1.49 - 1.40 (m, 3 H), 1.38 - 1.22 (m, 8 H), 1.20 - 0.98 (m, 7 H), 
0.64 (br. s., 2 H), 0.22 (br. s., 2 H), 0.15 - 0.03 (m, 2 H), -0.40 (br. s., 2 H)  
 
Synthesis of methotrexate cobalamin (Cbl-MTX): MTX (30 mg, 66 µmol), HBTU (25 mg, 66 
µmol), and DIPEA (58 µL, 332 µmol) were dissolved in DMF (5 mL) and stirred for 5 min.  
propylamineCbl (98 mg, 71 µmol) was added, stirred overnight, and then purified via reverse 
phase Lyophilization yielded Cbl-MTX as an orange solid (78 mg, 65%). ESI MS [M + 2 H+]+2 
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calcd. for C85H118CoN22O18P: m/z = 912.4032, found 912.4038; [M
 + 3 H+]+3 calcd. for 
C85H119CoN22O18P: m/z = 608.6047, found 608.9274. 
1H NMR (400MHz DMSO-d6) δ = 9.28 (s, 1 H), 9.07 (d, J=4.7 Hz, 1 H), 8.79 (s, 1 H), 8.73 - 8.77 
(m, 1 H), 8.67 - 8.72 (m, 1 H), 8.61 (br. s., 1 H), 7.77 - 7.88 (m, 2 H), 7.63 - 7.76 (m, 3 H), 7.48 - 
7.62 (m, 3 H), 7.32 - 7.47 (m, 2 H), 7.06 - 7.22 (m, 2 H), 6.90 - 7.02 (m, 1 H), 6.74 - 6.88 (m, 5 
H), 6.63 (br. s., 1 H), 6.20 - 6.35 (m, 1 H), 4.85 - 4.93 (m, 3 H), 4.71 - 4.80 (m, 1 H), 4.64 (dd, 
J=8.6, 4.7 Hz, 1 H), 4.12 - 4.34 (m, 3 H), 4.06 (br. s., 1 H), 3.69 (d, J=12.5 Hz, 2 H), 3.51 (d, J=9.8 
Hz, 1 H), 3.27 - 3.30 (m, 2 H), 3.22 - 3.26 (m, 2 H), 2.88 - 2.99 (m, 1 H), 2.72 - 2.82 (m, 1 H), 
2.69 (s, 1 H), 2.52 - 2.58 (m, 2 H), 2.31 - 2.48 (m, 10 H), 2.12 - 2.30 (m, 10 H), 2.08 (br. s., 1 H), 
1.72 - 2.01 (m, 9 H), 1.68 (br. s., 3 H), 1.39 (br. s., 3 H), 1.18 - 1.31 (m, 6 H), 1.13 (d, J=6.3 Hz, 3 
H), 0.92 - 1.03 (m, 3 H), 0.55 (br. s., 2 H), 0.00 ppm (d, J=7.0 Hz, 1 H) 
 
Synthesis of colchicine cobalamin (Cbl-COL): butyrateCbl (58 mg, 41 µmol), HBTU (10 mg, 26 
µmol), and DIPEA (15 µL, 86 µmol) were dissolved in DMF (2 mL) and stirred for 5 min.  Amino 
colchicine (10 mg, 28 µmol) was added and the solution was stirred overnight. Cbl-COL was then 
purified via reverse phase chromatography and the solvent was removed via lyophilization to yield 
an orange solid (37.4 mg, 82%). ESI MS [M + 2 H+]+2 calcd. for C86H118CoN14O20P: m/z = 
878.3858, found 878.3939.  
1H NMR (400MHz ,DEUTERIUM OXIDE) δ = 9.04 (s, 1 H), 7.34 (s, 1 H), 7.26 (s, 1 H), 7.14 (d, 
J = 11 Hz, 1 H), 6.97 (s, 1 H), 6.64 (br. s, 2 H), 6.32 (d, J = 4.7 Hz, 1 H), 4.75 (t, J = 4.7 Hz, 1 H), 
4.55 (d, J = 3.1 Hz, 1 H), 4.23 (d, J = 9.8 Hz, 1 H), 4.17 - 4.10 (m, 1 H), 3.94 (d, J = 8.6 Hz, 1 H), 
3.85 (t, J = 8.6 Hz, 2 H), 3.78 - 3.71 (m, 6 H), 3.69 - 3.63 (m, 2 H), 3.61 (d, J = 3.5 Hz, 1 H), 3.58 
(d, J = 3.9 Hz, 1 H), 3.35 (s, 3 H), 3.18 - 3.10 (m, 2 H), 3.06 - 2.98 (m, 1 H), 2.68 - 2.47 (m, 4 H), 
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2.36 - 2.20 (m, 7 H), 2.15 (m, 7 H), 2.00 (d, J = 8.2 Hz, 6 H), 1.63 (m, 7 H), 1.36 (br. s., 3 H), 1.24 
(s, 3 H), 0.98 (d, J = 6.3 Hz, 3 H), 0.91 (s, 2 H), 0.64 - 0.55 (m, 3 H), 0.51 (br. s., 2 H), 0.23 - 0.12 
(m, 2 H), -0.24 - -0.34 (m, 2 H), -0.39 - -0.51 (m, 2 H) 
 
Synthesis of FL800-butyrateCbl: FL800 (15.0 mg, 18.1 umol), DIC (6.8 mg, 53.9 umol), and N-
hydroxy succinimide (6.2 mg, 53.9 umol) were mixed in anhydrous DMF (350 uL) and allowed 
to react for 12 h. Water (30 uL) was then added to quench excess DIC and generate an FL800-
NHS stock solution. Etd-butyrateCbl (12.6 mg, 8.42 umol) was mixed with FL800-NHS ester 
solution (200 uL, 46.3 mM, 9.26 umol FL800-NHS) and DIPEA (29.3 uL, 168 umol) and allowed 
to react for 12 h. The solution was diluted with deionized water (2.8 mL) and purified via HPLC 
(semi-preparative C18 column) using a binary gradient solvent system (A:B, A: water w/ .1 v/v% 
TFA, B: CH3CN w/ .1 v/v% TFA).  Equilibration (10 min) was followed by an increasing gradient 
97:3 to 5:95 (50 min). Eluents were monitored at 700 nm, collected, and lyophilized to give a green 
solid (13.2 mg, 68%, λmax = 786 nm).  
ESI MS [M- + 3H+]+2 calcd. for C113H151N17O24PS3Co: m/z = 1158.4690, found 1158.4701, [M+ 
4H+]+3 C113H152N17O24PS3Co: m/z = 772.6487, found 772.6763. 
1H NMR (400MHz ,DMSO-d6)  = 8.59 (d, J = 13.3 Hz, 2 H), 8.11 - 8.01 (m, 2 H), 7.86 - 7.77 
(m, 1 H), 7.66 - 7.58 (m, 1 H), 7.47 (m, 3 H), 7.36 (t, J = 7.8 Hz, 2 H), 7.24 - 7.16 (m, 4 H), 6.98 
(s, 1 H), 6.80 (s, 1 H), 6.49 (d, J = 13.3 Hz, 2 H), 6.40 - 6.30 (m, 2 H), 4.32 (d, J = 7.0 Hz, 4 H), 
3.52 - 3.50 (m, 1 H), 3.14 - 3.10 (m, 1 H), 3.04 - 2.92 (m, 4 H), 2.77 (br. s., 3 H), 2.70 - 2.65 (m, 
1 H), 2.61 - 2.53 (m, 3 H), 2.38 (d, J = 5.1 Hz, 4 H), 2.26 (br. s., 7 H), 2.00 (br. s., 4 H), 1.95 – 
1.75 (m, 7 H), 1.67 (br. s., 4 H), 1.60 - 1.55 (m, 1 H), 1.41 (s., 9 H), 1.33 - 1.19 (m, 6 H), 1.12 (d, 
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J = 6.3 Hz, 2 H), 1.04 - 0.95 (m, 3 H), 0.66 - 0.57 (m, 2 H), 0.29 - 0.16 (m, 2 H), -0.30 - -0.48 (m, 
2 H) 
Synthesis of FL800-Cbl-COL: FL800-butyrateCbl (2.1 mg, 900 nmol), HCTU (486 μg, 1.2 
umol), and DIPEA (3.1 uL, 18 umol) were mixed in DMF (100 uL). After ten minutes of activation, 
amino colchicine (640 μg, 1.8 umol) was added and the solution was reacted for an additional 2 h. 
The solution was diluted with deionized water (2.9 mL) and purified via HPLC. Lyophilization 
gave a green solid (654 µg, 31% [from absorbance], λmax = 786 nm). ESI MS [M- + 3H+]+2 calcd. 
for C133H172N18O28PS3Co: m/z = 1328.0425, found 1328.0464, [M
- + 4H+]+3 calcd for 
C133H173N18O28PS3Co: m/z = 885.6977, found 885.6997. 
1H NMR (400MHz ,DMSO-d6)  = 8.59 (d, J = 13.3 Hz, 2 H), 8.11 - 8.01 (m, 2 H), 7.86 - 7.77 
(m, 1 H), 7.66 - 7.58 (m, 1 H), 7.47 (m, 3 H), 7.36 (t, J = 7.8 Hz, 2 H), 7.24 - 7.16 (m, 4 H), 6.98 
(s, 1 H), 6.80 (s, 1 H), 6.49 (d, J = 13.3 Hz, 2 H), 6.40 - 6.30 (m, 2 H), 4.32 (d, J = 7.0 Hz, 4 H), 
3.52 - 3.50 (m, 1 H), 3.14 - 3.10 (m, 1 H), 3.04 - 2.92 (m, 4 H), 2.77 (br. s., 3 H), 2.70 - 2.65 (m, 
1 H), 2.61 - 2.53 (m, 3 H), 2.38 (d, J = 5.1 Hz, 4 H), 2.26 (br. s., 7 H), 2.00 (br. s., 4 H), 1.95 – 
1.75 (m, 7 H), 1.67 (br. s., 4 H), 1.60 - 1.55 (m, 1 H), 1.41 (s., 9 H), 1.33 - 1.19 (m, 6 H), 1.12 (d, 
J = 6.3 Hz, 2 H), 1.04 - 0.95 (m, 3 H), 0.66 - 0.57 (m, 2 H), 0.29 - 0.16 (m, 2 H), -0.30 - -0.48 (m, 
2 H) 
 
Synthesis of Cy5SO3--butyrateCbl: Cy5SO3- (32 mg, 50 µmol) was mixed with TSTU (45 mg, 150 
µmol) and DIPEA (40 µL, 250 µmol) was dissolved in anhydrous DMF (2.5 mL) and allowed to 
react 3 h. Etd-butyrateCbl (50 mg, 33.3 µmol) was added to the reaction and allowed to react 
overnight. The product was purified using reverse phase chromatography and lyophilization 
yielded the product as a blue solid (62.5 mg, 89%). ESI MS [M-1 + 3 H+]+2 calcd. for 
178 
 
C101H139CoN17O24PS2: m/z = 1064.4360, found 1064.4344, [M
- + 4H+] calcd. for 
C101H140CoN17O24PS2: m/z = 709.9600, found 709.9589. 
1H NMR (400MHz ,DEUTERIUM OXIDE) d = 9.12 - 8.97 (m, 2 H), 7.99 - 7.81 (m, 2 H), 7.73 - 
7.58 (m, 2 H), 7.17 - 7.05 (m, 1 H), 6.80 - 6.67 (m, 1 H), 6.44 - 6.31 (m, 1 H), 6.15 - 5.96 (m, 2 
H), 4.35 (d, J = 7.8 Hz, 1 H), 4.26 (s, 1 H), 4.03 (d, J = 11.3 Hz, 1 H), 3.96 (d, J = 10.6 Hz, 1 H), 
3.87 - 3.73 (m, 2 H), 3.68 - 3.55 (m, 2 H), 3.40 (s, 1 H), 3.17 - 3.02 (m, 3 H), 2.87 (s, 1 H), 2.71 
(s, 1 H), 2.65 – 2.6 (m, 1 H), 2.56 - 2.50 (m, 2 H), 2.40 - 2.29 (m, 2 H), 2.28 - 2.17 (m, 3 H), 2.05 
(s, 3 H), 1.73 - 1.53 (m, 4 H), 1.51 - 1.39 (m, 4 H), 1.34 - 1.12 (m, 4 H), 1.01 (d, J = 6.3 Hz, 2 H), 
0.89 - 0.81 (m, 1 H), 0.70 - 0.59 (m, 2 H), 0.08 - -0.14 (m, 2 H), -0.53 - -0.71 (m, 2 H) 
 
Synthesis of Cy5SO3--Cbl-Dox: Cy5SO3--butyrateCbl (30 mg, 14 µmol), HATU (5.1 mg, 13 
µmol), and DIPEA (11.4 µL, 70 µmol) were dissolved in anhydrous DMF (700 µL). After 5 min, 
Dox (12.2 mg, 21 µmol) was added and reacted for 2 h. The product was purified via reverse phase 
HPLC and lyophilization provided a blue solid (25 mg, 67%). ESI MS [M-1 + 3H+]+2 calcd. for 
C128H166CoN18O34PS2: m/z = 1327.0180, found 1327.0130. 
1H NMR (DEUTERIUM OXIDE ,400MHz): δ = 9.18 (br. s., 1 H), 7.94 (br. s., 1 H), 7.79 (d, 
J=7.0 Hz, 1 H), 7.72 (t, J=8.0 Hz, 1 H), 7.40 - 7.62 (m, 2 H), 7.29 (d, J=9.4 Hz, 1 H), 7.14 (br. s., 
1 H), 6.71 (br. s., 1 H), 6.35 (br. s., 1 H), 6.26 (br. s., 1 H), 6.07 (d, J=13.3 Hz, 1 H), 5.47 (br. s., 
1 H), 5.34 (br. s., 1 H), 4.86 (br. s., 1 H), 4.34 - 4.50 (m, 1 H), 4.05 - 4.31 (m, 3 H), 3.89 - 4.05 
(m, 3 H), 3.80 (br. s., 1 H), 3.62 - 3.75 (m, 1 H), 3.44 - 3.54 (m, 1 H), 3.31 (d, J=12.9 Hz, 1 H), 
3.11 (br. s., 1 H), 2.89 - 3.00 (m, 1 H), 2.84 (br. s., 1 H), 2.69 - 2.72 (m, 1 H), 2.63 (br. s., 1 H), 
2.33 - 2.52 (m, 3 H), 2.19 - 2.32 (m, 3 H), 1.91 - 2.15 (m, 5 H), 1.73 (br. s., 3 H), 1.63 (d, J=11.7 
Hz, 2 H), 1.54 (d, J=9.0 Hz, 4 H), 1.38 (d, J=7.4 Hz, 2 H), 1.29 (d, J=6.3 Hz, 2 H), 1.23 (s, 1 H), 
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1.12 - 1.21 (m, 1 H), 1.06 (d, J=5.9 Hz, 1 H), 0.94 (br. s., 1 H), 0.68 - 0.84 (m, 1 H), 0.58 (s, 1 
H), 0.34 (s, 1 H), -0.24 ppm (br. s., 2 H) 
 
Synthesis of Cy5-Cbl-MTX: Cbl-MTX (35 mg, 19 µmol) and CDT (16 mg, 96 µmol) were 
dissolved in DMF (500 µL) under Ar and reacted for 2 h. Ethylene diamine (14.4 µL, 192 µmol) 
was added to the solution and allowed to react overnight. The product was precipitated and purified 
by flash chromatography (C18 w/o TFA) to yield Etd-Cbl-MTX (20 mg, 55%). Cy5 (7.7 mg, 15.9 
µmol), HBTU (5.7 mg, 15.1 µmol), and DIPEA (12.2 µL, 79.5 µmol) were mixed in DMF (600 
µL). After 5 min, Etd-Cbl-MTX (20 mg, 10.5 µmol) was added and reacted overnight. The 
reaction was diluted with H2O (2.4 mL), purified by HPLC, and lyophilized to give a blue solid 
(15.9 mg, 68%). ESI MS [M+ + H+]+2 calcd. for C120H160CoN26O20P: m/z = 1188.0705, found 
1188.0661, [M+ + 2H+]+3 calcd. for C120H161CoN26O20P: m/z = 792.3827, found 792.3809. 
1H NMR (400MHz ,DMSO-d6) δ = 8.70 (d, J=3.1 Hz, 1 H), 8.32 (t, J=12.7 Hz, 2 H), 7.64 - 7.77 
(m, 4 H), 7.61 (d, J=7.0 Hz, 2 H), 7.47 (s, 1 H), 7.33 - 7.42 (m, 4 H), 7.17 - 7.32 (m, 4 H), 6.81 
(br. s., 3 H), 6.72 (br. s., 2 H), 6.49 - 6.62 (m, 3 H), 6.21 - 6.33 (m, 3 H), 4.87 (br. s., 1 H), 3.59 (d, 
J=2.7 Hz, 3 H), 3.38 (q, J=7.0 Hz, 2 H), 3.24 (br. s., 2 H), 2.67 (br. s., 1 H), 2.32 (d, J=4.7 Hz, 6 
H), 2.23 (br. s., 3 H), 1.67 (s, 12 H), 1.51 (br. s., 4 H), 1.34 (br. s., 4 H), 1.19 - 1.29 (m, 5 H), 1.14 
(d, J=5.9 Hz, 2 H), 1.09 (t, J=7.0 Hz, 2 H), 0.94 (d, J=7.4 Hz, 3 H), 0.87 (br. s., 2 H), 0.52 (br. s., 
2 H), -0.08 - 0.09 (m, 2 H), -0.77 ppm (s, 2 H) 
 
2.5.3. Endosomal Loading and Release 
Treatment of REF52 cells with Ac-cAMP, CPT-cAMP, and Cbl-cAMP. Plated REF52 cells were 
rinsed with PBS and placed with L15 media (1% BSA) only (negative control and illumination 
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only control) or Ac-cAMP, Cbl-cAMP or CPT-cAMP (500 µM). Cells were illuminated (530 
nm, 10 min) with a Zeiss Colibri LED system followed by incubation (37 °C, 30 min). After the 
incubation, cells were fixed (4% paraformaldehyde, 10 min) and labeled with Dylight 488-
phalloidin via manufacturer’s protocol. Imaging of stress fibers was accomplished with an 
Olympus microscope at 4-X magnification with a FITC filter (λex= 475 ± 25 nm, λem= 540 ± 25 
nm, 200 ms exposure time). Images were processed using ImageJ. 
 
Treatment of HeLa cells with Cbl-Dox. Plated HeLa cells (5000 cells/well) were rinsed with PBS, 
and the media replaced with just L15 (1% BSA and 0.5% DMSO) or L15 media (1% BSA, 0.5 % 
DMSO) mixed with Dox or Cbl-Dox (10 µM).  The cells were irradiated with a Zeiss Colibri LED 
(530 nm) for 15 s, 30 s, 45 s, and 1 min followed by incubation (24 h). The cells were subjected to 
a viability assay utilizing Cell Titer 96® Aqueous One Cell Proliferation Assay (Promega, 
absorbance read at 520 nm). 
 
Photolysis of Cbl-Bod on a widefield microscope. Plated HeLa cells were treated with Cbl-Bod 
(500 nM, fluorescence increase and endosomal localization experiments, 125 nM for 
mitochondrial localization experiments, (λex – 650 nm λem - 665 nm) in L15 (1% BSA) and 
MitoTracker Green (40 nM, λex - 490 λem - 516 nm) or rhodamine B-dextran (1 mg/mL, λex – 570 
nm λem - 590 nm). Cells were incubated (37 °C, 30 min) followed by washing with PBS (3 times). 
Cells were illuminated and imaged using the Cy5 filter cube (λex = 650 ± 13 nm, λem = 684 ± 25 
nm) every minute for 15 min. MitoTracker Green (20 ms exposure time) was visualized after 
photolysis. Images were acquired with a 60x oil immersion UPlan S-Apo objective. Images were 
processed using a MetaMorph and ImageJ. (n = 10) 
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2.5.4 Delivery RBC-Membrane 
Drug LC-MS assay. Samples (75 µL) were injected onto a 1200 series Agilent LC-MS (Viva 
analytical C4 column) with a UV-Vis detector and 6110 quadrupole mass spectrometer. The mobile 
phase consisted of binary solvent system (A: B, solvent A: H2O w/ 0.1 v/v% Formic acid, solvent 
B: CH3CN 0.1 v/v% Formic Acid) that varied (A: B) from 97:3 (0 - 1 min), 1:4 (1 - 8 min), and 
held at 1:4 (8 – 10 min). Drug concentrations were determined using standard curves of the free 
drug standards at an absorbed wavelength. Area under the curve integrations of various 
concentrations of free drugs were used to construct standard curves. The location of product elution 
and their absorption are: 
MTX: Concentrations were determined by the absorbance trace at 300 nm from 3.1 - 3.7 min. 
COL: Concentrations were determined by the absorbance trace at 365 nm from 4.3 – 4.8 min.  
DEX: Concentrations were determined by the absorbance trace at 239 nm from 4.5 - 4.9 min. 
 
Octanol/water partition studies. 
MTX: Octanol (100 µL) containing C18-Cbl-MTX (5 µM) was mixed with PBS (500 µL) and 
equilibrated (30 min, dark) before centrifugation (10 min, 21,000 g).  Samples were photolyzed 
(525 nm LED, 1.50 mW/cm2) for 0, 1, 2, 5, 10, and 20 min followed by mixing and equilibration 
(15 min). Samples were again centrifuged and aliquots (100 µL) were taken from the aqueous layer 
and the concentration of MTX was determined by LC-MS. (n = 3) 
TAM: Octanol (100 µL) containing C18-Cbl-TAM (10 µM) was mixed with PBS (300 µL) and 
separated (30 min, dark) before centrifugation (10 min, 21,000 g). Samples were then photolyzed 
(525 nm LED, 1.50 mW/cm2) for 0, 1, 2, 3, and 10 min followed by mixing and equilibration (15 
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min). The aqueous layer was removed and measured for TAM fluorescence (λex – 555 nm, λem = 
570 - 600 nm) using a PTI Model LPS-220 fluorometer. (n = 3) 
 
Erythrocyte storage and loading (C18). Erythrocytes were washed with RBC buffer (3 times, PBS, 
1 mM MgCl2), suspended (10% hematocrit), and refrigerated (4 
oC) for up to a month. Lipidated 
compounds were added at various concentrations to erythrocytes (10% hematocrit). The 
erythrocytes were incubated (RT, 20 min), washed (3 times, PBS) and stored in RBC buffer (10% 
hematocrit). Loaded RBCs were stored up to 2 d before use. 
 
Widefield microscopy of Cbl-TAM loaded RBCs. Erythrocytes (10% hematocrit, 2 µL) loaded 
with C18-Cbl-TAM (10 μM) were added to RBC buffer (200 μL) and imaged using widefield 
microscopy. Images were taken using a Cy3 filter cube (20 μs exposure, 333 ms intervals).   
 
Hemolysis assay. Cbl drug conjugates (C18-Cbl-MTX, C18-Cbl-COL, or C18-Cbl-DEX) in PBS 
(100 µL) at varying concentrations were added to RBCs (100 µL RBC buffer, 10% hematocrit). 
Final C18-Cbl-drug concentrations were 0, 2.5, 5, 10, and 20 µM. RBCs treated with just PBS (0 
% hemolysis) or sodium dodecyl sulfate (SDS, 0.05%, 100% hemolysis) served as controls. After 
incubation (RT, 20 min), cells were centrifuged (300 g, 30 min) to remove the unloaded C18-Cbl, 
suspended and then refrigerated (4 °C) overnight. Samples were pelleted (1000 g, 5 min) and the 
supernatant (150 µL) analyzed by UV/Vis spectroscopy (550 nm). SDS treated samples’ 
absorbance (Lysed A555 nm) was considered complete hemolysis while PBS only blood was used 
as a blank absorbance (Blank A555 nm). The % hemolysis was calculated by:  
(Eq. 2.1) %Hemolysis = [(Sample A550 nm – Blank A550nm) / (Lysed A550 nm)] * 100% 
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RBC drug loading capacity. RBCs (10% hematocrit) were loaded with varying concentrations of 
C18-Cbl-MTX (1, 2, 4, and 6 µM), C18-Cbl-COL (2, 4, 6, 8, and 10 µM), and C18-Cbl-DEX (0.5, 
1, 2, 4, and 6 µM). The RBCs were diluted (5% hematocrit) and photolyzed (525 nm, 2 h). The 
cells were centrifuged (1000 g) and the released drugs’ supernatant concentration was determined 
by LC-MS. 
 
Treatment of HeLa cells with COL and C18-Cbl-COL loaded RBCs. Plated HeLa cells (1.5 x 10
5 
cells/well) were maintained in a humidity-controlled incubator (37 ºC, 5% CO2) with DMEM (10% 
FBS, 1% Pen-Strep). The following day, cells were treated with DMSO, free COL (Sigma C9754; 
1 mM stock in DMSO), or a suspension of C18-Cbl-COL (6 µM) loaded RBCs (250 µL, 5% 
hematocrit) with L-15 media. Cells exposed to the loaded RBCs were kept in the dark or irradiated 
to an LED (530 nm LED, 5 mW) for 5, 10, or 20 min and then incubated in the dark (37 ºC, 1 h) 
After incubation, cells were fixed (1 mL methanol, RT, 10 min). Cells were washed with PBS (2 
x 1 mL) and blocked (1 h, 5% donkey serum). Blocking was followed by overnight incubation (4 
ºC) with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution 
buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before 
incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 
1:500 dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were 
acquired with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 
40X phase contrast objective and a FITC filter cube (Semrock). MetaMorph software was 
employed for image analysis. 
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Treatment of HeLa cells with C18-Cbl-COL/C18-DY800 loaded RBCs. The COL procedure above 
was repeated but the HeLa cells were treated with a suspension of C18-Cbl-COL/C18-FL800 (5 
μM/ 5 μM) loaded erythrocytes in L-15 media (200 μL, 5% hematocrit) or 200 μL L-15 (control 
cells). Samples were either kept in the dark or exposed to a 780 nm LED array for 10, 20, or 30 
min using the appropriate filter sets. Post photolysis incubation and immunostaining procedures 
were repeated to image HeLa cell response. 
 
Treatment of HeLa cells with DEX and C18-Cbl-DEX loaded RBCs. Plated HeLa cells were (7.5 
x 104 cells / well) maintained in a humidity-controlled incubator (37 ºC, 5% CO2) with DMEM 
(10% FBS, 1% Pen-Strep). The following day, cells were treated with varying concentrations of 
DMSO, free DEX (1 mM stock in DMSO) or a suspension of C18-Cbl-DEX (1 µM) loaded RBCs 
(500 µL, 5% hematocrit) with L-15 media. DMSO and free DEX were incubated in the dark (37 
oC, 1 h). Cells incubated with RBCs were then either kept in the dark or exposed to 530 nm LED 
flood light (PAR38; 500 – 570 nm emission; 5 mW power) for 10, 20, or 30 min at room 
temperature and then incubated in the dark (1 h). At the conclusion of the incubation period, cells 
were fixed (4% PFA in PBS, 10 min, RT), washed with PBS, and then treated with methanol (1 
mL, RT, 5 min). Cells were washed (2 x 1 mL PBS) and incubated overnight (4 ºC) with rabbit 
anti-GRα antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% 
Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before incubation with anti-
rabbit AlexaFluor 488 secondary antibody (Life Technologies A21206) at 1:500 dilution in 
antibody dilution buffer for 1 h at room temperature. Cells were washed with PBS (3 x 5 min) and 
Hoechst 33342 (100 μg/mL in PBS) applied for 30 min before an additional wash with PBS.  
Images were subsequently acquired with an inverted Olympus IX81 microscope equipped with a 
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Hamamatsu C8484 camera, 40X phase contrast objective and a FITC filter cube (Semrock). 
Metamorph software was employed for image analysis. 
 
Treatment of HeLa cells with C18-Cbl-DEX/C18-Cy5 loaded RBCs. The DEX procedure above was 
repeated but the HeLa cells were treated with a suspension of C18-Cbl-DEX/C18-Cy5 (0.5 μM/2.5 
μM) loaded erythrocytes in L-15 media (200 μL, 5% hematocrit) or 200 μL L-15 (control cells). 
Samples were either kept in the dark or exposed to a 660 nm LED array for 10, 20, or 30 min using 
the appropriate filter sets. Post photolysis incubation and immunostaining procedures were 
repeated to image HeLa cell response. 
 
C18-Cbl-DEX light independent translocation test. The above procedure for DEX was repeated to 
determine C18-Cbl “jumping” between cells. However, HeLa cells were washed free of the RBC 
suspension (PBS, 3 x 1 mL) after incubation in the dark (1 h, 37 oC) and prior to photolysis. The 
washed HeLa cells were then exposed to the 530 nm LED and stained in the same way as above.  
 
Photolytic release of TAM and FAM from C18-Cbl-TAM and C18-Cbl-FAM bound RBCs. RBCs 
(10% hematocrit) were loaded with C18-Cbl-TAM (1 µM) or C18-Cbl-FAM (1 µM), and, for long 
wavelength experiments, lipidated fluorophores (5 µM). The erythrocytes were suspended and 
exposed to varying wavelengths. After photolysis, the erythrocyte solution was centrifuged (1,000 
g) and analyzed for released TAM (λex = 550 nm λem = 580 nm) or FAM (λex = 492 nm λem = 519 
nm) fluorescence using a SpectraMax® Gemini EM dual-scanning microplate spectrofluorometer. 
The total amount of bound C18-Cbl after washing was determined by complete photolysis (525 
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nm, 3h) and analysis of the supernatants fluorescence. The other experiments were normalized to 
this value to provide a fraction released at each wavelength. 
 
Assessment of the C18-Cbl-TAM:C18-Cy5 ratio for optimal TAM release. Erythrocytes (10% 
hematocrit) were loaded with varying ratios of C18-Cbl-TAM (0 to 10 μM) and C18-C18-Cy5 (0 
to 20 μM). Erythrocytes were then photolyzed (660 nm, 30 min), separated by centrifugation 
(1,000 g, 3 min) and the supernatant analyzed for TAM fluorescence (λex = 550 nm, λem = 580 nm) 
using a SpectraMax® Gemini EM dual-scanning spectrofluorometer. The fraction of liberated 
TAM by loading ratio was used to construct a map indicating ratios that gave robust release. 
 
Light power measurements. All light measurements were recorded with a Coherent Field Max II 
detector. Each measurement is reported as the average of 13 readings and the error is reported as 
the standard deviation. The light was measured in a fashion consistent with photolytic release of 
drugs erythrocytes. 
 
Confocal images of RBCs loaded with C18-Cy5. C18-Cy5 (5 μM) was loaded onto erythrocytes 
(10% hematocrit). The loaded erythrocytes (2 μL) were diluted in RBC (200 μL) buffer and imaged 
using confocal microscopy. Images were taken using 4% laser power, and 10 μs/pixel in line scan 
mode with a 635 nm laser. 
MTX photolysis from RBC Membranes. C18-Cbl-MTX (1 μM) and C18-fluorophore (5 μM, C18-
Cy5, C18-AF700, C18-Cy7, C18-DY800) were loaded onto RBCs  After loading, erythrocytes were 
suspended (5% hematocrit) and exposed light corresponding to the fluorophores’ λmax (30 min, 
660 nm, 725 nm, or 780 nm). Additional loaded erythrocytes were photolyzed (525 nm, 2h) 
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completely releasing bound MTX to determine the total amount of loaded C18-Cbl-MTX.  The 
erythrocytes were centrifuged (1,000 g) and supernatant analyzed for MTX using LC-MS. 
 
Release of COL and DEX from C18-Cbl-COL and C18-Cbl-DEX loaded RBCs. C18-Cbl-COL (5 
μM) or C18-Cbl-DEX (0.5 μM) were loaded with either C18-DY800 (5 µM) or C18-Cy5 (2.5 µM) 
fluorophores, respectively and then suspended (5% hematocrit). The C18-DY800 and C18-Cy5 
samples were exposed to 780 nm (30 min) or 660 nm (30 min), respectively. Both samples were 
also photolyzed (525 nm, 2 h) to completion for analysis of total bound drug. After photolysis, the 
solutions were centrifuged (1,000 g) and the supernatant analyzed for COL or DEX release by 
LC-MS. 
 
CETSA of HeLa cells treated with C18-Cbl-MTX loaded RBCs. Plated HeLa cells were maintained 
in a humidity-controlled incubator (37 ºC, 5% CO2) with DMEM (10% FBS, 1% Pen-Strep). The 
following day, cells were washed (PBS), then treated with a suspension of C18-Cbl-MTX-loaded 
erythrocytes in L-15 (300 μL, 5 μM MTX loading concentration, 5% hematocrit), L-15 (300 μL, 
control cells), or L-15 with free MTX (300 μL, 10 μM, positive control). Samples were then either 
kept in the dark, or exposed to a green LED light source (PAR38; 500 – 570 nm emission; 5 mW 
power) for 10, 20, or 30 min. At the end of the photolysis interval, all samples were incubated (1 
h, 37 ºC).  The cells were washed with PBS (3 x 1 mL) and trypsinized (300 μL 0.05% Trypsin 
Gibco, 5 min, 37 ºC). Trypsinized cells were then pelleted (5 min, 2000 rpm, 4 ºC), washed (PBS, 
1 x 300 μL), and then pelleted again. After removal of the supernatant, cell pellets were heated (52 
oC, 3 min), and then cooled (3 min, RT). Lysis buffer (30 μL, 25 mM Tris HCl/2 mM DTT/1X 
Pierce HALT protease and phosphatase inhibitor) was added to each pellet, which were then 
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subjected to 2 freeze-thaw cycles in liquid N2. The resulting solutions were then spun at 17000 g 
for 20 min at 4 ºC. The resulting supernatants were removed and combined with 6X LSB-BME 
and boiled (4 min, 95 ºC), then analyzed by western blot (overnight incubation at 4 ºC with Santa 
Cruz anti-DHFR E18 primary antibody (1:1000 in TBST/5%BSA)) and Cell Signaling anti- 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:2000), followed by incubation 
with the appropriate secondary antibodies.  
 
2.5.5. Hypotonic Loading and Release 
General internal loading procedure for RBCs. Erythrocytes were suspended at in buffer (10% 
hematocrit, L-15 media + 10% FBS), centrifuged (1000xg, 3 min), and the pellet washed with PBS 
(3 times). The RBC pellet and Cbl cargo was added to deionized water (900 μL) for swelling, 
mixed by gentle inversion, and incubated on ice (5 min). After incubation, concentrated PBS (10x, 
100 μL) was added to the RBC solution to form an isotonic solution (1x). The RBCs’ membranes 
were allowed to anneal for 30 min at room temperature. Washing (3x) in media (L-15 media + 
10% FBS) provided sealed RBCs. 
 
Fluorescent determination BODIPY®650 release from RBCs. Aliquots (200 µL) of Cbl-Bod 
loaded RBCs (5 µM, 10% hematocrit) were placed in small Eppendorf tubes and exposed to the 
varying irradiation times (660 nm, 3.30 mW/cm2, 0 – 5 min) or incubation conditions (dark, light, 
no swelling, loading after swelling, etc.). After treatment, the samples were centrifuged (1000xg, 
3 min) to separate the supernatant from the cells. The samples were analyzed for fluorescent counts 
(λex = 625 nm, λem = 670 nm) on a SpectraMax® Gemini EM dual-scanning microplate 
spectrofluorometer. Photolyzed Cbl-Bod standards were used in tandem to construct a fluorescent 
standard curve for supernatant concentration determinations. Concentrations of free Bod were 
189 
 
calculated from relating the samples’ counts to the best fit of the standard curve and were 
normalized to the fluorescence of mock loaded RBCs. 
 
Long Term Cbl-Bod Internalization. Aliquots (200 μL, 10% hematocrit) of RBCs were loaded 
with Cbl-Bod (5 μM) by the procedure discussed above. At each time point (0, 1, 2, 4, 7 d), the 
supernatant was removed and analyzed by fluorescence as discussed above. 
 
Hemolysis Assay. Samples and washes (10% hematocrit, 200 μL) of loaded (5 μM Cbl-Bod), 
unloaded, and non-swollen RBCs’ supernatants were separated from the RBCs. The absorbance 
(A550) @ 550 nm of each supernatant was monitored on a PerkinElmer Lambda 25 UV/Vis 
Spectrometer. A PBS only treatment (Blank A550 nm) and completely lysed sample (100%) was 
generated by treatment of RBCs with .05% SDS (Lysed A550 nm). Using these absorbance, the % 
hemolysis was calculated using Eq. 2.1. 
 
BODIPY®650 (Bod) Translocation. RBCs were hypotonically loaded with Cbl-Bod (5 µM) and 
suspended (10% hematocrit, L-15 media supplemented with 10% FBS). HeLa cells were plated 
(8 x 104 cells per dish) the day prior to the experiment. On the day of the experiment, cells were 
washed 2x with Hank’s balanced salt solution (HBSS) then incubated (37 oC, 5% CO2, 30 min) 
with a solution of ER-Blue/White marker and MitoTracker Green (both 1 µM). The solution was 
washed away and cells were either incubated (30 min) with RBCs loaded Cbl-Bod, or placed in 
L-15 media + 10% FBS without RBCs. During the incubation period, RBC-treated cells were 
photolyzed with an LED array (660 nm, 30 min). After the treatment period, RBCs were washed 
away (2x HBSS), and the HeLa cells were subsequently imaged live on a confocal microscope.  
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Cbl-MTX and Cy5-Cbl-MTX photolytic stabilization of HeLa cell DHFR. Cbl-MTX and Cy5-
Cbl-MTX (10 µM) were hypotonically loaded into RBCs (10% hematocrit, L-15 media + 10 % 
FBS).  HeLa cells were plated in 12-well tissue culture plates at a density of 1.0 x 105 cells per 
well and maintained in a humidity-controlled incubator (37 ºC, 5% CO2) with DMEM (10% 
FBS, 1% Pen-Strep). The following day, cells were washed with PBS (3 times), then treated with 
a suspension of the internally loaded erythrocytes (200 μL) or just L-15 with 10% FBS (control 
cells). Cells were then either kept in the dark at room temperature, or photolyzed (45 min) at 525 
nm for Cbl-MTX or 660 nm for Cy5-Cbl-MTX. At the end of the photolysis interval, all cells 
were incubated (45 min, 37 ºC) in a humidity-controlled incubator.  Next, cells were washed 
with PBS (3 x 1 mL) and trypsinized (300 μL 0.05% Trypsin (Gibco)) for 5 min at 37 ºC. 
Trypsinized cells were then pelleted (5 min, 2000 rpm, 4 ºC), washed with PBS (1 x 300 μL), 
and then pelleted again. After removal of the supernatant, cell pellets were heated in a 
temperature controlled heat block (52 ºC, 3 min), and then cooled (3 min) at room temperature. 
Lysis buffer (30 μL, 25 mM Tris HCl/2 mM DTT/1X Pierce HALT protease and phosphatase 
inhibitor) was added to each pellet, which were then subjected to 2 freeze-thaw cycles in liquid 
N2. The solutions were centrifuged (17000 g, 20 min, 4 ºC) and the resulting supernatants were 
removed. The supernatant was combined with 6X LSB-BME, boiled (95 ºC, 4 min), and 
analyzed by western blot overnight (4 ºC) with Santa Cruz anti-DHFR E18 primary antibody( 
1:1000 in TBST/5%BSA) and Cell Signaling anti-GAPDH antibody (1:2000). The overnight 
treatment is followed by incubation with the appropriate secondary antibodies.  
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Treatment of HeLa cells with Cbl-COL and Cy5-Cbl-COL internally loaded RBCs. Cbl-COL and 
Cy5-Cbl-COL (10 µM) were hypotonically loaded into RBCs (10% hematocrit, L-15 media + 
10% FBS).  HeLa cells were plated at a density of 1.0 x 105 cells per well and maintained in a 
humidity-controlled incubator (37 ºC, 5 % CO2) with DMEM (10% FBS, 1% Pen-Strep). The 
following day, cells were washed with PBS, then treated with a suspension of internally loaded 
red blood cells (200 µL in L-15 with 10% FBS) or just L-15 with 10% FBS (control cells). Cells 
were then either kept in the dark at room temperature, or photolyzed (45 min) at 525 nm for Cbl-
COL or 660 nm for Cy5-Cbl-COL. Cells were incubated (45 min, 37 ºC) in a humidity-controlled 
incubator post-photolysis.  At the conclusion of the incubation period, cells were washed with PBS 
(3 x 1 mL) and then fixed (1 mL methanol, room temperature, 10 min). Cells were washed with 
PBS (2 x 1 mL), blocked and permeabilized (20 min) in antibody dilution buffer (1% BSA; 0.3% 
Triton-X-100; PBS, 4 ºC). Blocking was followed by overnight incubation (4 ºC) with mouse anti-
tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before incubation with 
anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution in 
antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil objective 
and a FITC filter cube (Semrock). Metamorph software was employed for imaging analysis. 
 
Dox delivery from Cy5SO3--Cbl-DOX loaded RBCs. Cy5SO3--Cbl-DOX (10 µM) was 
hypotonically loaded into RBCs (10% hematocrit, L-15 media + 10% FBS). HeLa cells were 
plated at a density of 1.0 x 105 cells per well, allowed to recover in an incubator, and then washed 
with PBS. The cells were treated with the Cy5SO3--Cbl-DOX loaded RBCs (200 µL) and 
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HOESCHT 3233. The cells were imaged immediately in this order: DAPI (500 ms exposure), 
Texas Red (1000 ms exposure), and Cy 5.5 (1000 ms exposure). Cells were imaged/illuminated 
every 60 seconds. The frames shown in Figure 2.34 represent time points of 0 and 8 min. 
 
Orthogonal release of FL800-Cbl-COL and Cbl-Bod. HeLa cells were plated at a density of 1.0 x 
105 cells per well and maintained in a humidity-controlled incubator (37 ºC, 5% CO2) in DMEM 
(10% FBS, 1% Pen-Strep). Both FL800-Cbl-COL (10 µM) and Cbl-Bod (5 µM) were co-loaded 
into RBCs (10% hematocrit, L-15 + 10% FBS). The following day, cells were washed with PBS 
(3 times), then treated with the loaded RBC suspension (200 μL) or just L-15 with 10% FBS 
(control cells). Cells were then either kept in the dark, exposed to a 660 nm LED array or 780 nm 
LED array (40 min). Cells were allowed to further incubation (40 min) in the dark at room 
temperature.  A subset of cells were treated with both light conditions for 40 min each with 780 
nm irradiation being followed by a 660 nm irradiation. At the conclusion of the incubation period, 
cells were washed with PBS (3 x 1 mL) and then fixed (1 mL 4% paraformaldehyde in PBS, 10 
min), followed by further fixation in methanol (room temperature, 5 min). Cells were washed (2 x 
1 mL PBS), blocked and permeabilized in antibody dilution buffer (20 min, 4 ºC, 1% BSA; 0.3% 
Triton-X-100; PBS). Blocking was followed by overnight incubation (4 ºC) with mouse anti-
tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before incubation with 
anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution in 
antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil objective 
and a FITC filter cube (Semrock). Metamorph software was employed for imaging analysis.  
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CHAPTER THREE: B12-MEDIATED, LONG WAVELENGTH PHOTO-
POLYMERIZATION OF HYDROGELS1 
 
Chapter Abstract 
Medical hydrogel applications have expanded rapidly over the past decade. Implantation 
in patients by non-invasive injection is preferred, but this requires hydrogel solidification from a 
low viscosity solution to occur in vivo via an applied stimuli. Transdermal photo-crosslinking of 
acrylated biopolymers with photoinitiators and light offers a mild, spatiotemporally controlled 
solidification trigger. However, the current short wavelength initiators limit curing depth and 
efficacy, because they do not absorb within the optical window of tissue (600 - 900 nm). As a 
solution to the current wavelength limitations, I have developed a red light responsive initiator 
capable of polymerizing a range of acrylated monomers. Furthermore, I will demonstrate that its 
photo-activation can occur within a range of skin type models containing high biochromophore 
concentrations. 
3.1. Injectable Hydrogels and Their Medical Applications 
Hydrogels are networks of cross-linked hydrophilic polymers that swell in water to many 
times their dry polymer weight.1,2 This allows hydrogel properties to mimic the softness and water 
content of natural tissue making them indispensable tools in tissue restoration and engineering 
applications.1–5 This similarity with native tissue and the biocompatibility of many of the employed 
                                                          
1Some figures reproduced with permission from 1Rodgers, Z. L.; Hughes, R.M.; Doherty, L. M.; 
Shell, J. R; Molesky, B. P.; Brugh, A. M.; Forbes, M. D. E.; Moran, A. M.;  Lawrence, D. S. B12-
Mediated, Long Wavelength Photo-polymerization of Hydrogels Journal of the American 
Chemical Society 2015, 137, 3372–3378.  © 2015 American Chemical Society 
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polymers allows for gentle encapsulation of sensitive cargo, such as stem cells and proteins.6–10 
After implantation, these networks protect said cargo from the rigors of the body’s immune system 
and clearance, while the payload carries out its intended therapeutic function. For example, the 
burgeoning field of stem cell therapy critically depends on the engineering of hydrogel systems to 
provide protection and a support scaffold for differentiating cells. However, these materials are 
not limited only to tissue engineering as recent reviews have high-lighted their expanding clinical 
use in the treatment of lower back pain11, myocardial infarction12, cartilage tear13, macular 
degeneration14, and drug delivery10,15–18. 
Although a range of chemical and physical gel curing methods exist to induce polymer 
network formation, in situ cross-linking techniques that allow for injectable hydrogels are of 
particular interest for clinical use.19–22 Injection and subsequent in vivo gelation versus surgical 
implantation confers two distinct advantages. First, low viscosity solutions can be homogenized 
with a desired cargo and then directly injected into the treatment site via syringe. This greatly 
simplifies the implantation protocol, decreases treatment invasiveness, and lessens potential 
complications like infection and scarring. Second, as a general property of all liquids, low viscosity 
polymer solutions fill the injection sites prior to gelation. This is a huge advantage if you consider 
that soft tissue injuries, such as cartilage tears, can show complex damage patterns which makes 
prior hydrogel molding complicated. Furthermore, the damaged site’s shape would have to be 
imaged by MRI or ultrasound prior to treatment. Therefore, injectable systems eliminate the need 
to know the precise shape of the treatment location. 
Because of these advantages, injectable hydrogels have birthed a massive research effort 
into the engineering of polymers that form highly crosslinked networks upon application of a 
stimulus. In fact, reviews have appeared highlighting the large number of recent developments in 
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injectable scaffolds.23–26 Much like the DDSs discussed in the previous chapter, many injectable 
systems rely on the body’s internal stimuli to affect the structure and solvent interactions of the 
polymer chains.15,18 These changes in the polymer environment after injection induce physical 
cross-linking and cause a hydrogel network to form. Thermo-gelling polymers, like poly-N-
isopropyl acrylamides, undergo conformational changes that induce their solidification at the 
higher in vivo temperatures (37 oC). However, many of these systems are oligomer specific and 
sensitive to changes in gel components thus creating variability in gelation efficacy, cargo loading, 
and physical properties.23  
3.1.1. Implantation by Transdermal Photo-polymerization 
As an alternative, cross-linking via radical photo-polymerization offers broad material 
compatibility (Scheme 3.1). Most synthetic or natural polymers can be modified with radical 
sensitive acrylates, mixed with a radical generating photoinitiator, and then injected into the 
desired treatment site.5,27,28 Later, excitation of the photoinitiator with light transmitted through 
the skin causes radicals to form and propagate through the acrylate functionalities generating cross-
links. Surprisingly, this technique provides a very mild crosslinking environment and stem cell 
cargo tolerates the polymerization process well despite the bolus of radicals.29 In addition, photo-
lithographic techniques coupled to photo-polymerization allowing for spatiotemporal control of 
hydrogel fine structure and properties. For example, tissue engineers have used photo-lithographic 
techniques to pattern channels for stem cells to differentiate into functioning vascular 
networks.12,30 
3.1.2. Limitations to Transdermal Photo-polymerization 
The utility of photo-polymerizing injected hydrogel precursors through dermal tissue was 
demonstrated nearly two decades ago by Langer and coworkers31 and much more recently in actual 
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patients by Elisseeff.13 Unfortunately, the α-hydroxy phenyl ketones (Irgacure 2959 [I2959], λmax 
< 350 nm) and eosin Y (λmax~ 520 nm) photoinitiators they used compete for light with endogenous 
biological chromophores.32–34 This inner filter effect limited the accessible curing depths to just a 
few millimeters (1 - 5 mm) and increases curing variability in higher melanin skin types.13,35 For 
example, eosin Y can only cure to a depth of 5 mm in very pale, low melanin skin types (Fitzpatrick 
Type I-II). 
 In short, the current photoinitiators fail to take advantage of the optical window of tissue 
(600 - 900 nm) discussed extensively in previous chapters for in vivo activation of photodynamic 
therapy36,37, fluorescence guided surgery38, and drug delivery39,40. Sadly, biocompatible 
photoinitiators that undergo homolytic bond cleavage within this window are limited to inefficient 
two-photon groups that can only cure relatively small areas.41,42 As a solution, Burdick and co-
workers reported NIR initiation of V70 thermal initiators with excited gold nanorods.
43 However, 
gold nanorods require massive photon fluxes for their activation44,45, and thermal initiation requires 
high temperatures (~55 oC) for efficient and rapid activation.46 This hot environment is detrimental 
to surrounding tissue and potential cellular cargo. Indeed, the viability of this approach with 
cellular cargo has yet to be demonstrated. Consequently, the development of single photon, red 
light responsive photoinitiators would greatly improve transdermal photo-polymerization as a 
viable technique for in situ cured hydrogels. 
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Scheme 3.1. Photo-polymerization of hydrogel scaffolds. Low viscosity solutions of acrylate 
functionalized oligomers can be mixed with photoinitiators and cargo before injection. Light 
irradiated through the skin causes photoinitiator radical generation which induces the acrylates to 
crosslink into a hydrogel network encapsulating the cargo. Unfortunately, the most common 
biocompatible photoinitiators suffer poor activation in vivo because short visible light is absorbed 
by the skin. I2959 and lithium acyl phosphinates generate radicals directly via a Norrish type I 
scission, while eosin abstracts a hydrogen from co-initiators (triethanolamine) to sensitize the 
formation of radicals in response to green light.  
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3.2. Cobalamins as Long Wavelength Photoinitiators 
As a consequence of the low energy photons possess at longer wavelengths, any photo-
responsive molecule used to generate radicals within the desired 600 – 900 nm range must have a 
relatively low bond dissociation energy (30 - 50 kcal/mol). This prerequisite eliminates carbon-
carbon and most carbon heteroatom bonds (C-O, C-N) as scissionable motifs, since their 
homolytic bond dissociation energies hover near 75 to 120 kcal/mol (~240 – 380 nm).47 As 
discussed previously, excitation of alkylCbls (λex = 510 nm) induces a metal-to-ligand and σ-
bond-to-ligand charge transfer that decays to an alkyl radical and cobalt (II) species with high Φ 
(20 - 30%).48–52 During our investigations of the NIR induced scission of fluorophore modified 
Cbl’s weak Co-C bond (BDE ~ 30 kcal/mol), characterization of the photolyzed alkyl ligand 
revealed oxidized photoproducts indicative of alkyl radical trapping by molecular oxygen.52–54 
This led me to believe that the alkyl radical was still produced during long wavelength photolysis 
of Cbls. Therefore, we reasoned it may be possible to use these conjugates to respond to tissue 
penetrating light and initiate radical polymerization upon photolysis (Scheme 3.2). In this 
chapter, I will discuss the efficacy of this approach to induce polymerization at tissue friendly 
wavelengths. Moreover, I will show that these Cbl based initiators are biocompatible and work in 
a range of skin types with varying degrees of pigmentation.  
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Scheme 3.2. Photo-polymerization of hydrogels using Cbl based initiators. Excitation of 
fluorophore modified cobalamins induces homolytic bond cleavage and alkyl radical products at 
tissue penetrating wavelengths. These radicals can then propagate through acrylate monomers to 
induce a liquid oligomer solution to solidify into a hydrogel. The inverted samples on the right 
show polymer solutions (PEG-acrylate) before and after irradiation. The irradiated sample retains 
its form indicating successful gelation.  
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3.2.1. Cobalamin Photoinitiators: Design, Synthesis and Photophysical Properties 
The Cbl photoinitiators (EtCbl-1 and EtCbl-2) were prepared from vitamin B12 (CNCbl; 
Schemes 2.23, 3.3 – 3.6). We readily functionalized CNCbl at both the Co and the ribose 5’-
hydroxyl by methods previously discussed (Scheme 2.23). The ribose alcohol of CNCbl was 
initially converted to the activated ester with 1,1-carbonyl-di-triazole (CDT) which, upon reaction 
with ethylenediamine, furnished a primary amine handle through a carbamate linkage (Etd-Cbl). 
For this initial study, we chose ethylCbl (EtCbl) due to its reported high Φ of photo-homolysis (~ 
0.3), but we reason other primary alkyl ligands, such as propylamine, could allow for dual initiation 
and functionalization of hydrogels.52 Moreover, its conceivable attachment of peptides or small 
molecule activators to the photoinitiator could also be used to modify the hydrogel scaffold during 
initiation.55–58  Nevertheless, we derived the Etd-EtCbl intermediate from Zn-mediated reduction 
of Etd-Cbl to a super nucleophilic CoI species and subsequent alkylation with ethyl bromide 
(Scheme 3.4). Photoinitiator EtCbl-1 (ε = 8,500 M-1cm-1, λmax = 510 nm) was prepared by reacting 
the free amine of Etd-EtCbl with acetic anhydride (Scheme 3.5). EtCbl-1 extends the 
photoinitiator toolbox into the visible range, since examples of type I photoinitiators sensitive to 
light longer than 420 nm are limited (Figure 3.1).59 EtCbl-2 was synthesized via modification of 
the free amine in Etd-EtCbl with the NHS ester of Cy5, and it extends the photoinitiator toolbox 
deep into the red (λmax = 646 nm, ε = 250,000 M-1cm-1, Scheme 3.6, Figure 3.1). 
The normalized absorption spectra of EtCbl-1 and EtCbl-2 relative to that of tissue 
chromophores melanin and hemoglobin are shown in Fig. 3.1a. Both melanin and hemoglobin 
absorb light from the short visible up to 600 nm.35 The common photoinitiators I2959 and eosin Y 
display their maximal absorbance in this region (300 – 520 nm, Figure 3.1b). Clearly, EtCbl-1 
absorbs modestly at green wavelengths (~510 nm), whereas EtCbl-2 produces a much stronger 
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absorption band at 646 nm. Like eosin Y, the absorbance of EtCbl-1 significantly overlaps with 
melanin and hemoglobin. Conversely, the absorbance of EtCbl-2 resides well within the optical 
window of tissue and outside the reach of hemoglobin and melanin. 
3.2.2 Wavelength Dependent Photolysis and Quantum Yield Determination 
 We investigated the wavelength dependent photolysis of EtCbl-1 and EtCbl-2 by 
illuminating samples (10 µM) at 546 ± 10 nm, 646 ± 10 nm, and 730 ± 10 nm using a Xe flash 
lamp (5 - 10 mW/cm2). As determined by LC-MS (Figure 3.2 – 3.3), both EtCbl-1 and EtCbl-2 
are stable in the dark or when exposed to 730 nm as exemplified by the absence of the primary 
photoproduct, HO-Cbl (Scheme 3.7). However, both photoinitiators form the photoproducts when 
excited at the common 546 nm absorption band. By contrast, only EtCbl-2 suffers photolysis when 
exposed to 646 nm, indicating successful photolysis-tuning to Cy5’s primary absorption band 
(Figure 3.3).  
These results are consistent with the notion that homolytic cleavage and ethyl radical 
production occurs at the green and red wavelengths.54 We explicitly examined this conjecture 
using electron paramagnetic resonance (EPR) spectroscopy. EPR detects the formation of 
paramagnetic, radical species using unpaired electron spins in a similar manner to proton spin in 
NMR.60 The splitting patterns produced in an EPR spectrum contain fine details on the specific 
nature of the radical containing ligand. In order to observe the transiently stable ethyl radical, we 
employed phenyl-t-butyl nitrone (PBN) as a radical trap (Scheme 3.8). This trap’s unsaturation 
reacts with ethyl radicals to produce a stable and observable nitrosyl radical (Ethyl-PBN) with a 
specific splitting pattern produced by the ethyl ligand’s electronics.61 In the dark, both EtCbl-1 
and EtCbl-2 fail to produce any signal arising from paramagnetic species indicating Co-C bond 
stability in the absence of light (Figure 3.4). At 520 nm, both photoinitiators produce spectra with 
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the expected splitting pattern of triplet of doublets, as well as hyperfine couplings (aN~ 16.2-16.3 
G, aβ-H~ 3.34) that compare favorably to reported ethyl-PBN adducts (aN~ 16.3, aβ-H~ 3.4, Table 
3.1).61 By contrast, only EtCbl-2 generates the expected splitting pattern with similar hyperfine 
constants (aN~ 16.2 G, aβ-H~ 3.34 G) at 660 nm illumination, consistent with radical production at 
wavelengths deep within the optical window of tissue. 
 For photoinitiators to induce rapid gelation, the rate of radical production must be 
sufficiently high to allow for complete homolysis within seconds to several minutes. Factors that 
contribute to rapid photolysis are both a high ε and Φ of homolysis. By transient absorption, 
alkylCbls photolyze at 510 nm (α/β band) with near quantitative yields, but radical recombination 
within a solvent cage reduces the observed Φ to 20 - 30%.49,62 This Φhom is comparable to the 
reported Φ of other common initiators, such as ~29% for I2959 ( λmax < 300 nm) and ~25% for 
eosin Y (λmax ~ 510 nm, 20 mM triethanolamine co-initiator) system.32,34 We investigated the Φhom 
of both initiators exposed to 520 or 660 nm light with a constant photon flux (1 mW/cm2, Table 
3.1, Figure 3.5 - 3.6). Both initiators photolyze at nearly identical rates at 520 nm, but the quantum 
yield of EtCbl-2 is reduced (Φhom = 14.8 ± 0.3%) relative to EtCbl-1 (Φhom = 28.6 ± 1.7%), since 
EtCbl-2 absorbs more photons at this wavelength (Table 3.1). The higher optical density of EtCbl-
2 also has a significant effect on the Φhom at 660 nm (Φhom = 7.4 ± 0.4%). However, the greater 
photon absorption of EtCbl-2 enhances its photolytic rate and efficiency (ε Φhom) nearly fourfold 
relative to EtCbl-1 at 520 nm (Figure 3.6, Table 3.1).  
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Scheme 3.3. Structure of Cbl based photoinitiators. EthylCbl was chosen for the basic initiator 
structure, because it has the highest reported Φ for simple alkylCbls (~ 30%). EtCbl-1 was 
modified with an acetyl group as a control and extends the photoinitiator toolkit into the long 
visible spectrum since type I initiators responsive to wavelengths longer than 410 nm are limited. 
EtCbl-2 modified with Cy5 absorbs red light within the optical window of tissue.  
214 
 
 
 
 
 
Scheme 3.4. Synthesis of Etd-EtCbl starting material for initiator synthesis from Etd-Cbl. 
Reduction of the metal center with activated zinc then treatment with ethyl bromide yielded the 
Etd-EtCbl derivative in good yield.   
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Scheme 3.5. Synthesis of EtCbl-1 from Etd-EtCbl. Treatment of Etd-EtCbl with acetic 
anhydride easily furnished the capped Cbl derivative to serve as a green light control for nucleotide 
loop functionalization. The absorption spectra of the derivative is nearly identical to plain EtCbl.  
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Scheme 3.6. Synthesis of EtCbl-2 from Etd-EtCbl. Activation of Cy5 with TSTU produces the 
NHS ester of the fluorophore which reacts with Etd-EtCbl. EtCbl-2 responds to light within the 
red part of the spectrum.  
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Figure 3.1. Spectra of Cbl photoinitiators. a) Normalized visible spectra of EtCbl-1 (green) and 
EtCbl-2 (blue) relative to melanin (black) and hemoglobin (red). b) Absorption spectra of 
photoinitiators EtCbl-1 (green), EtCbl-2 (blue), eosin Y (red), and I2959 (black). I2959 and eosin 
Y are ubiquitous photoinitiators used in tissue engineering applications since they provide good 
biocompatibility.  
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Scheme 3.7. Aerobic HO-Cbl photolysis product of EtCbl-1 and EtCbl-2 as determined by LC-
MS.  
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Figure 3.2. LC-MS chromatograms of EtCbl-1 (20 µM) after being kept in the dark or illuminated 
at 546 ± 10 nm, 646 ± 10 nm, or 730 ± 10 nm for 10 min with a Xe flash lamp.  
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Figure 3.3. LC-MS chromatograms monitored of EtCbl-2 (20 µM) after being kept in the dark or 
illuminated at 546 ± 10 nm, 646 ± 10 nm, or 730 ± 10 nm for 10 min with a Xe flash lamp.  
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Scheme 3.8. Generalized EtCbl trapping scheme using phenyl-t-butyl nitrone (PBN, 8 mM). 
EtCbl-1 or EtCbl-2 (1 mM) were photolyzed with a green (2.2 mW/cm2) or red (2.4 mW/cm2) 
laser and then scanned for paramagnetic Ethyl-PBN adducts. If ethyl radicals are produced, they 
would add into the unsaturation site of PBN to produce a stable nitrosyl radical. This paramagnetic 
species can then be detected using an EPR spectrometer as a triplet of doublets with fingerprint 
coupling constants.   
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Figure 3.4. EPR spectra of a) EtCbl-1 and b) EtCbl-2 (1 mM) in the dark (black), or illuminated 
at 520 nm (green) or 660 nm (red) in the presence of the PBN spin trap (8 mM). c) Simulated 
spectra of trapped ethyl radical. The triplet of doublets hyperfines correspond well to previously 
reported literature values for ethyl-PBN adducts. (a
N
 ~ 16.2 G, a
β-H
 ~ 3.3 G vs. a
N
 ~ 16.3 G, a
β-H
 ~ 
3.4 G)61  
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Figure 3.5. Representative absorbance difference of EtCbl-1 and its photolysis product HO-Cbl-
Ac used for the photolytic rate determination. (EtCbl-1 – solid line, HO-Cbl-Ac – dashed line) 
The difference in the 350 nm absorbance was used to determine the amount of HO-Cbl products 
in solution during photolysis (eq 3.4).  
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Figure 3.6. Photolysis plot of EtCbl-1 and EtCbl-2. The mole fraction of EtCbl-1 (green) and 
EtCbl-2 (blue) converted to HO-Cbl-Ac and HO-Cbl-Cy5, respectively, (XHO-Cbl) versus 
irradiation time by a 520 nm (solid lines) or 660 nm (dashed lines) laser at a constant power flux 
(1 mW/cm2) is shown. EtCbl-1 and EtCbl-2 photolyze with a nearly identical rate at 520 nm, but 
EtCbl-2 photolyzes significantly faster at 660 nm than EtCbl-1 at 520 nm (~ 4 fold). EtCbl-1 
produces no photoproduct at 660 nm.  
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Table 3.1. Photochemical properties and hyperfine couplings from 
initiator photolysis. 
Initiator 
  
λ 
(nm) 
Φ 
(%) 
εΦa 
(M-1cm-1) 
aN 
(g) 
aβ-H
 
(g) 
EtCblb
 520 20-30 ~2000 16.3 3.4 
660 NR NR NR NR 
EtCbl-1 520 28.6 ± 1.7 2,366 16.3 3.3 
660 * * * * 
EtCbl-2 520 14.8 ± 0.3 2,405 16.2 3.3 
660 7.4 ± 0.2 9,435 16.2 3.3 
 a product of the ε and Φ where ε~ 8,275 M-1cm-1
 
(EtCbl-1 @ 520 
nm); 16,250 M-1cm-1 (EtCbl-2 @ 520 nm); M-1cm-1 (EtCbl-2 @ 
660 nm); 
b
from ref. 53. NR = not reported. *no detectable 
conversion. 
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3.2.3 Photo-polymerization of Acrylates 
 We determined the efficacy of Cbl-initiated polymerization with acrylated monomers using 
1H NMR (Scheme 3.9, Table 3.2). Both photoinitiators EtCbl-1 and EtCbl-2 provide efficient 
monomer conversions at 520 nm. However, only compound EtCbl-2 serves as an initiator of 
polymerization at 660 nm. Neither initiator induced monomer conversion when left in the dark 
(not shown). When polymerization was carried out in the presence of a bifunctional cross-linker 
(N,N’-methylenebisacrylamide or PEG-diacrylate, Mn~ 575 g/mol), rapid gelation (<5 min) occurs 
with the expected wavelength dependence (Figure 3.7). As the inverted samples demonstrate, 
neither EtCbl-1 nor EtCbl-2 induce gelation in the dark or at 730 nm. However, both compounds 
effectively induce hydrogel formation upon exposure to 520 nm. In addition, exposure of 
prepolymer solutions of EtCbl-2 to 660 nm, likewise rapidly generate hydrogels. To ensure that 
the Co-C bond scission is the primary factor in inducing gelation, HO-Cbl, Cy5, or a combination 
of both were used as control initiators (Figure 3.8). No gelation results at 520 or 660 nm, 
eliminating the possibility of thermal or photo-sensitization mechanisms to induce crosslinking.63  
We investigated how the Cbl initiators affected gel crosslinking by determining the mass 
swelling ratio (Wwet/Wdry) of gels photo-polymerized by EtCbl-1 or the conventional UV initiator, 
I2959, over a range of cross-linker and initiator concentrations (Figure 3.9 – 3.10). The mass ratio 
is roughly correlated to the density of crosslinks within the polymer network.64 For example, lower 
cross-linking density increases the mass of water retained at equilibrium as there is less elastic 
resistance within the polymer network to compete with water solvation. This provides a metric for 
comparison between the relative cross-linking densities of gels. We calculated the ratio by 
measuring the weight of gels (~1 cm diameter) swollen with water to equilibrium (~ 24 h) and then 
dividing by the dry polymer weight after solvent removal and lyophilization. As expected, the 
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ratios for both initiators decreased with increasing crosslinker concentration, but I2959 gave 
consistently lower ratios, especially at very low crosslinker concentrations. This indicates a higher 
amount of crosslinking relative to EtCbl-1, necessitating higher concentrations of crosslinker to 
achieve similar gel properties when using Cbls. This result may arise from the ability of I2959 to 
produce two reactive radicals per absorptive event versus one for EtCbl-1 or EtCbl-2. 
3.2.4 Encapsulated Cell Viability 
 Hydrogels are indispensable as tissue scaffolds for implanted cells and tissue 
regeneration.6–10 Therefore, cellular encapsulation within polymer networks requires mild gelation 
conditions to allow for high cell seeding. With this in mind, we determined the cytocompatibility 
of both initiators compared to the commonly used I2959 by encapsulating HEPG2 cells (105 per 
gel) within PEG-diacrylate gels (Mn~ 3,400 g/mol, 100 mM). Viability was determined by Z-stack 
cell counting after imaging encapsulated cells with a confocal microscope using a standard 
LIVE/DEAD stain (Figure 3.11). Cells exposed only to light (> 300 nm, 520 nm, or 660 nm), 
EtCbl-1, or solutions of PEGDA and EtCbl-1 in the dark showed similar survival rates when 
compared to cells receiving no treatment (Figure 3.11b). However, when PEGDA polymerization 
was initiated with light at each initiator’s (1 mM) primary excitation under aerobic conditions, all 
three displayed comparable viabilities [I2959 (76%), EtCbl-1 (81%), and EtCbl-2 (77%)]. 
Significant viability ensures that proliferation and seeding can be adjusted accordingly to the 
desired cell population. Others have noted that the cell line, the initiator, and the monomer 
composition can lead to variability in cell viability, suggesting that each situation will likely 
require some optimization to achieve desired gel properties and cellular cargo loading.29  
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Scheme 3.9.  Monomers used in photo-polymerizations and hydrogel formation.  
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Table 3.2. Photoinitiated monomer conversion using Cbl initiators. 
 
Initiatora 
 
Monomerb
 
Conversion % by λc
 
(nm) 
< 300 520 660 
  
 
 EtCbl-1 
Acrylamide 89 90 * 
Acrylic acid 93 93 15 
N-isopropyl acrylamide 93 96 * 
Hydroxyethyl acrylate 86 88 2 
PEG-monoacrylate 89 88 * 
  
 
 EtCbl-2 
Acrylamide 27 27 56 
Acrylic acid 87 59 72 
N-isopropyl   acrylamide 89 92 71 
Hydroxyethyl   acrylate 64 69 80 
PEG-monoacrylate 61 74 80 
a [initiator]= 200 µM  b[Monomer] = 1 M in D2O
  cdetermined by 
1
H 
NMR *indicates no detectable conversion. 
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Figure 3.7. Wavelength dependent hydrogelation of a) acrylamide (1.6M) and bisacrylamide (10 
mM) or b) PEG-monoacrylate (Mn~480 g/mol, 200 mM) and PEG-diacrylate (Mn~575 g/mol, 20 
mM). Samples were left in the dark or irradiated at 520, 660, or 730 nm using EtCbl-1 (top) or 
EtCbl-2 (bottom) initiators.  
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Figure 3.8. Control gelation experiments in the absence of EtCbl-1 and EtCbl-2. Solutions 
contain either Cy5, HO-Cbl, or a combination of both (200 µM). a) Acrylamide (1.6 M) + N,N’-
methylene bisacrylamide (10 mM) or b) PEG-monoacrylate (200 mM) + PEG- (20 mM) solutions 
were illuminated at either 520 nm (top) or 660 nm (bottom).  
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Figure 3.9. Hydrogel swelling ratios (Q) with varying cross-linker concentration. a) Acrylamide 
(1M)/bisacrylamide and b) PEG-monoacrylate (200 mM) / PEG-diacrylate hydrogel wet/dry 
weight ratios with varying bifunctional crosslinker concentrations using 200 µM of EtCbl-1 (dark 
circles) or I2959 (open circles) initiators irradiated at 520 nm or <300 nm, respectively.   
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Figure 3.10. Hydrogel swelling ratios (Q) with varying initiator concentrations. a) 
Acrylamide/bisacrylamide (1.6 M and 10 mM) b) PEG-monoacrylate/PEG-diacrylate (200 mM 
and 50 mM) hydrogel wet/dry weight ratios with varying initiator concentrations of EtCbl-1 (dark 
circles) or I2959 (open circles) initiators irradiated at 520 nm or <300 nm, respectively.  The 
variability seen in the Cbl solutions versus the I2959 may be due to the participation of the Cbl in 
reversible termination reactions with propagating polymers (Section 3.3).  
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Figure 3.11. HepG2 viability after hydrogel encapsulation with EtCbl initiators. a) LIVE/DEAD 
images of encapsulated HepG2 cells within PEG-diacrylate (Mn~3,400 g/mol, 100 mM) hydrogels 
using I2959, EtCbl-1, or EtCbl-2 and corresponding exciting wavelength as initiators. b) Cell 
viability of encapsulated HepG2 cells determined by simple cell counting. NT indicates no 
treatment (1- EtCbl-1, 2 – EtCbl-2).  
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3.2.5. Photolysis Through a Dermal Tissue Model 
Finally, we sought to demonstrate the utility of using red light initiation to activate 
photoinitiators through a dermal tissue model. Bio-chromophore concentration, particularly 
melanin, can fluctuate by body region and patient, producing variability in photon transmittance 
and curing.65 As noted above, wavelengths shorter than the optical window of tissue are defined 
by their significant absorbance by bio-chromophores. As expected, this behavior is exacerbated by 
increasing bio-chromophore concentrations (Figure 3.12). Furthermore, light transmission through 
tissue is rendered even more challenging due to light scattering, with shorter wavelengths 
scattering more significantly than longer ones. As a consequence of both factors, green light 
sensitive eosin Y systems used in transdermal curing are limited to low melanin skin types 
(Fitzpatrick I - II) and show reduced effectiveness with darker skin types (Fitzpatrick type III and 
greater).66 To test if red light induces photolysis of EtCbl-2 through “dermal” tissue, we used skin 
phantom solutions as optical models for dermal tissue (Figure 3.12d).65 These phantom solutions 
contain Intralipid® (3 v/v%); an emulsion of soybean oil commonly used in dermatology studies 
to mimic the light scattering properties of tissue.65,67 In addition, these phantoms contain constant 
concentrations of hemoglobin (10% hematocrit) but, to represent a variety of skin types, vary in 
melanin concentration ranging from 8.8 µg/mL (pale skin, Fitzpatrick type I - II) to 130 µg/mL 
(dark skin, Fitzpatrick type V - VI). 
Initiator solutions (10 µM) of EtCbl-1 and EtCbl-2 were irradiated using weak lasers (520, 
2.4 mW/cm2 for EtCbl-1 or 660 nm, 2.2 mW/cm2 for EtCbl-2) passed through skin phantom 
solutions in a cuvette (path length ~ 1 cm). Conversion to the HO-Cbl photoproducts was 
monitored by UV/Vis spectroscopy (Scheme 3.7, Figure 3.7, 3.13). As expected, control solutions 
containing only water showed rapid photolysis of both EtCbl-1 (52.5 nM/s) and EtCbl-2 (64.5 
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nM/s) due to limited light attenuation. However, Intralipid® (3 v/v%) solutions alone lowered the 
photolysis rate of both initiators presumably due to light scattering, but a moderate rate was still 
noted for both EtCbl-1 and EtCbl-2 (7.7 and 13.0 nM/s, respectively). Light scattering is a 
potential challenge for all phototherapies, but this limitation is typically overcome in 
photodynamic therapy by increasing light dosage and irradiation diameter.68 
When hemoglobin lysate (10 v/v%) and a small amount of melanin were introduced into 
the phantom solution ([melanin]~ 8.8 µg/mL, Fitzpatrick type I - II), EtCbl-1 failed to photolyze 
even after 30 min of 520 nm illumination. Photoinitiator EtCbl-1 photolyzes in the same range as 
eosin Y’s activation wavelength (λmax = 500 nm), implying photo-activation of any green light 
initiator may suffer when light encounters Fitzpatrick type I – II skin. On the other hand, EtCbl-2 
suffers photolysis at a similar rate when 660 nm light is passed through either Fitzpatrick type I - 
II (16.3 nM/s, [melanin]~ 8.8 µg/mL) or a type III - IV (16.7 nM/s, [melanin]~66 µg/mL) solution. 
At very high melanin concentrations (130 µg/mL, Fitzpatrick type V - VI) the photolysis rate does 
drop (10.6 nM/s) but still remains robust. Therefore, extension of the photolysis wavelength to 660 
nm may allow for broader applicability of transdermal photocuring in higher melanin containing 
skin types. This effect may be extended farther into the far red and NIR through use of a longer 
wavelength fluorophore absorbing in a region where biochromophore absorption and scattering is 
effectively zero. 
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Figure 3.12. Wavelength dependent, dermal light transmission of 300 nm (triangles), 520 nm 
(white circles), or 660 nm (black circles) in solutions of a) melanin, b) hemoglobin, or c) Intralipid. 
d) Fitzpatrick solutions used in transdermal photolysis study containing Intralipid (3 v/v%) and 
varying concentrations of melanin by skin type.  
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Figure 3.13. “Transdermal” photolysis rate of initiators with various Fitzpatrick skin type 
phantoms. EtCbl-1 (black bars) was photolyzed with a green 520 nm (2.4 mW/cm2) laser and 
EtCbl-2 (gray bars) with a red 660 nm laser (2.2 mW/cm2). At higher skin types, EtCbl-2 still 
undergoes ready photolysis compared to EtCbl-1. Since EtCbl-1 responds to wavelengths 
commonly used already for transdermal photopolymerization, these rates make it evident that 
EtCbl-2 and its activating wavelength are more suitable for in vivo applications. Moreover, the 
EtCbl-2 activates in high melanin concentrations which is a current limitation for transdermal 
photolysis.  
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3.2.6 Photoinitiator Summary 
 We have demonstrated that light-induced hydrogel formation can be mediated by alkylCbl 
based photoinitiators. Furthermore, we have shown that the wavelength of photoinitiation can be 
extended from green to red by simply appending a red light-absorbing chromophore. 
Photoinitiation proceeds via radical formation with good Φ and in demanding dermal tissue 
models. These properties suggest that alkylCbls should find utility for non-invasive hydrogel cell 
implantation by furnishing greater curing depths and limiting curing variability in higher melanin 
containing skin types. As a consequence, alkylCbl photoinitiators could find utility in medical 
conditions that range from damaged cartilage8,13 to glioblastoma69.  
3.3. Cobalt Mediated Radical Polymerization 
 In a typical, free radical polymerization, polymers with ill-defined structure form due to 
competing radical propagation and termination reactions.70 Nowadays, the desire to construct 
polymers with defined and complex structures has produced methods that control the 
polymerization process.71 Generally, reagents added to the reaction control the conversion of 
monomer to polymer by either reversible deactivation of a propagating chain or transferring the 
active species to a new chain to continue growth (chain transfer). These functions arrest the 
uncontrolled growth of radical polymerization to produce polymers with narrow and tunable 
molecular weights. Moreover, they greatly increase the lifetime of the propagating species which 
allows for the synthesis of complex structures such as block copolymers. These procedures utilize 
a variety of catalysts and additives, such as copper catalysts in atom-transfer radical 
polymerization72 and dithioethers in reversible addition-fragmentation chain transfer73.  
 Here, organometallic cobalt complexes have found utility as well.74,75 Coined 
photoiniferters, these molecules multitask to initiate, control, and terminate photopolymerizations 
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in cobalt-mediated radical polymerization (CMRP, Scheme 3.10). Upon photoinitiation, their Co-
C bond generates an initiating alkyl and a CoII radical. This CoII radical, referred to as “persistent”, 
can recombine with propagating polymer radicals to produce inactive chains. Light can reactivate 
the chains’ propagation by inducing another Co-C scission event. This on/off propagation is 
referred to as reversible deactivation and greatly reduces the concentration of propagating radicals. 
This effectively eliminates bimolecular termination to produce a pseudo-living polymerization.75–
77 Thus, chains grow at a rate dictated by the equilibrium constant between Co-capped and radical 
species. 
 The exact nature of the monomer and cobalt complex can cause variations between 
reversible deactivation and chain transfer.75 However, Vitamin B12 reduced to Co
II by ascorbic 
acid was already shown to be an effective spin trap of acrylates or chain transfer agent of 
methacrylates using thermally induced scission.78 Therefore, we became interested if a similar 
process was occurring with EtCbl under green light control. 
3.3.1. Effect of Varying EtCbl On Polymerization 
 Although these studies are only in their infancy, some of our initial work shows the 
possibility that Cbls can act as photoiniferters during radical polymerization. We first synthesized 
EtCbl by the same fashion as the photoinitiators used above (Scheme 3.4). It responds identically 
to light as EtCbl-1 with its peak absorption arising at 510 nm. To begin, we wanted to investigate 
the effect of increasing the EtCbl concentration within solution for a given polymerization. 
 Ar purged solutions of 2-hydroxyethyl acrylate (HEA, 1M) were mixed with varying 
concentrations of EtCbl in D2O and photolyzed with a 520 nm LED board (flux ~ 3 mW/cm
2). 
The rate of monomer conversion was determined using 1H NMR. As Figure 3.14 shows, the rate 
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of monomer conversion decreases with increasing EtCbl concentration. Equations 3.2 and 3.3/3.4 
show simplified rate equations for free radical propagation and CMRP, respectively.74 
(Eq. 3.1)  −
𝑑[𝑀]
𝑑𝑡
= 𝑘𝑝[M𝑖][R •] 
(Eq 3.2) −
𝑑[M]
𝑑𝑡
=  𝑘𝑝Keq(
[Co−R]
[Co•]
) 
(Eq 3.3)  Keq = (
[Co•][R•]
[Co−R]
) 
 Here, M is the monomer concentration, kp is the propagation rate constant, R• corresponds 
to the radical concentration, Co-R is the concentration of dormant species, and Co• is the 
concentration of radical trap. As these reveal, the radical concentration dictates the rate of 
propagation in both cases. One would expect the greater the amount of initiator used the more 
radicals that would be produced and, as a result, the faster the rate of propagation. However, we 
do not see this effect in our Cbl initiated systems. 
 Conversely, the rate of polymerization drops with increasing EtCbl. We ensured that the 
increased optical density of the solution did not prevent complete initiator photolysis using LC-
MS, and determined that all initiator was consumed within 10 min of irradiation for all three 
concentrations. Therefore, when considering the consequences of the equilibrium between 
dormant and active chains at a constant light flux, increasing the Cbl concentration seems to have 
the effect of pushing equilibrium toward the dormant state. This result makes sense when 
considering that more initial termination in higher EtCbl concentrations would lead to greater CoII 
(Co•) with which to reversibly deactivate. 
We further explored this conjecture that Cbl participated in the polymerization by 
examining the rate of polymerization when alternating between irradiation and dark states. We 
reasoned that if recombination of the Cbl and polymer chain was occurring, the rate of 
polymerization would drop when left in the dark because the Cbl would cap the growing chain. 
242 
Certainly, when HEA was polymerized, monomer conversion was robust under irradiation (Figure 
3.15). However, when the light was switched off the rate of monomer conversion dropped 
significantly. Illumination could successfully rescue the polymerization rate through several 
cycles. We ensured that this rescuing did not occur from leftover initiator, and LC-MS indicated 
that all of the initiator was consumed within the first twenty minutes. These results recapitulate 
our hypothesis of reversible Cbl trapping and capping of the polymer chain. 
These results of Cbl mediated polymerization controlled with green light are indeed 
encouraging but further study is needed to characterize the role Cbl plays in the polymerization 
process. Currently, we are investigating the effect of Cbl on the molecular weight distribution. 
Moreover, we hope to develop Cbl as a green photoiniferter for the construction of block co-
polymers. 
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Scheme 3.10. Cbl mediated radical polymerization. The Cbl can act as both a photoinitiator and 
control agent during polymerization. The CblII contains a persistent radical under anaerobic 
conditions which can undergo reversible deactivation with propagating polymers (trap). This 
eliminates uncontrolled growth and termination reactions. The rate of propagation depends on the 
concentration of radical in the system and therefore, depends directly on Keq. Keq can be forced 
one way or the other by varying the irradiation time and power or the Cbl concentration.   
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Figure 3.14.  Effect of Cbl concentration on the rate of polymerization. HEA (1 M) was 
photopolymerized in D2O with varying concentrations of EtCbl (white circles - 500 μM, triangles 
– 1 mM, dark circles – 2 mM) with green light (5 mW/cm2). a) Plot represents the monomer 
converted (%) to polymer over time. b) Plot represents the kinetic plot of monomer conversion 
represented as the natural log of the initial monomer concentration over the concentration at time 
(t). X denotes the time point where all the initiator was consumed as determined by LC-MS.  
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Figure 3.15. Effect of alternating irradiation on monomer conversion. HEA (1 M) was 
photopolymerized with EtCbl (1 mM) under alternating green light irradiation (520 nm, ~ 5 
mW/cm
2
). The gray bars indicate time intervals where the samples were left in the dark. The 
conversion of monomer to polymer was determined using 
1
H NMR. The rate of polymerization 
was significantly reduced in the dark even with complete initiator consumption (denoted by X).  
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3.4 Materials and Methods 
3.4.1 General 
CNCbl was purchased from Lallilabs, Inc. Cy5 was synthesized as previously described.79 
Acrylamide, N-isopropyl acrylamide, 2-hydroxyethyl acrylate (HEA), acrylic acid, polyethylene 
glycol diacrylate (PEGDA, Mn~ 575 g/mol), and polyethylene glycol monomethyl acrylate 
(PEGMA, Mn~480 gm/mol) were purchased form Sigma Aldrich. Polyethylene glycol diacrylate 
(Mn~3,400 g/mol) was purchased from Laysan Biomedical. HEA and PEGDA monomers were 
purified from their BHT and MEHQ inhibitors by standard elution through a silica gel column. All 
other reagents were used without prior purification. The 546 ± 10 nm bandpass filter was purchased 
from Newport. The 646 ± 10 and 730 ± 10 nm filters were purchased from Cheshire Optical.  
3.4.2 Synthesis 
Synthesis of ethylcob(III)alamin-ethylenediamine conjugate (Etd-EtCbl). Etd-Cbl (0.1 g, 73.8 
µmol) was dissolved in MeOH (5 mL, 5 w/v% NH4Br) and degassed with bubbling Ar for 20 min. 
Activated Zn (480 mg, 7.3 mmol) was then added and the solution was purged with Ar and shaken 
for 20 min resulting in a dark blue-green solution. Ethyl bromide (16.1 mg, 148 µmol) was added 
and the solution was shaken again for 1 h giving an orange solution. The solution was then 
precipitated into cold diethyl ether and washed (3 x 20 mL) with more chilled ether. The crude 
product was then dissolved into a minimal amount of water and purified by flash chromatography 
(semipreparative column C-18). *NOTE* At low pH values, alkylcobalamins are prone to water 
coordination at the axial-nitrogenous ligand so TFA was avoided. A binary gradient solvent system 
using H2O:CH3CN  (15 mL/min, 97:3) was equilibrated for 10 min. The gradient was then varied 
from 97:3 (0 min) to 30: 70 (30 min). Fractions were frozen and then lyophilized to remove the 
solvent yielding a red solid (85.6 mg, 85.6%). ESI MS [M + H+]+ calcd. for C67H100N15O15PCo: 
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m/z = 1444.6593, found 1444.5455; [M + 2H+]+2 calcd. for C67H101N15O15PCo: m/z = 722.8336, 
found 722.8182 
1H NMR (400MHz ,DMSO-d6) δ = 7.90 (br. s., 1 H), 7.71 - 7.60 (m, 1 H), 7.59 - 7.44 (m, 2 H), 
7.35 (br. s., 1 H), 7.25 (br. s., 1 H), 7.16 - 7.05 (m, 2 H), 6.92 (d, J = 15.7 Hz, 1 H), 6.74 (d, J = 
19.6 Hz, 1 H), 6.58 (br. s., 2 H), 6.40 - 6.20 (m, 2 H), 6.10 (br. s., 1 H), 4.30 (d, J = 8.2 Hz, 2 H), 
4.26 - 4.10 (m, 6 H), 4.00 (d, J = 11.3 Hz, 2 H), 3.69 (br. s., 2 H), 3.14 - 2.98 (m, 4 H), 2.86 (br. 
s., 3 H), 2.79 - 2.70 (m, 2 H), 2.47 (d, J = 3.9 Hz, 2 H), 2.43 (s, 4 H), 2.37 (br. s., 3 H), 2.34 - 2.22 
(m, 7 H), 2.21 - 2.14 (m, 7 H), 2.10 - 1.96 (m, 4 H), 1.91 - 1.72 (m, 6 H), 1.70 - 1.60 (m, 6 H), 1.38 
(br. s., 4 H), 1.31 - 1.18 (m, 8 H), 1.06 (d, J = 6.3 Hz, 3 H), 1.00 (s, 3 H), 0.58 - 0.43 (m, 4 H), -
0.72 (t, J = 7.4 Hz, 3 H) 
 
Synthesis of ethylcobalamin-acetamide initiator (EtCbl-1). Etd-EtCbl (25.0 mg, 17 μmol) and 
triethylamine (5.0 µL, 63 μmol) were dissolved in dry DMF (500 µL). Acetic anhydride (2.0 μL, 
19 μmol) was added and gently shaken at 45 oC for 12 h. The solution was diluted with DI-H2O 
(500 μL) and then purified by HPLC (semi-preparative C-18 column) using a binary gradient 
solvent system (H2O:CH3CN, 10 mL/min). Equilibration (10 min) was followed by an increasing 
gradient 97:3 to 5:95 (50 min). Eluents were monitored at 325 nm, collected, and lyophilized to 
give a red solid (19.3 mg, 77%). HR ESI MS. [M + H+] calcd. for C69H102N15O16PCo: m/z = 
1486.6699, found 1486.4546; [M + 2H+] calcd. for C69H103N15O16PCo: m/z = 743.8389; found 
743.9091.  
1H NMR (400MHz ,DMSO-d6) δ = 7.93 (t, J = 5.3 Hz, 1 H), 7.80 (br. s., 1 H), 7.61 (d, J = 14.5 
Hz, 1 H), 7.55 - 7.44 (m, 2 H), 7.35 (br. s., 1 H), 7.24 (t, J = 5.5 Hz, 1 H), 7.16 (br. s., 1 H), 7.09 
(br. s., 1 H), 6.94 (d, J = 19.2 Hz, 2 H), 6.78 (br. s., 1 H), 6.60 (br. s., 1 H), 6.29 (br. s., 1 H), 4.31 
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(d, J = 10.6 Hz, 6 H), 4.12 - 4.03 (m, J = 8.2 Hz, 4 H), 3.77 (br. s, 1H), 3.40 (br. s, 3H), 3.20 - 2.98 
(m, 9 H), 2.45 - 2.37 (m, 9 H), 2.28 (br. s., 1 H), 2.24 (d, J = 7.8 Hz, 6 H), 1.79 (s, 7 H), 1.68 (s, 4 
H), 1.43 (br. s., 3 H), 1.34 (d, J = 7.4 Hz, 2 H), 1.32 - 1.25 (m, 6 H), 1.20 (d, J = 5.5 Hz, 2 H), 1.15 
(d, J = 6.3 Hz, 3 H), 1.01 (s, 3 H), 0.55 (br. s., 3 H), -0.80 (t, J = 7.4 Hz, 3 H) 
 
Synthesis of ethylcobalamin-Cy5 (EtCbl-2). Stock solutions of Etd-EtCbl (58 mM) and Cy5-NHS 
ester (40 mM) were prepared each in dry DMF (50 μL). The Cy5 solution (25 μL) was mixed with 
a stock solution of Etd-EtCbl (17.3 μL), triethylamine (1 μL), and additional DMF (6.7 μL). The 
solution was then incubated at 0 oC for 8 h. The solution was diluted with DI-H2O (950 μL) and 
EtCbl-2 was isolated and purified by HPLC (semi-preparative C-18 column) using a binary 
gradient solvent system (H2O:CH3CN w/o TFA, 10 mL/min). Equilibration (10 min) was followed 
by an increasing gradient 97:3 to 5:95 (50 min). Eluents were monitored at 600 nm, collected, and 
lyophilized leaving a blue solid (1.6 mg, 87%). HR ESI MS [M+ + H+]+2 calc. for 
C99H137N17O16PCo: m/z= 954.9750, found- 955.0000; [M
+ + 2H+]+3 C99H138N17O16PCo: m/z= 
637.2303; found 637.2727. 
1H NMR (400MHz ,DMSO-d6) δ = 8.33 (t, J = 13.1 Hz, 1 H), 8.00 - 7.93 (m, 1 H), 7.75 (br. s., 1 
H), 7.62 (d, J = 7.4 Hz, 2 H), 7.44 - 7.33 (m, 3 H), 7.30 - 7.19 (m, 2 H), 6.55 (t, J = 12.3 Hz, 1 H), 
6.28 (t, J = 16.2 Hz, 2 H), 4.29 (br. s., 1 H), 4.13 - 4.04 (m, 2 H), 3.62 - 3.57 (m, 2 H), 3.24 (q, J 
= 6.5 Hz, 1 H), 3.11 - 2.98 (m, 1 H), 2.86 - 2.77 (m, 1 H), 2.39 (d, J = 8.2 Hz, 1 H), 2.24 (d, J = 
5.1 Hz, 1 H), 2.13 - 2.03 (m, 2 H), 1.68 (s, 8 H), 1.55 (td, J = 7.5, 14.7 Hz, 2 H), 1.40 - 1.31 (m, 2 
H), 1.27 (d, J = 5.9 Hz, 1 H), 1.14 (d, J = 6.3 Hz, 1 H), 0.99 (s, 1 H), 0.59 - 0.50 (m, 1 H), -0.79 - 
-0.88 (m, 3 H) 
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3.4.3 Photolysis Kinetics and Product Analysis 
LC-MS ESI analysis of wavelength dependent photolysis products. Initiators (20 μM, 100 μL) were 
photolyzed with a Xe flash lamp equipped with either a 546 ± 10, 646 ± 10, or 730 ± 10 nm 
bandpass filter. Exposed solutions were then analyzed using an Agilent 1200 series LC-MS 
scanning in positive ion mode. Samples were eluted using a gradient binary solvent system (A: 
0.1% v/v formic acid/H2O; B: 0.1% v/v formic acid/CH3CN) with a ratio of A:B varying from 
97:3 (0 - 5 min) to 10:90 (5 - 18 min). Photolysis product elution was detected at 300 nm. 
 
Electron paramagnetic resonance (EPR) detection of ethyl radical. Steady-state EPR spectroscopy 
was carried out using a JEOL FA-100 spectrometer operating at X-band (9.5 GHz) with 100 kHz 
field modulation.  Samples were inserted in 0.5 mm ID (1.0 mm OD) borosilicate glass capillaries, 
and then placed in the center of the TE011 cylindrical resonator of the spectrometer.  Spectra were 
collected over 4 to 15 min using a center field of 3362 G, a sweep width of 80 G, a field modulation 
strength of 0.8 G and microwave power of 1 mW. 
Samples consisted of EtCbl-1 or EtCbl-2 (1 mM) and spin trap, N-t-butyl- -
phenylnitrone (PBN, 8 mM) in degassed, deionized water.  Both initiators were run under three 
illumination conditions; dark, 520 nm illumination (~2.2 mW/cm2), or 660 nm illumination (~2.4 
mW/cm2).  The nitrone-radical adduct was detected and compared to literature hyperfines of ethyl-
PBN adducts.61 
 
Relative Quantum Yield (Φ) Determination. Stirred initiator solutions (12 μM, 3 mL) were 
continuously illuminated with either a 520 or 660 nm laser attenuated by a neutral density filter to 
a constant power flux (1 mW/cm2). Sample optical densities were previously determined within a 
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UV/Vis spectrophotometer, but a power meter (Thorlabs S120VC, 200 - 1100 nm) was placed in 
line with the excitation beam passing through the sample to record the absolute power being 
absorbed. The sample spectrum between 200 - 400 nm was analyzed every 8 seconds by delivering 
light (<3 µW) from a Mikropack DH-2000-BAL deuterium-halogen source through the sample to 
a Labview 8.5 detector at 90o to the excitation source. A shutter was used to limit light exposure 
when the spectrum was not being measured. 
By monitoring the change in sample absorbance at 350 nm (Figure 3.5), the concentration 
of the primary photo-product (HO-Cbl-Ac or HO-Cbl-Cy5) can be determined by eq. 3.4: 
(Eq. 3.4)     [𝐇𝐎 − 𝐂𝐛𝐥 (µM)] =
∆A350nm
14,300 M−1cm−1
∗  106µM 
Where ΔA is the change in sample absorption at 350 nm, and the denominator is the 
difference in extinction coefficients at 350 nm (ε350) between the photoproducts HO-Cbl-Ac, Cy5 
and the alkyl initiators EtCbl-1 and EtCbl-2. The initial photolysis rate is extrapolated from the 
linear portion of a plot comparing [HO-Cbl] vs. illumination time (Figure 3.6). From this rate, the 
quantum yield can be calculated by: 
(Eq. 3.5) Φ = [(mVNA)(hν)/ΔP] 
Here, m is the rate of photolysis in molar/s, V is the volume of the solution, NA is 
total power 
being absorbed by the sample at a given time. 
3.4.4. Photopolymerizations 
Monomer Conversion Assessment by NMR. Monomer (1 M) and initiator (200 μM, EtCbl-1 or 
EtCbl-2) were dissolved in D2O (1 mL) and degassed with Ar for 30 min. The mixture was 
transferred via cannulation into an Ar purged NMR tube. Samples were kept in the dark, 
illuminated in a UV oven (room temperature) or with 520 or 660 nm LEDs (~25 mW/cm2) for 1 h 
251 
with colored gel filters to narrow the LED emission width. Monomer conversions were determined 
by 1H NMR using a 400 MHz Varian.  
 
Monomer Conversion with Alternating Irradiation 2-hydroxethyl acrylate (HEA) was dissolved 
in water (25 v/v%) and then washed with hexane (10 x). The aqueous phase was then brined (250 
g/L) and extracted again with ether (4 x). The ether was dried then removed to provide pure HEA. 
HEA (1 M) and initiation (.5, 1, or 2 mM) was dissolved in D2O, placed in round bottom flask (10 
mL), and then purged with Ar for 30 min. The sample was placed over a 520 nm LED board and 
rapidly stirred. Samples were removed using a syringe, quenched in D2O (10 v/v% CD3OD), then 
analyzed by 1H NMR for monomer conversion. Aliquots of extracted solution were analyzed by 
LC-MS to analyze for intact initiator. 
 
Hydrogel Formation 
(1) Acrylamide/Bisacrylamide Acrylamide (1.6 M), N,N’-methylenebisacrylamide (10 mM), and 
photoinitiator (200 µM) were dissolved in DI water (400 µL), placed in a septum sealed vial, and 
then degassed for 20 min with Ar. Samples were left in the dark or exposed to a Xe flash lamp 
attenuated with bandpass filters at 546 ± 10 nm, 646 ± 10 nm, or 730 ± 10 nm for 5 min. Sample 
vials were inverted to determine successful gelation of the polymer solution. 
(2) PEG-monoacrylate/PEG-diacrylate The above procedure was repeated but this time using 
PEG-monoacrylate (200 mM) and PEG-diacrylate (20 mM). 
3.4.5. Swelling Ratio (Q)  
Determination with varying crosslinker: (1) Acrylamide/Bisacrylamide The bisacrylamide 
crosslinker concentration was varied (0 - 100 mM) in PBS buffer (10 mL) with initiator (200 µM) 
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and acrylamide (1.6 M). Solutions were degassed for 30 min by bubbling in Ar. A small amount 
of agarose (1 w/v%) was beaded along the bottom of a standard electrophoresis gel mold (8.25 cm 
x 7.5 cm x 1.5 mm) to prevent leakage. Degassed mixtures were cast and photolyzed at the 
initiator’s λmax for 1 h. Small sample discs (1 cm diameter) were punched from the gels and swelled 
for 24 h in PBS (3 mL). Discs were removed, dabbed to remove excess water from the gel surface, 
and then weighed. The discs were then lyophilized overnight and re-weighed to determine the dry 
polymer weight. Q was then calculated as the ratio between the wet mass to the dry polymer. 
(2) PEG-methacrylate/PEG-diacrylate The above procedure was repeated by varying PEGDA (0 
- 300 mM, Mn ~ 540 g/mol) with constant PEGMA (200 mM, Mn ~ 475 g/mol). 
 
Determination with varying initiator: 
(1) Acrylamide/Bisacrylamide Acrylamide/bisacrylamide gels (1.6 M, 10 mM) gels were formed 
in PBS buffer (10 mL) with varying levels of initiator (0 – 2.5 mM). Solutions were degassed for 
30 min by bubbling Ar and then cast in a gel mold as above. The mixtures were photolyzed, sample 
discs removed, and swollen as above. The Q ratios were computed as before. 
(2) PEG-acrylate/PEG-diacrylate PEG-acrylate/PEG-diacrylate (200 mM, 50 mM) were formed 
in PBS by the same method above with varying initiator (0 – 5 mM). 
 
Section 3.4.6. HepG2 cell encapsulation and viability 
Cell Culture HepG2 cells were maintained in a temperature-controlled tissue culture incubator (37 
˚C, 95% humidity, 5% CO2) in MEM alpha (with L-glutamine; Gibco) containing 10% Fetal 
Bovine Serum (Gibco) and 1% Pen-Strep (Gibco).  
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Initiation with EtCbl-1 or Irgacure 2959: Encapsulation by photopolymerization was performed 
at room temperature under aerobic conditions. HepG2 cells were trypsinized (0.25 v/v% Trypsin-
EDTA), pelleted by centrifugation and washed (2 x 5 mL PBS). Cells were suspended in PBS 
containing fibronectin (0.033 mg/mL) at a density of 3 x 106 cells/mL. A 30 µL aliquot of the 
resulting HepG2-fibronectin stock solution was combined with 70 µL of PEGDA (Mn ~3,400 
g/mol)/initiator solution to a final volume of 100 µL. Final solution concentrations were 100 mM 
PEGDA, 9.9 µg/mL fibronectin, and 1 mM initiator. The solution was placed in a 35 mm Mattek 
dish well and covered with a coverslip. Polymer solutions containing I2959 or EtCbl-1 were 
illuminated at 350 ± 10 nm (12.8 mW/cm2) or 546 nm ± 10 nm (21.6 mW/cm2), respectively, for 
5 min.  Following photo-polymerization, the hydrogel was washed with PBS (3 x 1 mL). After 
washing, fresh media (L-15 + 10% FBS) was added, and the hydrogel returned to the 37 ˚C 
incubator for 30 min. The sample was covered with MEM alpha media (10% FBS/ 1% Pen-Strep) 
and incubated for 24 h (5% CO2/95% humidity) before proceeding to the Live/Dead assay. 
Initiation with EtCbl-2: Photo-polymerization was again performed under aerobic conditions at 
room temperature. HepG2 cells were trypsinized (0.25 v/v% Trypsin-EDTA), pelleted by 
centrifugation and washed (2 x 5 mL PBS). Cells were suspended in PBS containing fibronectin 
(0.033 mg/mL) at a density of 3 x 106 cells/mL. A 46 µL aliquot of the resulting solution was 
combined with 50 µL of PEGDA solution (200 mM stock), 2.5 µL EtCbl-2 solution (20 mM 
stock), and 2 µL bovine serum albumin solution (BSA, 10 mg/mL). Final solution concentrations 
were 100 mM PEGDA, 9.9 µg/mL fibronectin, 200 µg/mL BSA, and 500 µM EtCbl-2. The 
solution was placed in a 35 mm Mattek dish well and polymerized using two 660 nm LEDs (100 
mW/cm2, 20 min exposure) positioned above and below the dish. Cells were cooled during 
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polymerization using a small fan. Washing, incubation, and staining protocol for EtCbl-1 and 
Irgacure 2959 was repeated for gels polymerized with EtCbl-2. 
Cell Viability/LIVE/DEAD assay. 24 h after polymerization, hydrogels were washed with PBS (2 
x 2 mL), and then incubated with 1 mL of the LIVE/DEAD assay solution (0.5 µL calcein-am 
stock solution and 2 µL ethidium bromide stock solution per mL of PBS; LIVE/DEAD Viability-
Cytotoxicity Kit; Molecular Probes, Inc.) for 25 min at room temperature and protected from light. 
Post-incubation, the hydrogels were washed with PBS (2 X 2mL), covered in fresh media (L-15 
plus 10% FBS) and immediately imaged. All microscopy studies were performed on an Olympus 
FV1000 point scanning confocal with an IX81 microscope base. Z-stacks were acquired at 10X 
magnification using optical slices 20 µm apart. To assess cell viability, a minimum of 200 cells 
was counted for each condition (live or dead). 
3.4.7. Photolysis Through Fitzpatrick Skin Models 
Melanin was dissolved in a solution of NH4OH (100 mM) to form a melanin stock solution 
(3 mg/mL). Hematocrit lysate stock solution (50% hematocrit) was prepared via sonicated lysis of 
erythrocytes in PBS. The sonicated solution was then centrifuged to remove residual membranes 
and subsequently filtered. All skin phantom solutions (3 mL) contained 3% v/v Intralipid® and 
erythrocyte lysate solution (10 % hematocrit). Melanin stock solution was added at varying 
concentrations depending on Fitzpatrick skin type (I – II ~8.8 μg/mL; III – IV ~66.0 μg/mL; V – 
VI ~130.0 μg/mL).65,67 
Initiator solutions of either EtCbl-1 or EtCbl-2 (10 μM) were placed in a cuvette (1 mL) 
and a skin phantom solution inserted between the initiator solutions and the light source; a 520 nm 
laser (2.4 mW/cm2) was paired with EtCbl-1 and a 660 nm laser (2.2 mW/cm2) was paired with 
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EtCbl-2. The rate of initiator photolysis was monitored by analyzing the change in absorbance at 
350 nm. Water and 3% v/v lipid solutions were used for control studies. 
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CHAPTER FOUR: FLUOROPHORE ASSISTED PHOTOLYSIS OF THIOLATO-
COB(III)ALAMINS 
 
Chapter Abstract 
Several Cbl species react with an equivalent of thiol yielding a stable β-axial CoIII-S bonded 
thiolato-Cbl complex, which are proposed important intermediates in many Cbl dependent, 
biological transformations. In stark contrast to related alkylCbl complexes, the photolability of the 
Co-S bond in thiolato-Cbls remains undetermined. In this chapter, we investigate the photolability 
N-acetyl-L-cysteinyl-Cbl derivatives at several wavelengths within the ultraviolet and visible 
spectrum. To aid in photolysis, I will demonstrate that attachment of fluorophore “antennae” to 
the Cbl scaffold can improve photolytic efficiency by an order of magnitude.  Additionally, EPR 
spectroscopy confirms previous conjectures that photolysis of thiolato-Cbls produces chemically 
useful thiyl radicals at wavelengths as long as 546 ± 10 nm. 
4.1 Thiolato-Cbls 
As discussed in the previous chapters, alkylCbls display intriguing photochemistry that has 
been the subject of extensive studies since the late 1960s.1–3 In these complexes, the extremely 
weak Co-C (~ 30 – 44 kcal/mol) bond undergoes homolytic scission to yield a CoII and alkyl 
radical pair upon absorption of visible light (< 600 nm).4–9 The absorptive transition occurring 
within these complexes is thought to arise from an initial metal-to-ligand and sigma-bond-to-
ligand charge transfer between the axial ligands (Nimidazole-Co-C) and the corrin ring.
10–14 As 
indicated before, alkylCbls display high photolability with observed, aerobic Φ of photolysis 
approaching 30%.1 
 263 
Not long after the vitamin’s discovery, Cbl’s high reactivity towards thiolates, particularly 
the cysteine residue of glutathione, was reported to provide stable, β-axial CoIII-S bonded 
complexes known as thiolato-Cbls (Scheme 4.1).15–17 This affinity for mercaptans and the high 
intracellular concentrations of glutathione (> 1 mM) led to the assumption that free Cbl within the 
body is rapidly bound to form glutathionylCbl (GSCbl).18 Thus, researchers have inferred that 
thiolato-Cbls are possible intermediates in the biosynthesis and trafficking of alkylCbls.19–24 For 
example, glutathione and cysteine can reduce Cbls to lower oxidation states necessary for 
alkylation to MeCbl or AdoCbl. Enzymes, like methionine synthase, and Cbl chaperone proteins 
have also shown a preference for GSCbl over other Cbl forms, such as HO-Cbl and 
CNCbl.20,21,25,26 Thiolato-Cbls have also demonstrated potent anti-inflammatory properties and 
several research groups have patented thiol derivatives for this purpose.27,28 Thus far, the precise 
biological function of thiolato-Cbls remains ambiguous making further their characterization 
important for understanding B12 chemistry and functions.  
4.2 Thiolato-Cbls’ Photochemistry 
When considering the breadth of experimental and theoretical studies devoted to alkylCbls’ 
photochemistry, reports of thiolato-Cbl photolability remain extremely limited. A few reports of 
thiolato-Cbls reference a general sensitivity towards light (t1/2 ~ 1.1 x 10
4 min for γ-
glutamylcysteinylCbl) decomposing the Co-S bond, but they expound no further on the 
issue.6,17,29,30 This large half-life suggests thiolato-Cbls resist photolysis significantly better than 
alkylCbls. Work by Dolphin supports this observation as his report showed that more than half of 
GSCbl remained intact after 72 h of photolysis with a tungsten lamp.17 
This lowered photosensitivity is surprising as thiolato-Cbl and alkylCbls produce similar 
UV/VIS spectra, especially in the γ absorption band (300 – 400 nm), indicating possible 
 264 
commonalities in bonding and electronic transitions (Figure 4.1). Indeed, the work of Birke and 
Brunold shows both alkyl and thiolate ligands bind the Co metal center with comparable covalency 
and donor strength.31,32 These recent reports have demonstrated that the visible excited states 
between the two species are in fact similar in nature. Brunold’s work with Raman spectroscopy 
also determined excitation (~ 568 nm) of thiolato-Cbls produces enhanced Co-S stretching and a 
correspondent weakening of the axial Co-S bond similar to photolysis in alkylCbls. This 
preliminary evidence supports the conjecture of their photolability.31  
As a result, we became interested in comparing the photo-susceptibility of thiolato-Cbls 
relative to alkylCbls, since the latter have found excellent utility in the development of light 
activated tools as detailed in the previous three chapters.33–38 AlkylCbl’s high Φ and ε allows for 
facile photocleavage with light in both the visible and NIR spectrum, but this extraordinary 
sensitivity can complicate their handling as even imaging during fluorescent microscopy leads to 
rapid degradation.38,39 Therefore, the hinted reduction of photolability in thiolato-Cbls could 
provide an advantage to more tightly control the photorelease of bioactive agents like cysteine 
containing peptides. 
As stated, the brief reports of GSCbl photolysis indicate these complexes are significantly 
more resistant to visible light than alkylCbls.6,17,29,30 Yet, the previous work discussed in earlier 
chapters points to a possible solution. We found that alkylCbls ligated to fluorophores have 
significantly improved photolysis rates and wavelength range when the bound fluorophore was 
excited directly.33,39 The fluorophore behaves as a light capturing antenna that harvests 
significantly more photons than free Cbl due to its large extinction coefficient (ε). The excited dye 
can then use the captured energy to sensitize Cbl photolysis. For example, coenzyme B12 modified 
with TAMRA (ε555 nm – 93,000 M-1cm-1) photolyzed ~250% faster than the unmodified vitamin 
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(ε510 nm – 8,300 M-1cm-1) when excited at the same wavelength. Since this approach worked with 
a range of fluorophores, we sought to employ an analogous strategy in this study to increase 
thiolato-Cbl photolysis rates throughout their absorption profile (300 – 550 nm). 
 Furthermore, we wanted to determine the photolytic fate of the thiol ligand. Previous 
reports imply bond cleavage occurs homolytically to provide thiyl radicals (Scheme 4.2).31 
However, this assumption is based on indirect observation of the corresponding CoII radical using 
EPR and UV/Vis absorption spectroscopy upon photolysis or thermolysis of model thiol-cobalt 
complexes.29,40,41 In short, no direct EPR detection of the thiyl product exists with trapping agents 
likely due to the rapid decomposition of thiol-nitrosyl trap adducts.29,42–44 It is thought that nitrosyl 
based traps such as 5,5’-dimethyl-pyrolline-N-oxide (DMPO) and PBN undergo rapid electron 
transfer to release trapped thiyl radicals as thiolates. This rapidly destroys any detectable 
paramagnetic species produced during photolysis of thiolato-Cbls.  
Determination of the thiol ligand’s fate could have profound implications as solvent caged 
thiyl-CoII radical pairs are thought to be key intermediates in Cbl dependent enzymes.40,45,46 Also, 
research into photo-generation of thiyl radicals has exploded in recent years due to the thiol-ene 
click’s importance in spatiotemporally controlled materials synthesis.47,48 Tissue engineers utilize 
this reaction between thiyl radicals and electron rich olefins to photo-pattern surfaces with thiol 
containing molecules (i.e. peptides and polymers), while nanotechnology use the thiol-enes’ 
quantitative yields for the construction of well-defined dendrimer nanoparticles.  
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Scheme 4.1. Formation of thiolato-Cbl from HO-Cbl and N-acetyl-L-cysteine (NAcSH). In the 
presence of an equivalent of thiol, HO-Cbl reacts via β ligand exchange to form stable CoIII-S 
bonded complexes. Using a modified literature report, we formed several fluorophore modified N-
acetyl-L-cysteinyl-Cbls [NAcSCbl-(1-4)] to investigate their photochemical properties.  
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Figure 4.1. Spectral overlay of HO-Cbl (red), MeCbl (blue), and NAcSCbl (green). The 
“atypical” spectral similarities of alkyl and thiolato-Cbls are clearly evident in the UV region.  
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Scheme 4.2. Homolytic scission of alkyl and thiolato-Cbls. The limited reports of thiolato-Cbls 
infer bond scission occurs via homolysis to release a thiyl radical, but studies have failed to directly 
detect this product. Instead, they infer formation via detection of longer lived CoII photoproducts 
with EPR and UV/Vis absorption spectroscopy.29,40,41 By contrast, the homolytic process in 
similarly bonded alkylCbls has been extensively studied and characterized.1,6,9  
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4.2.1. Thiolato-Cbl Photolability 
To date, GSCbl represents the most studied thiolato-Cbl. However, we were concerned that 
reported favorable glutathione interactions with Cbl side chains could confound photolability 
studies due to ligand retention within a solvent cage and inability for radical pair separation.24,30,49 
Therefore, we used a smaller cysteine derivative for our initial study and synthesized N-acetyl-L-
cysteinyl-Cbl (NAcSCbl) from HO-Cbl and N-acetyl-L-cysteine (NAcSH) via a modified 
procedure (Scheme 4.1).50 Under acidic conditions, an equivalent of the cysteine thiolate displaces 
H2O and binds the Co center via β ligand exchange to generate a CoIII-S bond with near quantitative 
yields. As opposed to complexes formed with native L-cysteine, the amine acetylation of NAcSH 
greatly improves the aerobic stability of NAcSCbl.  
Successful bond formation can clearly be seen from the change in the visible absorption 
spectrum (Figure 4.1) and LC-MS analysis (Figure 4.4). HO-Cbl produces a “typical” Cbl 
spectrum with one sharp transition arising at 350 nm (γ band) and a broad visible absorption 
centered on 525 nm (α/β band). HO-Cbl treatment with a solution of thiol causes a noticeable 
color change in solution from red to purple. The absorption spectrum reflects this by red shifting 
to an “atypical” spectrum with maxima arising at 334, 370 and 535 nm.31,32 As mentioned before, 
the similarities between the NAcSCbl and MeCbl spectra, especially at the γ bands (300 – 400 
nm), are striking indicating that perhaps both ligands have similar σ donor character and electronic 
transitions (Figure 4.1).  
We monitored the changes in the absorption spectrum of NAcSCbl (20 µM, 100 mM acetate 
buffer, pH 5.5) during photolysis to assess the extent of unreacted NAcSCbl as a function of time 
(Figures 4.2 – 4.3).1 NAcSCbl photolysis at 360 ± 10 nm produced significant spectral changes 
with isosbestic points at 340, 365 nm, and 540 nm. In agreement with previous studies, the 
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photoproduct spectrum resembled HO-Cbl, which was confirmed by LC-MS analysis (Figure 
4.4).17,29,30 Illumination of NAcSCbl at 360  ± 10 nm induces the formation of HO-Cbl at a rate 
approximately three orders of magnitude slower than a model alkylCbl (MeCbl, Table 4.1, Figures 
4.3, 4.5), while NAcSCbl samples stored in the dark display insignificant decomposition compared 
to the irradiated samples (Figure 4.6). 
Since NAcSCbl absorbs throughout the visible spectrum, we also investigated the photolysis 
of NAcSCbl using blue (405 ± 10 nm) and green (546 ± 10 nm) light by determining the propensity 
for photolysis measured as Φs (photolysis product formed per photons absorbed). The relative 
photolysis Φ of NAcSCbl under the three illumination conditions were determined by comparing 
the photolysis rates of NAcSCbl with those of MeCbl, since the Φ for the latter at all three 
wavelengths have been previously reported (Table 4.1, Figures 4.3, 4.5 – 4.10).1 The rates of 
photolysis were normalized using the MeCbl photolysis rate at 360 nm as a baseline and the Φ 
determined from the ratio of MeCbl and NAcSCbl rates using Eq 4.2. For all the wavelengths 
tested, the Φs for NAcSCbl are several orders of magnitude lower than those for 
MeCbl, indicating that the former are significantly less prone to photolysis. 
These lower Φs are responsible for the greatly reduced rate of NAcSCbl photolysis since the 
ε for both MeCbl and NAcSCbl are nearly identical at each wavelength tested. In addition, 
NAcSCbl displays a decreasing Φ with increasing wavelength with the Φ at 546 nm an order of 
magnitude lower than at 360 nm. This trend stands in stark contrast to most alkylCbls whose Φs 
remain relatively constant (20% – 30%) throughout their absorption spectra.1,14 The dramatic 
reduction in both Φ and rate of thiolato-Cbls photolysis relative to alkylCbls is intriguing, 
especially given the similarities in Co-ligand bonding interactions in both species noted by 
others.22,23 Moreover, theoretical analyses of Co-C and Co-S bonding suggest that the latter may 
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in fact be weaker with homolytic dissociation energies estimated at 26 kcal/mol for GSCbl and 37 
kcal/mol for MeCbl.4–9,31,32 
Assumptions as to why this decreased photolability occurs would be pure conjecture at this 
point. However, one possible explanation may be due to reduced diffusivity from the solvent caged 
radical pair of the heavier cysteine thiyl radicals to relatively small alkyl radicals. Additionally, 
crystal structures of model thiolatoCbls show favorable bonding interactions away from the Co-S 
bond improving the overall stability of the complex.24,30,49,51 Both of these conditions could lead 
to greater thiyl-CoII radical recombination and a concurrent reduction in the apparent Φ. Indeed, 
radical recombination within a solvent cage versus cage escape dictates the apparent Φ for 
alkylCbls.6,10,13,52–54 In addition, slight differences in bonding interactions do exist between the two 
species, such as π bonding interactions in thiolatoCbls, that are absent in alkylCbls.32 These 
differences further convolute the electronic transitions responsible and complicate the 
determination for the improved stability to light. However, explanations as to their precise role lie 
outside the scope of this study. 
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Figure 4.2. Change in absorption due to photolytic conversion of NAcSCbl (blue line, 20 µM) to 
HO-Cbl (red line) in acetate buffer (100 mM, pH 5.5). Black lines indicate intermediate photolysis 
times of 1, 2, 3 and 4 min (360 ± 10 nm). The changes in the spectrum at a given wavelength is 
used to calculate the amount of HO-Cbl in solution using equation 4.1. 
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Figure 4.3. Photoinduced conversion of NAcSCbl (squares, 20 µM, 100 mM acetate buffer, pH 
5.5) to HO-Cbl (circles) using a Hg arc lamp (360 nm). The plot is represented as the mole fraction 
(Xi) of each species in solution versus time (n = 3)  
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Figure 4.4. LC-MS chromatograms of NAcSCbl solution stored in the dark or 360 nm photolyzed 
with a Hg arc lamp for 20 min. The photolyzed solution (20 µM NAcSCbl, 100 mM acetate buffer, 
pH 5.5) was monitored at the two compound’s isobestic point of 540 nm. 
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Figure 4.5. Photoinduced conversion of MeCbl to HO-Cbl. Samples (20 µM, 100 mM acetate 
buffer, pH 5.5) were photolyzed using a Hg arc lamp (360 nm ± 10 nm) (n = 3)  
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Table 4.1. Φ, ε, efficiency (Φε) and normalized rate constants 
(kapp) for photolysis of MeCbl and NAcSCbl. 
  λ (nm)a MeCblb NAcSCbl 
Φc
 
  
360 
~ 0.30 (4.4 ± .8)  x 10-4 
ε 10,400 11,400 
Φε 3,100 5.0 ± 1.0 
kappd 1 ± .2 (1.6 ± .3) x 10-3 
Φc  
405 
~ 0.30 (1.3 ± .1) x 10-4 
ε 3,600 3,300 
Φε 1,100 0.42 ± 0.02 
kappd (3 ± .1) x 10-2 (1.1 ± .1) x 10-5 
Φc  
546 
  
  
~ 0.15 (1.5 ± .1) x 10-5 
ε 6000 6400 
Φε 900 0.10 ± 0.004 
kappd 0.13 ± .01 (1.5 ± .1) x 10-5 
a
Hg arc lamp illumination source equipped with optical band 
pass filters centered at the wavelength indicated (± 10 nm).
 
b
Literature  quantum yields are shown for MeCbl.
8 c
Calculated 
from equation 4.2.
 d
The constant was normalized to the rate of 
MeCbl photolysis at 360 nm where it cleaved fastest.  
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Figure 4.6. Photolytic conversion of NAcSCbl to HO-Cbl under illumination or left in the dark. 
NAcSCbl samples (20 µM, 100 mM acetate buffer, pH 5.5) were irradiated (360 ± 10 nm, circles) 
or left in the dark (squares). Conversion is represented as a mole fraction of HO-Cbl product in 
solution. 
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Figure 4.7. Photoinduced conversion of NAcSCbl to HO-Cbl with 405 nm light. NAcSCbl 
samples (squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(405 ± 10 nm) and monitored for conversion to HO-Cbl (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3)  
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Figure 4.8. Photoinduced conversion of MeCbl to HO-Cbl with 405 nm light. MeCbl samples 
(squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp (405 ± 10 
nm) and monitored for conversion to HO-Cbl (circles). Plot is presented as the concentration of 
HO-Cbl in solution.  (n = 3)  
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Figure 4.9. Photoinduced conversion of NAcSCbl to HO-Cbl with 546 nm light. NAcSCbl 
samples (squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(546 ± 10 nm) and monitored for conversion to HO-Cbl (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3)  
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Figure 4.10. Photoinduced conversion of MeCbl to HO-Cbl with 546 nm light. MeCbl samples 
(20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp (546 ± 10 nm) and 
monitored for conversion to HO-Cbl (circles). Plot is presented as the concentration of HO-Cbl 
in solution.  (n = 3)  
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4.2.2. Fluorophore Modified Thiolato-Cbl Photolability 
As a solution to the low rates of photolysis, we were interested in whether the previous 
fluorophore ligation approach used in alkylCbls’ photolysis would increase the rate of photolysis 
for thiolato-Cbls as well. Therefore, we attached Alexa Fluor 350 (Alexa3, λmax – 350 nm, 
NAcSCbl-2), 7-(diethylamino)-coumarin-3-carboxylic acid (DEAC, λmax – 423 nm, NAcSCbl-3), 
and TAMRA (λmax 555 nm, NAcSCbl-4) to the ribose 5ʹ-OH of NAcSCbl (Scheme 4.1). A 
molecule with an acetyl group instead of a fluorophore (NACSCbl-1) was also synthesized to 
serve as a control. The fluorophores used covered the three primary absorption bands present in 
Cbl spectrums and increase the overall photon absorbance of the complex (Figure 4.11). 
These fluorophore constructs were easily constructed from HO-Cbl through modification of 
the nucleotide ribose-5’-OH with 1,1’-carbonyl-di-triazole (CDT) followed by treatment with 
ethylenediamine (HO-Cbl-Etd, Scheme 4.3). This installs an amine functional handle for the 
attachment of N-hydroxysuccinimdyl (NHS) functionalized or uronium (TSTU) activated 
fluorophores (Scheme 4.4 – 4.5). Finally, the same treatment of these conjugates with NAcSH 
solution in acetate buffer yields the fluorophore modified NAcSCbl-(1-4) (Scheme 4.1). 
Once again, we determined the photolysis rate of NAcSCbl derivatives 1 – 4 by changes in the 
UV/Vis absorption spectrum (Figure 4.2, 4.12 – 4.14) and confirmed homolysis by LC-MS (Figure 
4.15 – 4.18). Not surprisingly, the Φ and relative reaction rate for the photolysis (360 nm) of the 
mono-acetylated derivative NAcSCbl-1 [kapp = (1.6 ± 0.2) x 10-3; Φ = (4.2 ± 0.5) x 10-4] and its 
unmodified counterpart NAcSCbl [kapp = (1.6 ± 0.3) x 10-3; Φ = (4.4 ± 0.8) x 10-4] are virtually 
identical (Tables 4.1-4.2, Figure 4.3, 4.19). The relative rate of 360 nm induced photolysis of the 
Alexa350 fluorophore derivative, NAcSCbl-2 [kapp = (3.0 ± 0.6) x 10-3; Φ = (3.4 ± 0.6) x 10-4], is 
enhanced nearly twofold versus the corresponding rates for NAcSCbl and NAcSCbl-1 (Table 4.1 
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– 4.3, Figures 4.3, 4.19 – 4.21). Since the Φ remains relatively the same for all three compounds, 
the rate increase tracks with a corresponding increase in the extinction coefficient of NAcSCbl-2 
implying that the rate change is due to increased photon absorption by the complex. In an 
analogous vein, DEAC modified NAcSCbl-3 [kapp = (1.1 ± 0.1) x 10-4; Φ = (1.1 ± 0.1) x 10-4] 
undergoes photolysis at 405 ± 10 nm an order of magnitude more rapidly than NAcSCbl [kapp = 
(1.1 ± 0.1) x 10-5; Φ = (1.3 ± 0.1) x 10-4] (Table 4.3, Figures 4.22). The Φ for both complexes are 
nearly identical, however, the  for NAcSCbl-3 is an order of magnitude larger than NAcSCbl’s 
indicating that the increase in photons absorbed is primarily responsible for the observed rate 
increase. Finally, NAcSCbl-4 displays an analogous trend for photolysis at 546 nm (Table 4.3, 
Figure 4.23). The relative photolytic rate of NAcSCbl-4 is an order of magnitude greater than 
NAcSCbl in spite of the fact that the Φ for both complexes are approximately the same [ΦNAcSCbl 
= (1.3 ± 0.1) x 10-4 versus ΦNAcSCbl-4 = (0.92 ± 0.05) x 10-4]. Once again, the primary driving force 
for the relative rates is the significantly greater photon capturing ability of NAcSCbl-4 at 546 nm 
(NAcSCbl = 6,400 M-1 cm-1 versus NAcSCbl-4 = 84,000 M-1 cm-1) (Table 4.1, 4.3).  
Relative to alkylCbls, the Φ of thiolato-Cbls are low. However, the photolytic efficiencies (Φε) 
exhibited by the fluorophore modified Cbls display comparable ligand release values to some 
recently reported, visible light responsive caging groups.55–58 Moreover, reduced photolability may 
provide an advantage, since the simple act of imaging the extremely susceptible alkylCbls induces 
rapid photocleavage. Finally, these results demonstrate that fluorophores can act as photon 
antennas, offering the means to modulate the rate of thiolato-Cbl photolysis.30 
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Figure 4.11. UV/Vis absorption spectra of fluorophore modified thiolato-Cbls. a) Normalized 
absorption and b) extinction coefficient (ε) of NAcSCbl-2 (blue), NAcSCbl-3 (green), and 
NAcSCbl-4 (red) are shown.  
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Scheme 4.3 Synthesis of HO-Cbl-Etd starting material. HO-Cbl was first activated with CDT 
and then treated with ethylenediamine to furnish HO-Cbl-Etd in moderate yield. 
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Scheme 4.4. Synthesis of HO-Cbl-1,3 precursors from HO-Cbl-Etd. Activation of acetic acid or 
DEAC with TSTU and then addition of HO-Cbl-Etd yielded the modified Cbls in good yield.  
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Scheme 4.5. Synthesis of HO-Cbl-2,4 precursors from HO-Cbl-Etd. Coupling was achieved by 
reaction of HO-Cbl-Etd with the NHS ester forms of Alexa350 and TAM to provide the HO-Cbl 
fluorophore modified derivatives.  
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Figure 4.12. Absorption spectra of 360 nm light-mediated conversion of NAcSCbl-2 (10 μM, blue 
line) to HO-Cbl-2 (red line) (100 mM acetate buffer, pH 5.5). Photolysis (360 ± 10 nm) time points 
of 0, 2, 4, and 6 min are shown.  
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Figure 4.13. Absorption spectra of 405 nm light-mediated conversion of NAcSCbl-3 (20 μM, blue 
line) to HO-Cbl-3 (red line) (100 mM acetate buffer, pH 5.5). Photolysis (405 ± 10 nm) time points 
of 0, 1, 2, and 3 h are shown.  
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Figure 4.14. Absorption spectra of 546 nm light-mediated conversion of NAcSCbl-4 (20 μM, blue 
line) to HO-Cbl-4 (red line) (100 mM acetate buffer, pH 5.5). Photolysis (546 ± 10 nm) time points 
of 0, 1, 2, and 3 h are shown. 
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Figure 4.15. LC-MS chromatograms of NAcSCbl-1 solution stored in the dark or irradiated at 360 
nm with a Hg arc lamp for 20 min. The photolyzed solution (20 µM NAcSCbl-1, 100 mM acetate 
buffer, pH 5.5) was monitored at the isobestic point of 540 nm. 
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Figure 4.16. LC-MS chromatograms of NAcSCbl-2 solution stored in the dark or irradiated at 360 
nm with a Hg arc lamp for 20 min. The photolyzed solution (10 µM NAcSCbl-2, 100 mM acetate 
buffer, pH 5.5) was monitored at the isobestic point of 540 nm.  
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Figure 4.17. LC-MS chromatograms of NAcSCbl-3 solution stored in the dark or irradiated at 360 
nm with a Hg arc lamp for 4 h. The photolyzed solution (20 µM NAcSCbl-3, 100 mM acetate 
buffer, pH 5.5) was monitored at the isobestic point of 540 nm.  
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Figure 4.18. LC-MS chromatograms of NAcSCbl-4 solution stored in the dark or irradiated at 546 
nm with a Hg arc lamp for 4 h. The photolyzed solution (10 µM NAcSCbl-4, 100 mM acetate 
buffer, pH 5.5) was monitored at the isobestic point of 540 nm. 
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Figure 4.19. Photoinduced conversion of NAcSCbl-1 to HO-Cbl-1 with 360 nm light. NAcSCbl-
1 samples (squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(360 ± 10 nm) and monitored for conversion to HO-Cbl-1 (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3) 
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Table 4.2. Photolytic properties of NAcSCbl-1 @ 360 nm 
  NAcSCbl-1 
Φb
 
4.2 ± 0.5 x 10-4
 
Ε 11400 
Φε 4.8 ± .6 
kappc
 
1.6 ± 0.2 x 10-4 
aHg arc lamp illumination source equipped with optical band 
pass filters centered at the wavelength indicated (± 10 nm).
 
bCalculated from equation 4.2.
 cThe constant was 
normalized to the rate of MeCbl photolysis at 360 nm where 
it cleaved fastest.  
 
 
 
Table 4.3. Φ, ε, efficiency (Φε) and normalized rate constants 
(k) for photolysis of NAcSCbl-2, NAcSCbl-3, and NAcSCbl-4. 
  NAcSCbl-Fluorophorea 
NAcSCbl-2 
(360 ± 10 nm) 
NAcSCbl-3 
(405 ± 10 nm) 
NAcSCbl-4 
(546 ± 10 nm) 
Φb (3.4  ± .6) x 10-4 (1.1 ± .1) x 10-4 9.2 ± .5 x 10-6 
ε 27,100 37,800 84,000 
Φε 9.3 ± 1.7 4.2 ± 0.2 0.77 ± 0.04 
kappc (3.0 ± .6) x 10-3 (1.1 ± .1) x 10-4 (1.1 ± .1) x 10-4 
aIlluminated with Hg arc lamp source equipped with optical 
filters corresponding to the fluorophore’s λ max (Alexa350 at 
360 nm, DEAC at 405 nm, and TAMRA at 546 nm ± 10 nm). 
bCalculated from equation 4.2.
 cThe constant was normalized to 
the rate of MeCbl photolysis at 360 nm where it cleaved fastest.  
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Figure 4.20. Photoinduced conversion of NAcSCbl-2 to HO-Cbl-2 with 360 nm light. NAcSCbl-
2 samples (squares, 10 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(360 ± 10 nm) and monitored for conversion to HO-Cbl-2 (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3)  
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Figure 4.21. Comparison of the photolytic conversion of NAcSCbl and NAcSCbl-2 at 360 nm. 
NAcSCbl (white circles) and NAcSCbl (black squares) were photolyzed with a Hg arc lamp and 
conversion to their HO-Cbl photoproducts was monitored over time and represented as the mole 
faction (XHO-Cbl) versus illumination time (360 ± 10 nm).  
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Figure 4.22. Photoinduced conversion of NAcSCbl-3 to HO-Cbl-3 with 405 nm light. NAcSCbl-
3 samples (squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(405 ± 10 nm) and monitored for conversion to HO-Cbl-3 (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3)  
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Figure 4.23. Photoinduced conversion of NAcSCbl-4 to HO-Cbl-4 with 546 nm light. NAcSCbl-
4 samples (squares, 20 µM, 100 mM acetate buffer, pH 5.5) were irradiated using a Hg arc lamp 
(546 ± 10 nm) and monitored for conversion to HO-Cbl-4 (circles). Plot is presented as the mole 
fraction (Xi) of both species in solution.  (n = 3)  
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4.3. Thiyl Radical Detection 
Finally, we determined the photolytic fate of the NAcSH ligand by EPR. Previous reports have 
postulated that thiolato-Cbls undergo decomposition to generate a CoII and thiyl radical species 
(Scheme 4.2).29,31,41,52 However, these studies have not validated these assumptions through direct 
thiyl radical observation. Therefore, solutions of NAcSCbl and NAcSCbl-4 (1 mM, 100 mM 
acetate buffer, pH~ 5.5) were photolyzed in the presence of the radical trap PBN (100 mM) and 
then analyzed by EPR spectroscopy (Scheme 4.6). Predictably, both complexes failed to produce 
any signal from paramagnetic species trapping (Figure 4.24) when left in the dark. However upon 
illumination at 546 ± 10 nm, the expected triplet of doublets splitting was produced for both 
compounds with identical hyperfine couplings (Figure 5b-c, aN~ 16.2 G, aH~ 3.8 G). For 
comparison purposes, we generated and trapped a NAcSH thiyl radical produced by horseradish 
peroxidase catalyzed oxidation (100 mM TRIS buffer, 1 mM EDTA pH~ 8.0).43 This procedure 
yielded thiyl radicals with very similar hyperfines (Figure 5d, aN~ 15.7 G, aH~ 3.8G).43 A small 
variation in aN is seen in the enzyme generated thiyl, but this effect likely arises from the difference 
in buffer pH and ionic strength required for peroxidase activity.59 The difficulty in detecting these 
species should be credited as a limitation to their earlier, failed identification, because the thiyl 
EPR signal decays rapidly with time. Indeed, the samples used in this study were quickly scanned 
after photolysis to ensure maximum signal intensity before decay. 
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Scheme 4.6. PBN trapping of NAcSH radical produced from NAcSCbl or NAcSCbl-4 photolysis 
at 546 nm. The PBN (100 mM) traps the NAcSH radical produced from NAcSCbl and NAcSCbl-
4 (1 mM, 100 mM acetate buffer, pH 5.5)  photolysis with a Hg arc lamp (546 nm). The trapped 
adduct produces hyperfine coupling constants in the EPR spectra as a fingerprint of the trapped 
radical. 
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Figure 4.24. EPR spectra of NAcSCbl and NAcSCbl-4. The splitting patterns above show 
NAcSCbl a) left in the dark, b) photolyzed at 546 nm, c) NAcSCbl-4 at 546 nm or d) the spectrum 
of a peroxidase generated cysteinyl radical. PBN (100 mM) was used as the thiyl trap in the 
presence of NAcSCbl or NAcSCbl-4 (1 mM) in acetate buffer (100 mM, pH 5.5). The peroxidase 
procedure for radical generation was adapted from ref.43.   
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4.4. Conclusion 
We have demonstrated that thiolato-Cbls undergo ready photolysis at wavelengths throughout 
their absorption spectrum. Overall, the efficiency of photolysis is significantly lower than seen in 
alkylCbls but still comparable to many common caging groups.56,57 NAcSCbl photolysis occurs 
much more efficiently with UV illumination than with visible light, but we have demonstrated that 
we can increase the rate of photolysis at these wavelengths by attaching appropriate fluorophores. 
In addition, this indicates that long wavelength, green light photolysis results in the expulsion of 
the cysteine ligand as a thiyl radical. In the future, our efforts will focus on further investigating 
the photolability of thiolato-Cbls and their applications ranging from light induced peptide60 and 
drug delivery61 to photo-induced thiol-ene clicks.47,48 
4.5 Materials and Methods 
4.5.1. General. Alexa Fluor 350 (Alexa350) was purchased from Life Technologies, 7-
diethylaminocoumarin-3-carboxylic acid (DEAC) was purchased from Pharmachem International, 
and TAMRA was purchased from AnaSpec. All other reagents were purchased from Sigma-
Aldrich. All reagents were used without further purification. Samples were photolyzed using an 
Oriel mercury arc lamp (200 W). A UV bandpass filter (UG-1) centered at 360 nm and Hg line 
filters (405 ± 10 nm and 546 ± 10 nm) were purchased from Newport. 
4.5.2. Synthesis.  
Synthesis of HO-Cbl ethylenediamine (HO-Cbl-Etd). HO-Cbl (0.1034 g, 75 μmol) and 1,1΄-
carbonyldi-(1,2,4-triazole) (CDT; 0.2457 g, 820 μmol) were added to an oven-dried round bottom 
flask. The vessel was purged with Ar. Dry DMF (3 mL) was added to the flask and the mixture 
stirred at room temperature for 1 h. Ethylenediamine (0.4351 g, 720 μmol) was added to the 
reaction mixture and stirring continued for another 18 h. The desired compound was purified by 
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reverse phase flash chromatography (C-18 column) using a linear gradient binary solvent system 
(solvent A: 0.1% TFA/H2O; solvent B: 0.l% TFA/CH3CN) with a ratio of A:B that varied from 
97:3 to 35:65 over 10 column volumes. Removal of solvent by lyophilization afforded a red solid 
(0.0673 g, 63%). ESI MS [M+ -OH]+ calcd. for C65H94N15O15PCo: m/z = 1414.6123, found 
1414.6030. [M+ -OH, +H]+2 calcd for C65H95N15O15PCo: m/z = 707.8101, found 707.8069. 1H 
NMR (400 MHz, D2O)  = 7.12 (s, 1 H), 6.48 (s, 1 H), 6.42 (s, 1 H), 6.25 (s, 1 H), 6.18 (d, J = 3.0 
Hz, 1 H), 4.57 (d, J = 12.0 Hz, 1 H), 4.30 - 4.21 (m, 3 H), 4.19 (t, J = 3.4 Hz, 1 H), 4.14 - 4.03 (m, 
2 H), 3.59 (d, J = 14.4 Hz, 1 H), 3.53 (d, J = 10.9 Hz, 1 H), 3.43 (dd, J = 5.1, 11.1 Hz, 1 H), 3.27 
- 3.15 (m, 4 H), 3.01 - 2.96 (m, 1 H), 2.95 - 2.86 (m, 1 H), 2.74 (d, J = 7.1 Hz, 2 H), 2.72 - 2.69 
(m, 2 H), 2.66 (s, 6 H), 2.59 (s, 6 H), 2.57 - 2.47 (m, 1 H), 2.39 (s, 2 H), 2.24 (s, 3 H), 2.19 (s, 4 
H), 2.16 - 1.98 (m, 5 H), 1.88 (d, J = 8.7 Hz, 7 H), 1.84 - 1.74 (m, 2 H), 1.45 (d, J = 7.1 Hz, 7 H), 
1.35 (s, 4 H), 1.32 (s, 4 H), 1.30 - 1.29 (m, 1 H), 1.22 (d, J = 6.3 Hz, 4 H), 1.04 - 0.86 (m, 2 H), 
0.48 (s, 3 H). 
 
 Synthesis of HO-Cbl-1. N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uranium tetrafluoroborate 
(TSTU, 0.0065 g, 22 μmol), acetic acid (0.0010 g, 18 μmol) and N,N-diisopropylethylamine 
(DIPEA, 0.0074 g, 57 μmol), were mixed for 2 h in a DMF:dioxane:water solution (2:2:1, 250 
μL). HO-Cbl-Etd  (0.0057 g, 4.0 μmol) was added and the reaction mixed for 18 h. The desired 
compound was purified by HPLC (semipreparative C-18 column) using a linear gradient binary 
solvent system (solvent A: 0.1% TFA/H2O; solvent B: 0.1% TFA/CH3CN) with a ratio of A:B that 
varied from 97:3 (0 min) to 10:90 (40 min). Removal of solvent by lyophilization afforded a red 
solid (0.0051 g, 88%). ESI MS [M+ -OH, +H]+2 calcd. for C67H96N15O16PCo: m/z = 728.3115, 
found 728.2964. 
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1H NMR (400 MHz, D2O)  = 7.12 (s, 1 H), 6.48 (s, 1 H), 6.42 (s, 1 H), 6.26 - 6.23 (m, 1 H), 6.18 
(d, J = 2.9 Hz, 1 H), 4.57 (d, J = 12.0 Hz, 1 H), 4.31 - 4.21 (m, 3 H), 4.19 (t, J = 3.4 Hz, 1 H), 4.14 
- 4.02 (m, 2 H), 3.59 (d, J = 14.3 Hz, 1 H), 3.53 (d, J = 10.8 Hz, 1 H), 3.43 (dd, J = 4.8, 11.1 Hz, 
1 H), 3.27 - 3.16 (m, 4 H), 3.00 - 2.96 (m, 1 H), 2.90 (dd, J = 9.7, 14.4 Hz, 1 H), 2.74 (d, J = 7.2 
Hz, 2 H), 2.72 - 2.69 (m, 2 H), 2.66 (s, 6 H), 2.59 (s, 5 H), 2.56 (d, J = 4.1 Hz, 1 H), 2.55 - 2.51 
(m, 1 H), 2.39 (s, 2 H), 2.24 (s, 3 H), 2.19 (s, 4 H), 2.14 (br. s., 1 H), 2.13 - 2.01 (m, 4 H), 1.88 (d, 
J = 8.6 Hz, 7 H), 1.84 - 1.74 (m, 2 H), 1.45 (d, J = 7.0 Hz, 6 H), 1.32 (s, 4 H), 1.35 (s, 3 H), 1.31 - 
1.28 (m, 1 H), 1.22 (d, J = 6.3 Hz, 4 H), 1.01 - 0.86 (m, 2 H), 0.48 (s, 3 H). 
 
Synthesis of HO-Cbl-2. Alexa350 N-succinimidyl ester (0.0017 g, 4.1 μmol), HO-Cbl-Etd (0.0091 
g, 6.4 μmol), and DIPEA (0.0030 g, 23 μmol) were mixed in DMF for 18 h. The desired compound 
was purified by HPLC (semipreparative C-18 column) using a linear gradient binary solvent 
system (solvent A: 0.1% TFA/H2O; solvent B: 0.1% TFA/CH3CN) with a ratio of A:B that varied 
from 97:3 (0 min) to 10:90 (40 min). Removal of solvent by lyophilization afforded a red solid 
(.0055 g, 78%). ESI MS [M+ -OH, +2H]+2 calcd for C77H104N16O21PSCo: m/z = 855.3176, found 
855.3137. 
1H NMR (400 MHz, D2O)  = 7.97 (s, 1 H), 7.09 (s, 1 H), 6.62 (s, 1 H), 6.46 (s, 1 H), 6.38 (s, 1 
H), 6.17 (d, J = 3 Hz, 1 H), 6.15 (s, 1 H), 4.55 (d, J = 12.1 Hz, 1 H), 4.31 - 4.17 (m, 7 H), 4.09 (d, 
J = 7.7 Hz, 1 H), 3.97 (d, J = 10.4 Hz, 1 H), 3.58 (d, J = 14.0 Hz, 1 H), 3.53 - 3.48 (m, 1 H), 3.46 
(d, J = 2.5 Hz, 2 H), 3.36 (dd, J = 5.5, 10.6 Hz, 1 H), 3.28 - 3.22 (m, 1 H), 3.17 (dd, J = 7.7, 15.2 
Hz, 2 H), 3.02 - 2.85 (m, 2 H), 2.76 - 2.65 (m, 3 H), 2.65 – 2.48 (12 H) 2.38 (br. s., 2 H), 2.30 - 
2.17 (m, 6 H), 2.13 (s, 3 H), 2.09 – 1.98 (m 2 H), 1.91 - 1.83 (m, 4 H), 1.82 - 1.70 (m, 1 H), 1.48 - 
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1.38 (m, 5 H), 1.37 -  1.26 (m, 5 H), 1.22 (d, J = 6.2 Hz, 3 H), 0.97 - 0.82 (m, 1 H), 0.47 (br. s., 3 
H). 
 
Synthesis of HO-Cbl-3. HO-Cbl-3 was synthesized and purified in the same manner as HO-Cbl-
2 using TSTU (0.0070 g, 23 µM), 7-(diethylamino)coumarin-3-carboxylic acid (0.0031 g, 12 µM), 
DIPEA (0.0052 g, 40 µmol), and HO-Cbl-Etd (0.0107 g, 75 µmol) to afford an orange solid 
(0.0086 g, 79%). ESI MS [M+, -OH, +H]+2 calcd for C79H107N16O18PCo: m/z = 828.8510, found 
828.8352.  
1H NMR (400 MHz, D2O)  = 8.25 (s, 1 H), 7.30 (d, J = 9.1 Hz, 1 H), 7.06 (s, 1 H), 6.66 (d, J =9.1 
Hz, 1 H), 6.43 (s, 1 H), 6.40 (s, 1 H), 6.28 (s, 1 H), 6.15 (s, 1 H), 6.11 (d, J = 2.6 Hz, 1 H), 4.49 (d, 
J = 10.8 Hz, 1 H), 4.26 - 4.14 (m, 4 H), 4.10 - 4.03 (m, 1 H), 3.68 (t, J = 5.9 Hz, 1 H), 3.56 (d, J = 
14.4 Hz, 1 H), 3.50 - 3.34 (m, 6 H), 3.21 (t, J = 5.9 Hz, 1 H), 2.87 (dd, J = 9.5, 14.3 Hz, 1 H), 2.68 
(d, J = 12.9 Hz, 4 H), 2.62 - 2.44 (m, 4 H), 2.35 (s, 2 H), 2.17 (s, 3 H), 2.11 (s, 3 H), 1.83 (s, 3 H), 
1.39 (s, 2 H), 1.28 (t, J = 15.7 Hz, 6 H), 1.19 (d, J = 6.2 Hz, 2 H), 1.15 - 1.04 (m, 6 H), 0.40 (br. 
s., 3 H). 
 
Synthesis of HO-Cbl-4. HO-Cbl-4 was synthesized and purified in the same manner as HO-Cbl-
2 using TAMRA N-succinimidyl ester (0.0023 g, 43 µmol), HO-Cbl-Etd (0.0101 g, 7 µmol), and 
DIPEA (0.0056 g, 43 µM) to afford an orange solid (0.0062 g, 77%). ESI MS [M+ -OH]+ calcd for 
C90H115N17O19PCo: m/z = 1827.7625, found 1827.7492. [M+ -OH, +H]+2 calcd for 
C90H116N17O19PCo: m/z = 914.3852, found 914.3815.  
1H NMR (400 MHz, D2O) = 8.49 (s, 1 H), 8.09 (d, J = 7.7 Hz, 1 H), 7.50 (d, J = 7.9 Hz, 1 H), 
7.13 (dd, J = 3.8, 9.5 Hz, 2 H), 7.08 (s, 1 H), 6.84 (d, J = 9.6 Hz, 2 H), 6.59 (s, 2 H), 6.48 (s, 1 H), 
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6.40 (s, 1 H), 6.21 (s, 2 H), 4.60 - 4.50 (m, 1 H), 4.31 - 4.16 (m, 6 H), 4.12 (d, J = 8.9 Hz, 2 H), 
3.62 - 3.47 (m, 4 H), 3.42 (br. s., 3 H), 3.12 (s, 9 H), 2.75 - 2.49 (m, 14 H), 2.38 (s, 2 H), 2.21 (s, 
4 H), 2.10 (s, 4 H), 2.07 - 1.97 (m, 4 H), 1.87 (s, 5 H), 1.42 (s, 8 H), 1.30 (d, J = 3.0 Hz, 8 H), 1.16 
(d, J = 6.2 Hz, 5 H), 0.91 (d, J = 11.3 Hz, 2 H), 0.46 (br. s., 3 H).  
 
Synthesis of N-acetyl-L-cysteinyl Cbl (NAcSCbl, ribose 5ʹ-OH acetylated N-acetyl-L-cysteinyl Cbl 
(NAcSCbl-1) and N-acetylcysteinyl Cbl-fluorophore conjugates (NAcSCbl-2, NAcSCbl-3, and 
NAcSCbl-4). NAcSCbls were synthesized using a procedure modified from the literature.19,31 To 
an acetate buffered (185 µL, 100 mM, pH 5.5) solution of HO-Cbl (10 mg, 7.38 µmol, 1 eq.) was 
added 48 µL of N-acetylcysteine (NAcSH) solution (200 mM, 9.59 µmol, 1.3 eq). The product 
was precipitated in cold acetone (2.5 mL, 10 volumes) and triturated with cold acetone (3x). The 
dark red precipitate was re-dissolved in 500 µL of acetate buffer and the purity and yield checked 
by LC-MS and absorbance.  
 NAcSCbl. Dark red solid, yield (57%) and purity (97%). ESI MS [M, -H, +3Na]2+ calcd. for 
C67H95N14O17PSCoNa3: m/z = 779.2742, found 779.2827. 
1H NMR (400 MHz, D2O)  = 7.19 (br. s., 1 H), 6.91 (br. s., 1 H), 6.37 (br. s., 1 H), 6.26 (d, J = 
6.26 Hz, 1 H), 6.05 (s, 1 H), 4.59 (t, J = 5.5 Hz, 1 H), 4.53 (d, J = 9.4 Hz, 1 H), 4.32 - 4.16 (m, 3 
H), 4.06 (d, J= 8.4 Hz, 1 H), 4.02 – 3.93 (m, 2 H), 3.86 (d, J = 12.7 Hz, 1 H), 3.71 (dd, J = 13 Hz, 
3.6 Hz, 1 H), 3.55 (br. s., 1 H), 3.37 - 3.24 (m, 3 H), 3.05 - 2.88 (m, 5 H), 2.84 - 2.65 (m, 4 H), 
2.64 - 2.45 (m, 11 H), 2.44 - 2.28 (m, 7 H), 2.20 (br. s., 7 H), 2.09 - 2.01 (m, 7 H), 1.96 (br. s., 2 
H), 1.87 (s, 3 H), 1.81 (s, 3 H), 1.76 (m, 1 H), 1.37 (br. s., 10 H), 1.27 (br. s., 2 H), 1.23 – 1.18 (m, 
1 H), 1.06 - 0.83 (m, 1 H), 0.38 (br. s., 2 H).  
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Ribose 5ʹ-OH acetylated N-acetyl-L-cysteinyl Cbl (NAcSCbl-1). Red solid, yield (85%) and purity 
(98%). ESI MS [M +Na]+ calcd. for C72H104N16O19PSCoNa: m/z = 1641.6352, found 1641.6921. 
[M +2Na]+2 calcd. for C72H104N16O19PSCoNa2: m/z = 832.3125, found 832.3166. [M -H, +3Na]+2 
calcd. for C72H103N16O19PSCoNa3: m/z = 843.30355, found 843.30982.  
1H NMR (400 MHz, D2O)  = 7.13 (s, 1 H), 6.9 (s, 1 H), 6.33 (s, 1 H), 6.19 (d, 1 H), 6.01 (s, 1 H), 
4.56 - 4.45 (m, 2 H), 4.30 - 4.20 (m, 2 H), 4.20 - 4.10 (m, 2 H), 4.07 (dd, J=12.5 Hz, J= 2.3 Hz, 1 
H), 4.01 (d, J= 9.8 Hz, 1 H), 3.9 (t, J= 6.7 Hz, 1 H), 3.51 (d, 1 H), 3.27 (d, J= 10.6 Hz, 1 H), 3.23 
- 3.14 (m, 4 H), 3.04 - 2.94 (m, 1 H), 2.75 - 2.64 (m, 3 H), 2.63 - 2.46 (m, 6 H), 2.44 (s, 3 H), 2.39 
(s, 2 H), 2.37 – 2.27 (m, 2 H), 2.22 (s, 3 H), 2.15 (s, 4 H), 2.08 (d, J = 13.3 Hz, 2 H), 1.99 (m, 1 
H), 1.87 - 1.81 (m, 6 H), 1.78 – 1.71 (m, 5 H), 1.45 - 1.37 (m, 2 H), 1.35 (s, 6 H), 1.31 (s, 4 H), 
1.23 (s, 3 H), 1.16 (d, J = 6.3 Hz, 3 H), 0.99 - 0.81 (m, 2 H), 0.36 (br. s., 3 H). 
 
N-acetyl-L-cysteinylcobalamin-AlexaFluor350 conjugate (NAcSCbl-2). Red solid, yield (81%) 
and purity (92%). ESI MS [M -H, +2Na]+ calcd. for C82H109N17O24PS2CoNa2: m/z = 1915.6138, 
found 1915.6365. [M -H, +3Na]+2 calcd. for C82H109N17O24PS2CoNa3: m/z = 969.3018, found 
969.3753. 
1H NMR (400 MHz, D2O) = 7.89 (s, 1 H), 7.13 (br. s., 1 H), 7.05 (s, 1 H), 6.88 - 6.70 (m, 2 H), 
6.14 (d, J = 5.1 Hz, 1 H), 5.95 (s, 1 H), 4.53 - 4.48 (m, 1 H), 4.43 (br. s., 1 H), 4.12 (dd, J = 9.6, 
17.8 Hz, 2 H), 3.96 (d, J = 9.0 Hz, 1 H), 3.88 (d, J = 10.6 Hz, 1 H), 3.80 - 3.73 (m, 1 H), 3.70 - 
3.63 (m, 1 H), 3.53 - 3.47 (m, 1 H), 3.22 - 2.96 (m, 3 H), 2.95 - 2.75 (m, 2 H), 2.64 - 2.46 (m, 3 
H), 2.43 - 2.21 (m, 5 H), 2.17 - 1.89 (m, 8 H), 1.84 - 1.34 (m, 13 H), 1.33 - 1.15 (m, 7 H), 1.13 - 
0.85 (m, 4 H), 0.47 - 0.16 (m, 2 H). 
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N-acetyl-L-cysteinyl Cbl-diethylaminocoumarin conjugate (NAcSCbl-3). Orange solid, yield 
(74%) and purity (96%). ESI MS [M, -H, + 3Na]+2 calcd. for C84H114N17O21PSCoNa3: m/z = 
943.8430, found 943.8364.  
1H NMR (400 MHz, D2O)  = 8.28 (s, 1 H), 7.32 (br. s., 1 H), 7.07 (s, 1 H), 6.84 (d, J = 9.2 Hz, 1 
H), 6.73 - 6.60 (m, 1 H), 6.44 - 6.24 (m, 2 H), 6.17 - 6.08 (m, 1 H), 5.81 (br. s., 1 H), 4.49 (br. s., 
1 H), 4.35 - 4.20 (m, 2 H), 4.12 (d, J = 10.6 Hz, 1 H), 4.04 (d, J = 9.0 Hz, 1 H), 3.91 (br. s., 1 H), 
3.70 (t, J = 5.7 Hz, 1 H), 3.59 - 3.41 (m, 4 H), 3.41 - 3.26 (m, 4 H), 3.26 - 3.18 (m, 1 H), 2.79 - 
2.60 (m, 3 H), 2.58 - 2.26 (m, 10 H), 2.19 – 2.09 (m., 4 H), 2.08 – 2.01 (m, 2 H), 1.99 – 1.89 (m, 
2 H), 1.85 (s, 3 H), 1.77 (br. s., 2 H), 1.45 - 1.29 (m, 5 H), 1.28 - 1.02 (m, 11 H), 0.40 (s, 2 H). 
 
N-acetyl-L-cysteinyl Cbl-TAMRA conjugate (NAcSCbl-4). Pink solid, yield (66%) and purity 
(98%). ESI MS [M+]+ calcd for C95H123N18O22PSCo: m/z = 1989.7850, found 1989.7780. [M+ 
+H]+2 calcd for C90H124N18O22PSCo: m/z = 995.3664, found 995.3922. [M+ +Na]+2 calcd for 
C95H123N18O22PSCoNa: m/z = 1006.3874, found 1006.3831. [M+ -H, +2Na]+2 calcd for 
C95H122N18O22PSCoNa2: m/z = 1017.3784, found 1017.3744.  
1H NMR (400 MHz, D2O)  = 8.52 (d, J = 9.4 Hz, 1 H), 8.09 (br. s., 1 H), 7.55 - 7.37 (m, 2 H), 
7.17 - 6.95 (m, 4 H), 6.82 – 6.75 (br. s., 2 H), 6.41 (br. s., 2 H), 6.35 (br. s., 1 H), 6.24 (br. s., 1 H), 
4.48 (d, J = 9.5 Hz, 1 H), 4.35 - 4.14 (m, 3 H), 4.06 (br. s., 1 H), 3.90 (br. s., 1 H), 3.75 - 3.68 (m, 
1 H), 3.65 - 3.52 (m, 2 H), 3.51 - 3.36 (m, 3 H), 3.33 - 3.27 (m, 1 H), 3.26 (d, J = 5.3 Hz, 1 H), 
3.22 - 3.19 (m, 2 H), 3.15 (d, J = 6.0 Hz, 2 H), 3.04 (br. s., 13 H), 3.01 - 2.93 (m, 2 H), 2.71 - 2.59 
(m, 3 H), 2.58 - 2.26 (m, 12 H), 2.24 - 1.98 (m, 10 H), 1.89 - 1.71 (m, 6 H), 1.45 - 1.21 (m, 9 H), 
1.21 - 1.07 (m, 5 H). 
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4.5.3. LC-MS ESI Analysis of NAcSCbl and Photolysis Products. NAcSCbl-1 - 4 (40 µM, 100 
µL) and photolyzed samples (20 µM, 100 µL) were initially analyzed using an Agilent 1200 series 
LC-MS equipped with a reverse phase C18 column scanning in positive ion mode. Samples were 
eluted using a binary gradient solvent system (A: 0.1% v/v acetic acid/H2O; B: 100% CH3CN) 
with a ratio of A:B varying from 95:5 (0 - 4 min) to 1:9 (5 - 18 min) and then held constant (18 - 
20 min). Elution was detected at 280 and 540 nm. Purity of the complexes was determined using 
the area under the curve of the 540 nm absorption since all starting materials and products share 
the same extinction coefficient at this wavelength. For full product characterization, purified HO-
Cbl and NAcSCbl synthesis products were dissolved in MeOH (25 µM) and injected via 
electrospray ionization onto a high resolution Thermo LTQ-FT-ICR-MS (< 1.2 ppm) scanning in 
positive ion mode. For 1H NMR analysis, the precipitates of NAcSCbl-1 - 4 were washed for a 
final time with deuterated acetone and then dried overnight before being scanned with a 400 MHz 
Varian NMR. 
 
4.5.4. Photolytic Rate and Quantum Yield Estimation. Samples of NAcSCbl, NAcSCbl-(1-4), 
and MeCbl (20 µM, 1 mL, 100 mM acetate buffer, pH 5.5) were placed in a room temperature 
water bath and photolyzed with a Thermo Oriel Hg Arc lamp equipped with a UV bandpass filter 
(UG-1, 360 nm) and Hg line filters (405 ± 10 nm and 546 ± 10 nm). Samples were scanned between 
300 – 600 nm on a PerkinElmer Lambda 2 UV/Vis spectrophotometer for changes in the absorption 
spectra. The amount of HO-Cbl-(1-4) in solution was determined by: 
 
(Eq. 4.1)   [𝐻𝑂 − 𝐶𝑏𝑙 (µ𝑀)] = (
∆𝐴𝜆
𝜀𝜆
) ∗ 106 µ𝑀 
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Where ΔAλ and Δελ are the change in the absorbance and extinction coefficient (M-1cm-1), 
respectively, at a given wavelength. The relative rate of photolysis was estimated from the initial 
slope of the [HOCbl] versus time and the ln[HOCbl] versus time (n = 3). The slope of the 
ln[HOCbl] vs. time (t) provided a relative rate constant for the reaction (kapp-NAcSCbl). MeCbl 
served as a normalizing chemical actinometer, since its ε and Φ has been reported throughout its 
absorption spectra (Figures S24 - S26).1 Since the solution was dilute and sensitive to changes in 
absorption with time, the rate of MeCbl photolysis at 360 nm was normalized to an apparent 
constant (kapp) of 1 and the samples’ ΦNAcSCbl at a given wavelength were determined by32: 
 
(Eq. 4.2) 
𝑘NAcSCbl
𝑘𝑀𝑒𝐶𝑏𝑙
∗εΦMeCbl
εNAcSCbl
=  ΦNAcSCbl 
 
 Where k is the photolysis rate of NAcSCbl-(1-4) normalized to the photolysis rate of 
MeCbl @ 360 nm, εNAcSCbl is the extinction coefficient of NAcSCbl-(1-4) at a given wavelength, 
and εΦMeCbl is the product efficiency of MeCbl photolysis.62 
4.5.5. Thiyl Radical Detection by Electron Paramagnetic Resonance (EPR). Immediately after 
photolysis or addition of peroxide (vide infra), steady-state EPR spectroscopy was conducted using 
a JEOL FA-100 spectrometer operating at X-band (9.5 GHz) with 100 kHz field modulation. 
Samples were contained in 0.5 mm ID (1.0 mm OD) quartz capillaries and inserted into the center 
of the TE011 cylindrical resonator of the spectrometer. Spectra were collected over 4 min at a center 
field of 3362 G, a sweep width of 80 G, a field modulation of 0.8 G, and microwave power of 1 
mW. Computer simulation was used to determine the g factors and electron-nuclear hyperfine 
interactions. (1) Light-triggered cobalamin-derived thiyl radicals. Solutions of either NAcSCbl or 
NAcSCbl-4 (1 mM, 100 uL) were mixed with phenyl t-butyl nitrone (PBN, 100 mM) in acetate 
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buffer (100 mM, pH 5.5) and then purged with N2 for 10 min. Samples were loaded into a quartz 
capillary (0.5 mm ID, 1.0 mm OD) and then left in the dark or photolyzed (546 ± 10 nm) using a 
Hg arc lamp for 10 min. The samples were immediately scanned as the thiol-PBN adduct signal 
decayed with increasing post illumination time. (2) Peroxidase generated thiyl radicals. NAcSH 
radicals were generated from horseradish peroxidase catalyzed oxidation according to a literature 
procedure.43 Briefly, NAcSH (5 mM), PBN (100 mM), p-phentidine (500 µM), and horse radish 
peroxidase (2 µg/mL, ~2 units/mL) were mixed in phosphate buffered saline (100 µL, 100 mM, 1 
mM EDTA, pH 8.0) and then purged with N2 for 10 min. Hydrogen peroxide (250 µM) was quickly 
added to initiate oxidation, the solution loaded into a quartz capillary, and scanned immediately 
since the thiol-PBN adduct signal decays with time.  
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